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Highly conserved pathogen proteins are ideal components for broadly cross-
protective vaccines, but tend to be poorly immunogenic. The presence of particulates 
in a vaccine has been known for more than 100 years to enhance a vaccine’s efficacy, 
yet only in recent decades has rational nanoparticle vaccine design emerged from 
advances in our understanding of immunology. While most vaccine nanoparticles 
seek to encapsulate or coat antigen onto particles, protein nanoparticles are made 
entirely of crosslinked antigen. This form of nanoparticulate antigen does not require 
the addition of stabilizing additives, and the nanoparticle is both the antigen and the 
immunostimulatory adjuvant. Without added excipients or adjuvants, protein 
nanoparticles drastically reduce the possibility of off-target immune responses, and 
their abiotic nature makes them amenable to cold chain-independent storage and use.  
Protein nanoparticle vaccines have been made from conserved influenza matrix 
protein 2 peptides (M2e), and triggered specific, adaptive immune responses that 
soluble protein could not.   
Given the enhanced immunogenicity of M2e nanoparticles, we sought to 
understand the immunological mechanisms behind protein nanoparticle-mediated 
adjuvancy, whether protein nanoparticles could enhance the immunogenicity of 
other types of influenza antigens, and whether protein nanoparticle adjuvancy could 
be further enhanced by the addition of molecular adjuvants. The work described 
herein (1) tests an expanded range of recombinant influenza proteins as viable 
components of influenza protein nanoparticle vaccines, (2) examines the 
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immunological basis behind protein nanoparticle adjuvancy in vitro and in vivo, (3) 
assesses long-term, cold chain-independent storage of protein nanoparticle vaccines, 
and (4) explores using molecular adjuvants as nanoparticle coatings for enhancing 
vaccine efficacy.  
Nanoparticle size and coating were found to be important design criteria for 
immunogenic protein nanoparticles, and in vivo biodistribution and in vitro dendritic 
cell processing of nanoparticles yielded insights into mechanisms of protein 
nanoparticle adjuvancy. Extended room-temperature wet storage of nanoparticles 
for up to 3 months was shown to yield no loss in immunogenicity, and the molecular 
adjuvants flagellin and immunoglobulin were shown to enhance various aspects of 
the immune response in a mouse immunization model. As cold chain-independent 
storage is an important goal for disseminating new types of vaccines to the 
developing world, protein nanoparticles have proven to be an attractive and stable 
platform technology for the co-delivery of antigen and immunostimulatory adjuvant. 
Furthermore, the ability of immunoglobulin (Ig) to enhance immune responses to 
protein nanoparticles underscores the importance of innate immunofeedback 
mechanisms mediated by this protein, and should be explored further. In addition to 
providing a host-derived means of enhancing adjuvancy, Ig-opsonized protein 
nanoparticles could serve as a tool for further investigations in the broader field of 
immunoengineering. Our work establishes protein nanoparticle vaccines as a 
promising, versatile platform technology for enhancing the adjuvancy of recombinant 
subunit protein antigens.
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CHAPTER 1. INTRODUCTION 
1.1 The Next Generation of Influenza Vaccination 
Traditional vaccine development has followed an “isolate-inactivate-inject” 
paradigm[1], in which whole pathogens are cultured in vitro, inactivated to make them less 
virulent, and injected into a person to induce a protective immune response. This method 
works well for some pathogens, but the immunology behind why some whole pathogens 
make good vaccines and others don’t remains unclear. The whole pathogen approach is 
especially ineffective for pathogens that mutate rapidly, such as influenza. 
Influenza epidemics affect 5-15% of the world’s population every year, and cause 
approximately 500,000 deaths annually [2]. The traditional approach to generating 
effective influenza vaccines relies on sampling the currently circulating influenza viruses, 
and formulating a vaccine with multiple subtypes of the virus. Currently, the World Health 
Organization (WHO) collects data from more than 120 influenza research centers globally 
to decide which influenza subtypes need to be included in each year’s flu vaccine [3, 4]. 
As an example, since the H3N2 subtype of the influenza A virus was discovered in 1968, 
the vaccine strain of H3N2 has been updated almost 30 times, and the WHO analyzes data 
from approximately 3000 H3N2 viruses every year [3]. This method is labor-intensive, not 
guaranteed to be effective every year, and requires people to get annual influenza vaccines.  
The next generation of influenza vaccines aims to circumvent problems with 
mutating viruses using recombinant protein expression. Instead of reacting to influenza 
strains as they emerge, recombinantly-engineered subunit antigens can be rationally 
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designed with common elements of multiple strains to induce cross-protective immunity. 
Recombinant protein expression is also an efficient and scalable process for producing 
these more well-defined antigens [5]. Traditional influenza vaccine virus production 
requires infection and culturing of virus in embryonated chicken eggs, which is a low-yield 
process that requires 3-6 months to produce a vaccine, and is unsuitable for responding to 
pandemic influenza outbreaks [6]. Furthermore, the purification process often results in 
contaminating egg proteins, such as ovomucoid ovalbumin, that render the vaccine 
unsuitable for people with egg allergies [7].  
1.2 Recombinant Influenza Antigen Choices  
Influenza virus subtypes are typically defined by their surface antigens 
hemagglutinin (HA) and neuraminidase (NA). Hemagglutinin binds sialic acid residues 
found on mammalian and avian cells, and enables the virus to gain entry into cells via 
endocytic pathways, where the virus can then replicate [8]. Neuraminidase is responsible 
for cleaving nascent viruses from infected cells to allow for secondary infection. 
Generating neutralizing antibodies against HA that can block viral entry is crucial to 
preventing replication and generating a protective immune response, and HA is considered 
the most important component of an influenza vaccine [9].  
As such, two common assays are used to probe HA structure and function in 
assessing a vaccine’s efficacy. Hemagglutinin’s ability to bind to sialic acid residues on 
cells is used in the hemagglutination assay, in which dilutions of HA are used to crosslink 
red blood cells (RBCs). Visible detection of crosslinked RBCs can be used as a quick, in 
vitro test of the conformation of recombinantly-expressed HA or the stability of influenza 
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viruses. The complement of the hemagglutination assay is the hemagglutination inhibition 
(HAI) assay. In this test, antiserum from individuals vaccinated or infected with influenza 
is used to block hemagglutination. The number of dilutions that a serum sample can 
successfully block RBC crosslinking by HA protein or influenza virus is proportional to 
the concentration of neutralizing antibodies present in the serum. 
Currently, there are 18 known subtypes of HA [10], and it is this variability, 
combined with the high rate of intra-subtype HA mutation, that makes HA such a difficult 
target to immunize against. Conserved antigens are proteins common to all strains of 
influenza, and are consequently attractive antigen targets for incorporation into a universal 
influenza vaccine. The extracellular portion of the influenza matrix protein M2 (M2e) is 
highly conserved among all strains of influenza. The M2 protein is an ion channel 
responsible for the virus’s endosomal escape, and the small, functional nature of this 
protein necessitates its conserved sequence [11, 12]. Antibodies to M2e have been found 
to have neutralizing activity and can prevent influenza infection [13], but are very rarely 
elicited following an influenza infection or vaccination. The larger HA protein occludes 
the smaller M2 protein on the outside of the virus, and is considered the more 
immunodominant epitope, as antibodies are often raised to HA first. A subunit vaccine 
containing M2e could provide cross-strain protective immunity. 
The HA protein also has conserved sequences, but these are on the membrane-
proximal “stalk” region. The membrane-distal “head” region is the more immunogenic 
portion of the protein, and is less conserved. HA stalk proteins fall into two conserved 
phylogenetic groups [10]. Group 1 contains H1, H2, H5, H6, H8, H9, H11, H12, H13, H16, 
H17 and H18, while group 2 contains H3, H4, H7, H10, H14 and H15. Antibodies raised 
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against the HA stalk region can also be neutralizing[14], making the HA stalk also an 
attractive candidate for a universal influenza vaccine antigen. 
Given the conserved portions of M2e and HA can elicit neutralizing antibodies, 
universal influenza vaccines will most likely contain conserved antigen sequences from 
M2e and the two HA stalk proteins [10]. Recombinant protein expression allows for 
customized delivery of vaccine antigens, rather than relying on the native proportions of 
those antigens found on the pathogen. While recombinant proteins will play an important 
role in the development of a universal influenza vaccine, recombinant expression of 
specific, non-conserved influenza proteins will also be useful in developing a rapid 
response to pandemic influenza outbreaks. We explore vaccines with both types of 
influenza antigens in Chapter 2. 
1.3 The Necessity of Adjuvants  
While the antigenic targets for a universal influenza vaccine have been established, 
these proteins generally have poor immunogenicity on their own [15]. Adjuvants are 
additives to vaccines that are commonly employed to boost the immune response to vaccine 
antigens. Adjuvants generally fall into two categories: molecular adjuvants and particulate 
adjuvants [16]. Molecular adjuvants bind specific immunoreceptors that trigger stimulatory 
immune cell pathways, enhancing the immune system’s perceived danger of the vaccine 
antigen. Many of the molecular adjuvants are components of bacteria and viruses, such as 
CpG DNA, double-stranded RNA, lipopolysaccharides, and bacterial proteins such as 
flagellin [8]. The innate immune system has evolved to recognize many pathogen-
associated molecular patterns (PAMPs), and molecules that are perceived as inherently 
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foreign trigger inflammatory immune responses. Because the underlying cellular pathways 
these molecules activate are still not fully elucidated, an incorrect or inappropriate amount 
of inflammation can be triggered by the wrong type or dose of a particular molecular 
adjuvant. Freund’s complete adjuvant, an oil-in-water emulsion of heat-killed 
mycobacteria, is one of the most potent adjuvants known, and is used to generate 
polyclonal antibodies in mice [17]. It also generates excessive inflammation and is 
commonly used as a model inducer of anaphylactic shock, and is thus unsuitable for human 
use due to its potency [18]. To generate clinically suitable adjuvants, the National Institute 
of Allergy and Infectious Diseases  (NIAID) anticipates spending at least $70 million on 
vaccine adjuvant research from 2014-2019 [19]. However, as of this writing, only three 
adjuvants have been approved by the Food and Drug Administration for use in vaccines 
[19, 20]. Safety concerns over administration of PAMP-based adjuvants have slowed the 
translation of these adjuvants into the clinic [21]. Currently, only one TLR ligand-based 
adjuvant, MPL, has been approved for use in humans [22], and its use has been associated 
with injection-site reactions and transient flu-like symptoms [23]. 
Particulates are another class of adjuvants. The presence of micro- and 
nanoparticles in vaccines has been shown to enhance immune responses to co-administered 
antigen. Since the discovery that aluminum hydroxide crystals, or alum, enhances 
adjuvancy in influenza vaccines[24], numerous efforts have been made to understand and 
harness particulate-based vaccine adjuvancy [25-27]. Alum was initially thought to serve 
as an antigen depot, allowing for sustained release of antigen to the immune system over 
time [16]. Other hypotheses of alum’s mechanism of action include initiating cellular 
damage [28], consumption by and inflammation of antigen-presenting cells [29, 30], and 
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adsorption of the innate immune proteins of the complement system [30]. The various 
proposed mechanisms of alum-mediated adjuvancy have motivated a wide range of 
engineered micro- and nanoparticle vaccines to mimic the adjuvant effects of alum in a 
biodegradable and more immunostimulatory form. One common design strategy is to make 
vaccine particles that imitate the size and shape of pathogens, given the effectiveness of 
inactivated whole-pathogen vaccines. Since the size of viruses and bacteria generally range 
from 100 nm – 1 μm, this thesis will focus on the design of nanoparticle vaccines. 
Vaccine nanoparticle design generally follows two strategies: internal 
encapsulation of antigen and/or native antigen display on a particle surface. Biodegradable 
polymers such as chitosan and poly lactic-co-glycolic acid (PLGA) have been studied 
extensively for nanoparticle vaccine encapsulation [31], though many different polymers 
have been investigated [32]. Incorporation of antigens in a nanoparticulate polymer matrix 
has shown that controlled release of antigen to the immune system gives an advantage over 
vaccination with soluble antigen [16, 32, 33]. Recently, surface-based display of antigen 
on nanoparticles, such as on virus-like [32], protein [34] and polymeric [33, 35] particles 
has gained increasing attention. The shift towards surface antigen display has been driven 
by two insights: (1) an immunological understanding that surface receptor engagement on 
antigen presenting cells (APC) is essential for optimal interfacing with the innate and 
adaptive immune systems [36], and (2) the discovery that APC engagement with 
nanoparticles themselves triggers inflammatory responses [25, 29, 37].  
Vaccine nanoparticles are designed to present specific antigens and epitopes in the 
context of enhanced immunogenicity conferred by particulate matter. However, the 
immunomodulatory effects of nanoparticles have been shown to be a function of many 
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factors, including nanoparticle size [38-40], shape [41, 42], charge [43], surface chemistry 
[44], and administration route [45]. Given the diversity of vaccine nanoparticle types [36] 
and immunological responses observed, universal design principles have been difficult to 
elucidate. Molecular adjuvants are a more well-defined class of immunostimulants, but 
cannot replicate the exact mechanisms of nanoparticle-mediated adjuvancy. The 
immunogenic vaccines of the future will most likely contain both molecular and particulate 
adjuvants, and we explore the interplay between the two types of adjuvants in Chapter 5.  
1.4 The Immunology of Vaccine Efficacy 
Any rational vaccine design that incorporates molecular and nanoparticulate 
adjuvants must be based on the principles of immunology. The following sections outline 
the various components of the immune system we hypothesize to be interacting with 
nanoparticle vaccines. 
1.4.1 Antigen Presentation by Dendritic Cells 
While multiple cell types interact with vaccine nanoparticles, dendritic cells (DCs) 
have been identified as the most potent antigen presenting cells (APCs) [46]. Dendritic 
cells are characterized by long, branching projections that stem from their cell body, and 
sample the periphery of the body for foreign antigens. Their ability to process antigens and 
present them in an immunostimulatory or tolerizing context makes them master regulators 
of the immune system [47].  
Dendritic cell processing and presentation of antigens to B and T cells of the 
adaptive immune system transforms an innate immune response into an adaptive one. This 
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bridging of the two arms of the immune system is essential for generating protective 
immunity [8]. The current model of antigen presentation requires three types of signaling 
to be initiated by dendritic cells: (1) presentation of antigen-derived peptide on the major 
histocompatibility complex (MHC), (2) costimulatory surface presentation of maturation 
factors CD40, CD80, or CD86, and (3) soluble cytokine secretion. Upon encountering 
foreign protein antigen, a dendritic cell will digest the antigen into smaller peptides to be 
loaded onto externally-presented MHC I and/or MHC II, and upregulate surface maturation 
markers. The dendritic cell will then migrate to the nearest lymphatic vessels to reach a 
lymph node, where the peptide-MHC complex (pMHC) will be presented to T cells. Each 
T cell has a unique T cell receptor (TCR) that recognizes one type of peptide bound to the 
MHC complex. Upon correct TCR-pMHC complex binding, and T cell CD28 binding 
either CD80 or CD86 on the DC, the T cell starts to proliferate and begins the adaptive 
immune response. CD4+ T cells are known as helper T cells, and are responsible for 
stimulating antibody production by B cells and triggering proliferation of CD8+ T cells. 
CD8+ T cells are known as cytotoxic T cells, and are responsible for surveying and killing 
host cells infected with viruses or intracellular bacteria [8]. 
While the first two signals are essential for DC maturation and successful antigen 
presentation, it is hypothesized that the types of cytokines secreted vary in response to the 
type of antigen being presented, and that this is what allows dendritic cells to effect a wide 
range of immune responses [48]. In addition to various cytokine signals, different 
subpopulations of DCs, such as myeloid and lymphoid DCs, can also elicit different types 
of immune responses [49]. Myeloid DCs are differentiated from the same precursors as 
macrophages, and are responsible for antigen uptake in the periphery of the body and 
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transport to the lymphatic system [50]. Lymphoid DCs are lymph node-resident dendritic 
cells that share a precursor with T cells, and are thought to be involved in promoting 
immunological tolerance. Recently, lymph node-resident follicular dendritic cells (FDCs) 
were shown to play an important role in promoting B cell development, but are not related 
to conventional lymphoid DCs, being derived from vascular endothelium instead [51]. 
FDCs bind immune complexes, or antibodies associated with antigen. FDCs present these 
immune complexes to B cells undergoing germinal center reactions, a process that 
generates antibodies of higher affinity and of diverse effector functions [8, 48]. 
While dendritic cell stimulation of T cells has been extensively studied and 
characterized, dendritic cell interactions with B cells are proving to be of great importance 
as well. Whereas T cell epitopes are linear peptide fragments, B cell epitopes can be 
conformational and non-linear [8]. B cells can also be stimulated by antigen directly as 
well, and multimeric epitope display, such as that found on the surface of a nanoparticle, 
is a known to enhance B cell activation [8]. Nanoparticle vaccines that aim to deliver 
peptides or proteins to dendritic cells, B cells or T cells should take into account antigen 
type and appropriate costimulatory molecule delivery.  
Peripheral dendritic cell contact with vaccine antigen delivery is not the only means 
of antigen presentation to the adaptive immune system. Vaccine targeting to the draining 
lymph nodes using nanoparticle size is a strategy for enhancing antigen delivery to 
dendritic cells[52], and 100-200 nm has been found to be the upper limit on nanoparticle 
size for passive drainage to the lymphatic system[52, 53]. Particles in the 500-2000 nm 
range are actively trafficked to the lymph nodes by antigen presenting cells. At the cellular 
level, size effects also tend to vary among different nanoparticle materials [38, 39, 54, 55]. 
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However even within the extensively-studied category of polystyrene nanoparticles, 
nanoparticle sizes ranging from 40 nm [54] to 3 µm [56] have been suggested as optimal. 
We explore the roles of nanoparticle size and the biodistribution of our nanoparticles 
further in Chapter 3.   
1.4.2 Toll-Like Receptors as Triggers of Inflammation 
Pathogen-associated molecular patterns (PAMPs) are macromolecules that interact 
with specific pattern recognition receptors (PRRs) on or inside dendritic cells and 
macrophages [8, 27]. Receptors that bind bacterially-derived or virally-derived 
macromolecules are hypothesized to initiate adaptive immune responses geared toward 
those particular classes of pathogens [8, 57]. Toll-like receptors (TLRs) are a class of 
membrane-bound PRRs that have been extensively studied for vaccine adjuvant use [58-
60].  
For influenza vaccines in particular, flagellin has shown potential as an effective 
PAMP adjuvant. Flagellin, or FliC, binds to TLR-5 on antigen presenting cells, and its 
signaling has been associated with enhanced antibody responses [60]. A systems biology 
analysis of sera samples of humans immunized with a trivalent influenza vaccine showed 
a strong correlation between serum TLR-5 receptor upregulation 3 days post-vaccination 
and strong HAI titers 4 weeks post-vaccination [61]. The route of flagellin-mediated 
adjuvancy is unclear. Flagellin has been anchored into influenza virus-like particles [62], 
and FliC-antigen fusion proteins have seen promising results in clinical trials [63]. 
However, mice given flagellated E. coli bacteria orally responded better to a subcutaneous 
influenza vaccine than mice fed unflagellated bacteria, indicating that flagellin may not 
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need to be incorporated directly into the vaccine [64]. We examine the role of flagellin 
location in a nanoparticle vaccine formulation in Chapter 5. 
1.4.3 T Cell Responses and the TH1/TH2 Bias 
In studying CD4+ T cell responses upon dendritic cell activation, immunologists 
found two distinct patterns of T cell activation. In the presence of mature dendritic cells 
and IL-12, T cells display a TH1 response, marked by IFN-γ, IL-2 and TNF-β secretion and 
the activation of macrophages to kill intracellular pathogens. In the presence of mature 
dendritic cells and IL-4, T cells display a TH2 response, marked by secretion of IL-4, IL-5, 
IL-10 and IL-13 and activation of eosinophils and mast cells [8, 65]. TH1 responses are 
often referred to as cell-mediated immune responses, due to their predominance during 
infections involving intracellular bacteria and viruses. TH2 responses are antibody-
predominant responses, and are elicited in response to parasitic worms and allergens. The 
type of helper T cell response generated by a vaccine or infection is crucial – induction of 
the correct immune response can be protective, while the inappropriate response can be 
fatal [66].   
Directing appropriate T cell responses is an important feature of nanoparticle 
vaccine design. Alum adjuvants are known to bias T cell responses towards a TH2 response, 
which is inappropriate for influenza and other viral vaccines [16]. Nanoparticle size and 
shape were recently shown to play a role in determining TH1 vs TH2 responses, with 200 
nm spherical particles eliciting a TH1 response and 1500 nm rods eliciting a TH2 response 
[67]. To evaluate TH1 vs TH2 responses after an immunization, antigen stimulation of 
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mouse splenocytes in an ELISPOT assay allows for convenient quantification of IFN-γ or 
IL-4 production in the absence of a pathogen challenge. 
1.4.4 The Role of Antibodies and Immunofeedback 
Immunoglobulins, or antibodies, play a vital role in the immune response, and there 
is increasing attention being paid to them in the development of immunotherapeutics. 
Antibodies are secreted by B cells and have a variety of effector functions. In addition to 
binding pathogens and neutralizing their surface protein activity, antibodies interact with 
the host immune system to promote different types of immune responses. Two 
immunoglobulin G (IgG) proteins can bind to the complement protein C1q to initiate the 
complement response. The complement system is an innate immune response that initiates 
on antibody-opsonized pathogens or particles, and results in a membrane-lytic protein 
complex that can lyse membrane-bound pathogens [8]. Complement is regarded as an 
innate immune mechanism, and complement-activating nanoparticle vaccines have been 
proposed as an enhancer of innate danger signals [68, 69]. Recently, however, the 
complement system has been found to play a role in initiating adaptive immunity and 
immunological memory, as a child with a genetic defect in the complement system was 
found to suffer from recurring infections [70]. 
In addition to activating the complement system, antibodies can serve as an 
interface between antigen and antigen-presenting cells. Dendritic cells and macrophages 
have Fc receptors that bind antibodies and antibody-bound antigen. In mice and humans, 
several different Fc receptors for IgG (FcγRs) have been identified with respect to their 
ability to activate or suppress immune responses. Targeting vaccine antigens to these 
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receptors for immunostimulation relies on (1) the FcγR being a well-characterized means 
of entry into macrophages and dendritic cells [71], and (2) intracellular domains underneath 
FcγRs leading to pro-inflammatory signaling when crosslinked by IgG [8, 72]. 
The Fcγ receptors FcγRI, FcγRIIA, FcγRIIC and FcγRIIIA are activating, but 
FcγRIIB has been identified as an inhibitory Fc receptor, increasing the threshold for B 
cell, neutrophil and macrophage activation [8, 73]. Genetic deletion of the FcγRIIB 
receptor in mice leads to an increased likelihood of several autoimmune diseases [74], 
indicating its importance in regulating a balanced immune response. Furthermore, Fc 
receptor-targeted vaccine antigen administered to dendritic cells ex vivo triggered immune 
responses in the presence and absence of FcγRIIB, suggesting inhibitory receptors play a 
minor role in attenuating vaccine responses [75].  
Follicular dendritic cells (FDCs) were mentioned previously as holding antigen-
antibody immune complexes (ICs) with Fc receptors to present antigen to germinal center 
B cells to promote somatic hypermutation and class switching. It was recently discovered 
that immune complexes on FDCs undergo endocytosis to a non-degradative compartment 
and are recycled back to the FDC surface periodically; antigen was found to be retained in 
FDCs up to 16 days after immunization [76]. These findings could suggest a possible role 
for FDCs in mediating immunological memory, and underscore the importance of Ig-
bound antigen in promoting an adaptive immune response.   
The use of ICs as vaccines has been an area of extensive research. The presence of 
antibodies on antigen has been seen to increase the resulting antibody response by 1000-
fold in the case of soluble antigen, or reduce it by 99% in the case of red blood cells [77, 
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78]. Despite the apparent negative correlation between antigen size and immunogenicity, 
there is preliminary evidence that antibody-opsonized nanoparticulates are more 
inflammatory than soluble immune complexes [79]. Soluble immune complex vaccines 
have demonstrated efficacy in pre-clinical models for malaria [80], HIV [81], ebola [82], 
and other diseases. A recent clinical trial of a hepatitis B soluble immune complex vaccines 
failed, demonstrating that challenges still remain with this type of immunization [83]. It is 
possible that soluble ICs still face the same problem as recombinant protein antigens; the 
small size of both lead to rapid clearance and low immunogenicity. We explore the addition 
of immunoglobulins as adjuvants on our nanoparticle vaccines in Chapter 5. 
1.4.5 Integrating Immunology into Nanoparticle Vaccine Design Principles 
The various cells of the immune system respond to physical and macromolecular 
cues differently, and discovering immunostimulatory combinations of both is an active area 
of research that translates fundamental immunological findings into new types of 
nanotherapeutics. In Chapter 3 of this work, we explore the effects of nanoparticle size and 
coating on in vitro dendritic cell responses, but dendritic cell stimulation is only one aspect 
of an effective vaccine response. In Chapter 5, we examine the role of adjuvant coatings in 
an in vivo mouse immunization model, to obtain a more complete image of how molecular 
and nanoparticulate adjuvants synergize with each other.  
1.5 Influenza Vaccine Nanoparticles 
Many different strategies have been pursued for generating influenza nanoparticle 
vaccines. Virus-like particles (VLPs) are most similar to influenza viruses in being bound 
by a lipid bilayer membrane. VLPs are commonly generated by infection of insect cells 
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with recombinant baculoviruses expressing the proteins of choice [84, 85]. Hemagglutinin, 
neuraminidase, and influenza matrix proteins are common antigens inserted into influenza 
VLPs, and adjuvants such as flagellin can be incorporated into the VLP membrane as well 
[62, 86]. One of the benefits of VLPs is the stable presentation of membrane-bound 
antigens on the nanoparticle surface, eliminating the need to engineer membrane-bound 
antigens into stable, soluble proteins. The membrane-bound nature of the VLP is also a key 
drawback – these semi-permeable vesicles are unstable to osmotic stresses, and changes in 
salt concentration can lead to vaccine particle lysis [15]. 
Self-assembling protein nanoparticles (SAPNs) are composed entirely of protein, 
which reduces the concern of osmotic stress instability. SAPNs are formed from individual 
proteins that are genetic fusions of an antigen to a self-assembly tag, which causes a 
solution of proteins to assemble into higher-order structures upon post-purification 
refolding [87]. Self-assembly motifs are commonly employed to create protein trimers and 
tetramers [59, 88], and tetrameric M2e peptide has been used as a type of self-assembling 
protein vaccine [89]. Larger SAPN self-assembly motifs can enable 24mer [34] and even 
60mer [90] self-assembly. Kanekiyo et al. made influenza SAPNs by genetically fusing 
hemagglutinin to ferritin, a self-assembling 24mer [34]. The 24mer ferritin protein complex 
consists of 8 junctions where 3 proteins meet. Since hemagglutinin has a trimeric structure 
in its native form, this base was ideal for assembling native hemagglutinin on the surface. 
The extensive computation that goes into designing these nanoparticle structures, however, 
is non-trivial [91]. Furthermore, the incorporation of non-antigenic self-assembly motifs 
increases the risk of an off-target immune response upon immunization [92]. 
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Both VLPs and SAPNs aim for multimeric antigen display on the nanoparticle 
surface as a design strategy. This pathogen-mimetic configuration is immunogenic, but 
achieving it in VLPs and SAPNs comes at the cost of stability and potential off-target 
immunogenicity, respectively. Our approach to making protein nanoparticle vaccines, 
desolvation, presents a workaround to both of these problems. 
1.6 Desolvated Protein Nanoparticles 
Desolvated protein nanoparticles are formed entirely from protein by solvent-
directed assembly [93]. Desolvation introduces an unfavorable solvent to a protein solution 
to increase protein-protein interactions, causing proteins in solution to coalesce into 
nanoparticles. These protein nanoparticles are easier to form in contrast to those made via 
a self-assembly sequence in the protein, such as SAPNs [94]. Without an engineered self-
assembly tag on the antigen to direct nanoparticle formation, the chances of an off-target 
immune response[92] to the tag are also decreased. Desolvated protein nanoparticles were 
originally made from albumin [95, 96]. Recently, protein nanoparticles have been shown 
capable of intracellular delivery of folded, active enzymes[97]. The delivery of properly 
folded antigen protein is especially desirable in nanoparticle vaccine design. 
The desolvation process in this work uses 100% ethanol dripped in slowly over a 
solution of stirring protein antigen. The thermodynamically unfavorable interaction 
between the protein and the solvent force the proteins to cluster together into nanoparticles. 
A crosslinker is then added to covalently stabilize the nascent nanoparticles and prevent 
aggregation or disintegration. Glutaraldehyde is a commonly used crosslinker to link 
primary amines, such as those found on lysines and the N termini of proteins. While 
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glutaraldehyde has been used in the past to crosslink protein nanoparticles [59, 97], our 
work uses the crosslinker 3,3’-dithiobis[sulfosuccinimidylpropionate], or DTSSP. DTSSP 
is an amine-reactive crosslinker like glutaraldehyde, but contains a central disulfide bond 
that has the potential to break once the particle is inside the cell. Nanoparticle breakup 
inside antigen presenting cells could facilitate greater proteolytic degradation, and could 
help enhance the amount of peptides displayed on MHC I and II during antigen 
presentation.     
The first desolvated protein nanoparticles for vaccines were originally made with the 
conserved, tetrameric influenza matrix protein M2e [59]. In comparison to soluble M2e 
protein, M2e protein nanoparticles were able to induce strong antibody and T cell 
responses, and protect mice against 5xLD50 influenza A Phi/82 and Cal/09 challenges. 
These results demonstrated that protein nanoparticles could dramatically enhance the 
immunogenicity of non-immunogenic antigen. Unlike other vaccine nanoparticles, protein 
nanoparticles are made entirely of biodegradable, crosslinked antigen, minimizing the 
possibility of off-target immune responses. Their abiotic nature also enhances their 
amenability to cold chain-independent storage, a desirable property for vaccine transport 
to the developing world. We will examine the ability of protein nanoparticles to survive 
cold-chain-independent storage in Chapter 4. 
1.7 The Objectives of the Thesis 
Our overall goal is to develop protein nanoparticle vaccines as a viable platform 
technology that can be used to enhance the adjuvancy of different types of protein antigens 
[98]. To that end, the objectives of this thesis are to (1) translate our initial successes with 
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M2e protein nanoparticles into other types influenza antigen nanoparticles, (2) understand 
the mechanism of nanoparticle adjuvancy, (3) explore extended storage of nanoparticle 
vaccines for the possibility of cold chain-independent storage, and (4) test the ability of 
molecular adjuvant coatings to boost protein nanoparticle immunogenicity.  
Our first goal, in collaboration with Dr. Baozhong Wang’s lab, creates nanoparticles 
with either trimerized H7 hemagglutinin (3HA) or flagellin-fusion proteins with M2e or 
hemagglutinin (HA) stalk sequences inserted into the hypervariable region of flagellin. 
Protein nanoparticles made with these proteins immunized mice in an influenza challenge 
model. 
Second, our fundamental mechanistic studies (1) explore the role of nanoparticle size 
and coating on dendritic cell inflammation and maturation responses in vitro, and (2) 
examine in vivo biodistribution and T and B cell responses to nanoparticles and soluble 
protein. Our in vitro studies examining the fundamental properties of size and coating were 
done with ovalbumin (OVA) as a model antigen, while the in vivo studies were performed 
with trimerized hemagglutinin (3HA) nanoparticles. 
Third, our extended nanoparticle storage studies test whether protein nanoparticles 
can be stored at room temperature or 37°C and retain their immunogenic potential in vivo. 
Since hemagglutinin (HA) has a simple, in vitro readout of protein function in the 
hemagglutination assay, and hemagglutination is a prerequisite for HA immunogenicity, 
these stability studies were performed with 3HA nanoparticles. 
Finally, to examine the potential contributions of molecular adjuvants to enhancing 
nanoparticle-mediated adjuvancy, we added several types of protein adjuvants as coatings 
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on model ovalbumin protein nanoparticles. Flagellin (FliC), a Salmonella-derived protein, 
was added as a soluble adjuvant or crosslinked to the nanoparticle surface to determine the 
role of adjuvant location on the resulting immune response. Immunoglobulin (Ig) is a host-
derived protein that is involved in regulating the immune response [77], and could enhance 
the immune response to the nanoparticles without the addition of a pathogen-derived 
component. We examined coatings of immunoglobulin G (IgG) and immunoglobulin M 
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CHAPTER 2. RECOMBINANT INFLUENZA PROTEIN 
NANOPARTICLES 
2.1 Hemagglutinin and M2e as Influenza Antigens 
The finding that desolvated M2e nanoparticles could protect mice against a lethal 
influenza challenge demonstrated that protein nanoparticles could enhance subunit antigen 
immunogenicity. M2e is only one of the antigens found on influenza, and incorporating 
additional antigens into protein nanoparticles could broaden the repertoire of anti-influenza 
antibodies generated after a vaccine. In particular, the incorporation of hemagglutinin into 
an influenza vaccine increases the chances that the vaccine will generate neutralizing 
antibodies that can protect the host from viral infection. Unlike M2e, hemagglutinin is a 
full-length protein with a functional tertiary structure. Exposing a full-length protein to 
ethanol could cause protein denaturation, and a loss of conformational epitopes could 
reduce the vaccine’s efficacy. Though desolvation is a fairly simple process for generating 
peptide nanoparticles [1], it poses challenges for generating nanoparticles of full-length 
proteins, which we explore in the studies below.     
The following chapter is divided into two subsections, each examining protein 
nanoparticles made with a different type of antigen. We first look at protein nanoparticles 
made with a trimerized form of H7 hemagglutinin (3HA), and examine the role of 
immunization route in generating effective immune responses. The second half of the 
chapter is devoted to hemagglutinin stalk proteins and M2e expressed in genetic fusion 
with flagellin, a TLR-5-activating protein adjuvant, and examining the role that the 
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molecular adjuvant flagellin can play in enhancing the immunogenicity of protein 
nanoparticles. 
2.2 H7 Hemagglutinin 
 In 2013, a new strain of influenza A H7N9 emerged in eastern China with a 
mortality rate of 35% [2], the highest mortality rate ever reported for H7 viruses [3]. The 
virus’s spread was fortunately limited by its avian-to-human transmission route. Were the 
virus to acquire the sustained ability to spread from person-to-person, it could result in 
widespread infection and mortality [4, 5].  
 Preventing influenza infection requires the formation of neutralizing antibodies 
against hemagglutinin. The hemagglutinin protein is 63 kDa, contains a variable head and 
a conserved stalk domain, and is responsible for facilitating the virus’s entry into cells [6]. 
The head domain binds sialic acids on the surface of mammalian and avian cells, and 
antibodies against this head domain are ideal for blocking infection.   
 H7 hemagglutinin is known to be an especially poor immunogen, and inactivated 
virus vaccines require the use of adjuvants to boost their efficacy [4].  Recombinant H7 
hemagglutinin has been produced, and its use in place of whole virus or virus-like 
particles[7] could decrease the chance of off-target immune responses [2]. Unlike the H7 
20nm sub-viral particles described by Pushko et al [2], our protein nanoparticles are an 
order of magnitude bigger (~270 nm) and deliver more antigen per nanoparticle. Given the 
urgency of developing an effective vaccine for this new strain of influenza, and the 
prevailing paradigm of pathogen-mimetic vaccine nanoparticle design, our virus-sized 
 30 
protein nanoparticles seem well-suited to enhance the adjuvancy of recombinant H7 
hemagglutinin. 
2.3 Materials and Methods 
2.3.1 3HA Synthesis 
Recombinant, trimerized H7 hemagglutinin (3HA) was synthesized by baculovirus 
infection of Sf9 and Tni cells, and purified by nickel-NTA (Ni-NTA) affinity 
chromatography as described previously [1].  
2.3.2 Hemagglutination assay 
To test the hemagglutinating activity of 3HA and 3HA nanoparticles, a modified 
hemagglutination assay (Virapur, San Diego, CA) was performed with turkey red blood 
cells (RBCs) (Lampire Biological Labs, Pipersville, PA). Briefly, 5 μg of protein or protein 
nanoparticles in 100 μL of phosphate-buffered saline was serially diluted by half across 11 
wells of a 96-well plate. 50 μL of 0.5% turkey RBCs were then added to each well, and 
incubated at room temperature for 1 hour. The hemagglutination titer was read as the last 
well in the serial dilution that did not form a red button of settled RBCs. 
2.3.3 Nanoparticle Synthesis 
The assembly of 3HA into protein nanoparticles by desolvation was performed as 
previously described with modification . In brief, ethanol was dropped into the 3HA 
solution at a rate of 1 mL/min under constant stirring at 600 rpm. The solution contained 
1.6 mg/ml of protein in PBS and was desolvated with a 4:1 volume ratio of ethanol to 
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protein solution. The particles were collected by centrifugation, and resuspended in sterile 
PBS with sonication.  To coat an additional layer of 3HA molecules onto the 3HA 
nanoclusters, 800 µg soluble 3HA protein was added at a concentration of 1.6 mg/mL to 
480 µg desolvated 3HA nanoclusters and an amine crosslinking reaction was performed 
using 3 mM 3,3´-Dithiobis[sulfosuccinimidylpropionate (DTSSP, Thermo Scientific, 
Waltham, MA ) for 12 hours while stirring to stabilize the nanoparticles. Coated 
nanoclusters were collected by centrifugation, and protein concentration was measured by 
a BCA assay according to the manufacturer’s instructions (Thermo Scientific) to estimate 
the total protein content in nanoparticles. Dynamic light scattering (DLS) was performed 
in PBS with a Malvern Zetasizer Nano ZS (Malvern Instruments, Westborough, MA) to 
assess nanoparticle size distributions. For scanning election microscopy studies, coated 
3HA nanoparticles were resuspended in water, dried, and sputter coated with carbon prior 
to visualization with a Zeiss Ultra60 FE scanning electron microscope at 5.0 kV. 
2.3.4 In vitro Characterization  
JAWS II murine dendritic cells (DCs, passages 6-15) were cultured in α-Minimal 
Essential Media (α-MEM) with 10% fetal bovine serum (FBS) and 5 ng/mL murine GM-
CSF (Peprotech, Rocky Hill, NJ). Cells were plated at a density of 105 cells/mL in 24-well 
plates for in vitro measurement of inflammation and maturation responses. After 24 hours 
of incubation post-plating, cells were stimulated with 10 μg/mL of soluble 3HA or coated 
3HA nanoclusters in fresh complete media. 1 µg/mL of LPS in complete media was used 
as a positive control treatment. TNF-α, a secreted marker of inflammation, was assessed in 
supernatants after 6 hours of stimulation by ELISA according to the manufacturer’s 
instructions (R&D Systems, Minneapolis, MN).  
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A cell surface marker of DC maturation, CD86, was assessed by flow cytometry 
after 24 hours of stimulation. Cells were harvested and washed with PBS. Fc receptors 
were blocked by TruStain fcX (Biolegend) for 10 minutes on ice. Cells were then incubated 
with PE-conjugated rat anti-mouse CD86 (clone GL-1) or isotype control (clone RTK2758) 
antibodies for 30 minutes on ice. After two washes, cells were fixed with 1% 
paraformaldehyde and analyzed with a BD Accuri C6 flow cytometer (BD Biosciences, 
San Jose, CA). Data were analyzed with FlowJo software (FlowJo LLC, Ashland, OR). 
Bone marrow-derived dendritic cells were harvested and cultured as previously 
described [8]. Briefly, bone marrow progenitor cells were collected from femurs and tibias 
from 6-8 week old female Balb/c mice and cultured in RPMI 1640 (ATCC, Manassas, VA) 
supplemented with 10% heat-inactivated FBS, 50 µM β-mercaptoethanol, 1% penicillin-
streptomycin, 2mM sodium pyruvate, 1x non-essential amino acids (Thermo Scientific, 
Grand Island, NY), and 25 ng/mL each of IL-4 and GM-CSF (Peprotech, Rocky Hill, NJ). 
Cells were matured for one week, and the media was changed on days 2, 4 and 6. On Day 
7, cells were harvested by scraping and plated for experiments at a density of 1*105 
cells/mL in 24-well plates. The next day, BMDCs were stimulated with either 10 μg/mL 
soluble 3HA or 3HA nanoparticles for 24 hours. Supernatants were collected and tested for 
IL-1β by ELISA according to the manufacturer’s instructions (R&D Systems). 
2.3.5 Immunization and Challenge 
All animal studies were approved by the Emory University Institutional Animal 
Care and Use Committee (IACUC) under protocol number 2001659. Female, 6-8 week old 
Balb/c mice (Jackson Labs, Bar Harbor, ME) were immunized with 10 μg 3HA 
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nanoparticles in 100 μL PBS once or twice at 4 week intervals through the intra-nasal(i.n.) 
or intra-muscular(i.m.) routes. Blood samples were collected 3 weeks after priming and 
boosting by submandibular venipuncture to test for serum antibodies. Four weeks after the 
priming or boosting immunization, mice were challenged with a 10xLD50 i.n. challenge of 
mouse-adapted influenza A/Anhui. Body weight loss and survival rates were monitored 
daily over a 2 week period post-infection. Weight loss of ≥25% was used as a humane 
endpoint for euthanasia per IACUC guidelines.  
2.3.6 Sample collection and analysis 
Blood collected from immunized mice by submandibular venipuncture was 
allowed to clot at 4°C for at least 30 minutes, and was centrifuged at 2700 x g for 5 minutes 
to collect serum. Serum samples were decanted and stored at -20°C for further analysis. 
Anti-HA serum antibody concentration was determined by ELISA as described previously 
[1] using 1μg/mL 3HA in PBS as a coating antigen.  
2.3.7 Statistical analysis 
Statistical significance was determined by a two-tailed Student's t-test in comparing 
two different conditions. Two-way ANOVA was used to analyze the significant difference 
among 3 or more groups. P-values less than 0.05 was considered to be significant (*, p < 
0.05; **, p < 0.005; ***, p < 0.001). The analysis was performed with GraphPad Prism 




2.4 Results and Discussion 
Protein nanoparticles made from trimerized hemagglutinin (3HA) were 273 ± 125 
nm in diameter by DLS (Figure 1). The smaller average size observed by scanning electron 
microscopy in comparison to dynamic light scattering could be explained by the drying 
process used to prepare an SEM sample, indicating that the nanoparticles are porous in 






Figure 1. Representative size distribution of 3HA nanoparticles as determined by 
dynamic light scattering (DLS) (left), and SEM micrograph of the nanoparticles 
(right), scale bar = 200 nm. 
After observing the lower hemagglutinating potential of monomeric HA compared 
to 3HA, it was decided that nanoparticles would be made from the trimeric 3HA (Figure 
2). Coated 3HA nanoparticles were also shown to possess an 8-fold greater agglutinating 
capability than uncoated 3HA nanoparticles (agglutinating 3 more wells, and thus 
possessing a 23-fold greater agglutinating capacity). Since greater agglutinating capability 
is indicative of greater preservation of functional protein structure, which is critical for 
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neutralizing antibody development, our immunization studies proceeded with coated 3HA 
nanoparticles. 
 
Figure 2. Hemagglutination assay results showing relative hemagglutinating potential 
of (from top) trimeric HA, monomeric HA, coated and uncoated 3HA protein 
nanoparticles, and PBS. (Courtesy of Dr. Li Wang) 
To further underscore the superiority of coated 3HA nanoparticles to uncoated 3HA 
nanoparticles, we examined TNF-α responses in dendritic cells. TNF-α is an inflammatory 
cytokine released by antigen presenting cells, and is important in increasing vascular 
permeability around the site of injection, leading to even greater recruitment of  antigen 
presenting cells [9]. Coated 3HA nanoparticles performed significantly better than 
uncoated nanoparticles, which both performed better than soluble protein in eliciting TNF-
α responses from dendritic cells (Figure 3). 
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Figure 3. TNF-α secretion by JAWS II dendritic cells after 6 hours of stimulation. 
s3HA = soluble 3HA, 3HAU = uncoated 3HA nanoparticles, 3HAC = coated 3HA 
nanoparticles, LPS = lipopolysaccharide control. Error bars represent the standard 
deviation of 3 samples. 
Upon intra-muscular (i.m.) or intra-nasal (i.n.) administration of coated 3HA 
nanoparticles, two i.m. injections was found to be the best method of nanoparticle 






Figure 4. Total IgG and IgG subtype concentrations after various administrations of 
3HA nanoparticles. Error bars represent one standard deviation from the average (n 
= 7-8 samples each). (Courtesy of Dr. Jong Rok Kim). 
 
Following a 10xLD50 challenge of influenza A H7N9 virus, almost all of the mice 
given H7N9 nanoparticles survived (Figure 5). In the single i.n. immunization group, one 
mouse died following the challenge. Mice given 1 immunization i.m. or i.n. lost 
approximately 10% body weight 4-8 days post-challenge, but eventually recovered. Since 
the 3HA nanoparticles were able to provide protective immune responses and induce high 
antibody levels, and since 3HA has a convenient, in vitro readout of function in the 
hemagglutination assay, we chose these nanoparticles to be our model for extended cold-




Figure 5. Percent survival (left) and percent weight change (right) following a 
10xLD50 intranasal challenge of H7N9 influenza A virus. Error bars on the right 
represent the standard error of the mean of 7-8 mice per group. (Courtesy of Dr. 
Ralph Tripp (UGA), Dr. Jong Rok Kim) 
To better understand the mechanism of nanoparticle adjuvancy, we looked at the 
production of IL-1β by dendritic cells stimulated with our nanoparticles. Like TNF-α, IL-
1β is also an inflammatory cytokine that acts on the vascular endothelium. Although many 
types of antigens from viral RNA to bacterial toxins  can trigger IL-1β release [10], 
particulate antigens and adjuvants in particular have been associated with its release from 
antigen presenting cells via activation of the NLRP3 inflammasome [11]. Our finding that 
3HA nanoparticles trigger greater IL-1β release than soluble 3HA protein (Figure 6) is 
consistent with previous findings in the literature, and suggests that the NLRP3 




Figure 6. BMDC production of IL-1β after 24 hours of stimulation. SOL = Soluble 
3HA, NPs = Coated 3HA nanoparticles. Error bars represent the standard deviation 
of 3 samples. (Courtesy of Dr. Jong Rok Kim)  
 
Surface CD86 expression of dendritic cells was measured to assess dendritic cell 
maturation. CD86 is upregulated in dendritic cells undergoing maturation, a process crucial 
for antigen presentation to the adaptive immune system. We found that soluble 3HA 
protein was unable to trigger dendritic cell maturation, while 3HA nanoparticles could 
(Figure 7). The finding that dendritic cell maturation occurs in response to nanoparticulate, 
but not soluble antigen signifies the enhanced adjuvancy of protein nanoparticles is at least 
partly mediated at the level of antigen-presenting cell interactions. Although the 3HA 
nanoparticles were protective, our in vitro studies with dendritic cells presented here have 
only scratched the surface in determining the mechanism of nanoparticle adjuvancy. We 
continued our mechanism studies by testing biodistribution and adaptive immune cell 




Figure 7. CD86 expression on JAWS II dendritic cells after 24 hours of stimulation. 
Each curve represents the fluorescence distribution of 10,000 cells. (Courtesy of Dr. 
Jong Rok Kim) 
2.5 Flagellin-HA Stalk Fusion Proteins 
Toll-like receptors are devoted to recognizing pathogen-associated molecular 
patterns (PAMPs), and are a key component of the innate immune system [9]. Stimulation 
of specific TLR receptors on dendritic cells provokes an innate immune response, and is a 
commonly employed strategy used to guide development of new types of PAMP and 
PAMP-derived adjuvants [12]. Flagellin, or FliC, is a toll-like receptor 5 (TLR-5) agonist, 
but can also bind to the intracellular receptors Naip5 and NLRC4 to trigger inflammatory 
responses [13, 14]. FliC has been extensively studied as an adjuvant for influenza vaccines. 
Influenza virus-like particles (VLPs) made with FliC enhanced virus-specific IgG 
responses in comparison to VLPs lacking FliC [15]. VLPs containing FliC-M2e fusion 
proteins also enhanced systemic and mucosal IgG and IgA production, respectively [16]. 
Currently, a FliC-fusion protein with 4 tandem copies of M2e (STF2.4xM2e) has 
completed a Phase II clinical trial successfully [17]. 
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Replacing the hypervariable region of FliC with an antigen protein sequence is 
known to boost the humoral immune response to the protein sequence inserted [18]. Given 
the conserved nature of M2e and the HA stalk protein, it is hypothesized that protein 
nanoparticles made from M2e and HA stalk FliC-fusion proteins would enhance the 
adjuvancy of these component antigens. The HA stalk domain is highly conserved across 
influenza viruses, and HA stalk types fall under two phylogenetic groups of influenza 
viruses, group 1 (H1-like) and group 2 (H3-like) [19]. To obtain a set of antigens that could 
immunize against all types of influenza viruses, an H1-FliC fusion protein (fPR8) and an 
H3-FliC fusion protein (fAiChi) were used in conjunction with an H3N2 M2e-FliC fusion 
protein (fM2e) to make protein nanoparticles.    
2.6 Materials and Methods 
2.6.1 Protein Expression and Purification 
Plasmids for FliC-fusion proteins fPR8 and fAiChi were obtained from the lab of Dr. 
Baozhong Wang, and the protein was expressed in E. coli BL21. The inclusion body-bound 
proteins were purified by non-native Ni-NTA purification, dialyzed against refolding 
buffer and PBS for 1.5 days each, and stored at -80°C for further use [20]. 
2.6.2 Nanoparticle Synthesis 
To preserve TLR-5 stimulating activity, a desolvation-free method for creating the 
nanoparticles was used. Nanoparticles were formed by DTSSP crosslinking (Thermo 
Scientific, Waltham, MA), followed by diafiltration to remove excess soluble protein. 500 
µL of fM2e or a mixture of fM2e and fPR8 or fAiChi at a 1:1 mass ratio was stirred at 
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speed of 600 rotations per minute with final protein concentration of 2.2 mg/mL and 0.197 
mM final concentration of DTSSP at 4°C for 1 hour. Soluble protein and excess crosslinker 
was then removed by buffer exchange with fresh PBS using a 300 kDa diafiltration tube 
(Pall Corporation, Port Washington, NY). Dynamic light scattering (DLS) was performed 
in PBS with a Malvern Zetasizer Nano ZS to assess the size distribution of the collected 
nanoparticles. 
2.6.3 TLR-5 Stimulation Assay 
FliC fusion activity was characterized by a TLR-5-dependent luciferase activation 
assay in vitro. HEK 293T cells (ATCC, Manassas, VA) were grown in DMEM 
supplemented with 10% fetal bovine serum (FBS), and cultured in humidified 5% CO2 at 
37°C. Cells were incubated overnight at a density of 2*106 cells/well in a 6-well plate, and 
transfected the following day with 10 μg pUNO1-hTLR5, 2 μg pGL4.32-[Luc2/Nf-
κB/Hygro] (Invivogen, San Diego, CA) and 15 μL Lipofectamine 2000 (Invitrogen, Grand 
Island, NY) in DMEM with 1% FBS. Transfected cells were plated the following day at a 
density of 5*104 cells/well in a 96-well plate in DMEM with 1% FBS. Cells were then 
stimulated for 5 hours by 1:5 serially diluted nanoparticles and FliC protein in serum-free 
media. Bright-Glo Luciferase Assay reagent (Promega, Madison, WI) was diluted 1:1 with 
serum-free DMEM and used to assess luciferase activity according to the manufacturer’s 
instructions. Luminescence was measured using LUMAT LB9501 (Berthold, TN). 
2.6.4 BMDC Culture and IL-1β Activity 
Bone marrow-derived dendritic cells were harvested and cultured as previously described 
[8]. Briefly, bone marrow progenitor cells were collected from femurs and tibias from 6-8 
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week old female Balb/c mice and cultured in RPMI 1640 (ATCC, Manassas, VA) 
supplemented with 10% heat-inactivated FBS, 50 µM β-mercaptoethanol, 1% penicillin-
streptomycin, 2mM sodium pyruvate, 1x non-essential amino acids (Thermo Scientific, 
Grand Island, NY), and 25 ng/mL each of IL-4 and GM-CSF (Peprotech, Rocky Hill, NJ). 
Cells were matured for one week, and the media was changed on days 2, 4 and 6. On Day 
7, bone marrow-derived dendritic cells were plated at 105 cells/mL in 24-well plates for in 
vitro measurement of secreted IL-1β levels. After 24 hours of incubation, cells were 
stimulated with 10 µg/mL of fM2e, fM2e/fPR8 or fM2e/AiChi nanoparticles in fresh 
complete medium. IL-1β was assessed in supernatants after 24 hours of stimulation by 
ELISA (R&D Systems, Minneapolis, MN).  
2.6.5 Immunization and Challenge studies 
Female, 6-8 week old Balb/c mice (Charles River, Wilmington, MA) were 
intranasally immunized with 10 µg fM2e nanoparticles, 10 µg fM2e/fPR8 nanoparticles, 
10 μg fM2e/AiChi nanoparticles, or PBS as a control. Ten mice per group were immunized 
twice i.m. at 4-week intervals. To compare antibody responses, sera were collected 2 weeks 
after each immunization by submandibular venipuncture. For challenge infections, mice 
from the fM2e, fM2e/fAiChi, and PBS groups were anesthetized with isoflurane, then 
intranasally infected with a 4xLD50 dose of A/Aichi/2/68 (H3N2) 4 weeks after the boost 
immunization. Mice were observed daily to monitor changes in survival rate and body 
weight, with 25% body weight loss being the humane endpoint for euthanasia according to 
IACUC guidelines. All animal studies were approved by the Emory University Institutional 
Animal Care and Use Committee (IACUC) under protocol number 2001659. 
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2.6.6 Serum Antibody Assessment 
Serum was collected as described above and as in Section 2.1.2.6, and assessed for anti-
M2e and anti-H1/H3 HA responses. M2e sequences from influenza H1N1, H3N2, H5N1, 
and H7N9 viruses were tested, and their sequences can be found in Appendix A. 1 μg/mL 
antigen was used for ELISA, and was carried out as described previously [1]. 
2.6.7 Statistical analysis 
Statistical significance was determined by a two-tailed Student's t-test in comparing two 
different conditions. Two-way ANOVA was used to analyze the significant difference 
among 3 or more groups. A P-value less than 0.05 was considered to be significant. The 
analysis was done by using GraphPad Prism (version 5.0) software for Windows 
(GraphPad Software, San Diego, CA). 
2.7 Results and Discussion 
In these studies, desolvation-free protein nanoparticle synthesis was used to preserve 
FliC-fusion proteins’ ability to activate TLR-5. Of the protein nanoparticle types tested so 
far, these proteins tested were the first ones to have a molecular adjuvant expressed in 
genetic fusion to the antigen of interest. 
Desolvation of the fPR8 and fAiChi proteins resulted in a loss of TLR-5 stimulating 
activity, and coating the nanoparticles by the method used to make 3HA nanoparticles 
resulted in extremely poor yields. A new type of desolvation-free protein nanoparticle was 
designed for this study; one that consisted of crosslinker and antigen with no ethanol added 
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to compact the nanoparticles together. Because of this, the desolvation-free nanoparticles 
were considerably smaller than those made by desolvation, as shown in Table 1. 
Table 1. Desolvation-free nanoparticle size and zeta potential 
Nanoparticle Type Size [nm] Stdev [nm] ζ Pot. [mV] St dev [mV] 
fM2e 54 13.5 -7.1 0.26 
fM2e/fPR8 46.7 24.1 -10.9 1.43 
fM2e/fAiChi 81.7 18.9 -7.94 0.83 
The ability of the nanoparticles to activate TLR-5 was demonstrated by TLR-5-
dependent NF-κB luciferase production (Figure 8). All nanoparticle types were able to 
stimulate luciferase production on a similar order of magnitude to soluble flagellin (FliC), 
indicating that the TLR-5 binding domains of fM2e, fPR8, and fAiChi were preserved in 









Figure 8. Luciferase activity in cells transfected with NF-κB-promoted luciferase 
and TLR-5. 4M2e = fM2e (Courtesy of Dr. Jong Rok Kim)  
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The various desolvation-free nanoparticle types were incubated with JAWS 
dendritic cells and tested for IL-1β stimulating activity (Figure 9). All nanoparticle types 
were found to significantly upregulate IL-1β production. Due to flagellin’s inherent ability 
to activate the inflammasome and subsequent IL-1β production through NLRC4 binding 
[21], we cannot conclude whether the IL-1β production is a result of the nanoparticle-
activated NLRP3 inflammasome, the flagellin-activated NLRC4 inflammasome, or a 












Figure 9. IL-1β production in JAWS 
dendritic cells 24 hours after stimulation with 
various nanoparticle types. Error bars 
represent the standard deviation of 3 
samples. (Courtesy of Dr. Lei Deng) 
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Following two i.m. immunizations of 10 μg of each of the nanoparticle types, the 
ability of the desolvation-free nanoparticles to elicit antibodies to various M2e peptides 
was assessed. Since all particle types contained fM2e, it was of interest to see if this protein 
could elicit cross-reactive antibodies against different sequences of M2e. All types of 












 In addition to measuring M2e-specific responses, hemagglutinin-specific responses 
were also assessed after immunization. As expected, each nanoparticle type containing 
hemagglutinin induced antibodies against its particular strain of hemagglutinin, but not the 
other one (Figure 11). These findings are consistent with the conserved nature of M2e, but 
not of the HA stalk across these phylogenetic groups. 
 
Figure 10. M2e-specific IgG concentrations as assessed by 
ELISA. Error bars represent the standard deviation of 6 serum 









Four weeks after a boost immunization, mice in groups immunized with fM2e and 
fM2e/fAiChi nanoparticles were challenged i.n. with a 4xLD50 dose of an H3N2 influenza 
virus. All mice given nanoparticles survived this challenge (Figure 12), and the addition of 
fAiChi into the nanoparticles did not improve post-challenge survival or weight loss 








Figure 12. Post-H3N2 challenge survival of mice immunized with fM2e or 
fM2e/fAiChi nanoparticles. (Courtesy of Dr. Lei Deng)  
Figure 11. H1- and H3-hemagglutinin-specific IgG responses induced by each 
type of nanoparticle. Error bars represent the standard deviation of 6 serum 





Figure 13. Post-H3N2 challenge body weight change of mice immunized with fM2e or 
fM2e/fAiChi nanoparticles. Data shown is the average weight of 11 mice. (Courtesy 
of Dr. Lei Deng) 
The comparable ability of fM2e and fM2e/fAiChi nanoparticles to protect mice from 
a 4xLD50 challenge suggests that the flagellin-adjuvanted M2e may be sufficient for 
providing protection (Figure 12, Figure 13). This is supported by the ability of fM2e 
nanoparticles to induce antibodies against M2e peptides from an H3N2 influenza virus 
(Figure 10), and also by the finding that H3N2-challenged mice immunized with M2e 
nanoparticles lost on average twice as much weight as mice given fM2e nanoparticles. 
Although the fAiChi fusion protein was able to activate TLR-5 and induce anti-HA 
antibodies, these additional antibodies were not necessary for protection against infection.     
Flagellin-fusion proteins have been reported to have sequence-dependent stability 
issues with protein aggregation [18], limiting their viability as a platform technology for 
immunization. Since a nanoparticle can co-localize antigen and adjuvant proteins together, 
it may not be necessary to use FliC-fusion proteins to co-deliver antigen and adjuvant. 
Furthermore, whether a 1:1 molar ratio of antigen:adjuvant is necessary has not been 
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established, and decreasing the amount of adjuvant used with the nanoparticles could 
improve the vaccine safety profile. To examine whether co-administration of soluble FliC 
with protein nanoparticles or coating of protein nanoparticles with FliC enhances the 
immune response, we explore the role of adjuvant location in Chapter 5. 
2.8 Overall Conclusions 
In the preceding studies, we modified the protein nanoparticle synthesis procedure 
to accommodate two additional types of proteins – trimerized hemagglutinin, and flagellin-
fusion proteins. Overall, this chapter has explored ways of creating protein nanoparticles 
from full-length proteins. Challenges associated with desolvant-mediated denaturation of 
proteins were overcome by avoiding protein-desolvant contact – either by crosslinking 
proteins to the surface of desolvated 3HA protein nanoparticles or by crosslinking fM2e, 
fPR8 or fAiChi together in PBS.    
Uncoated 3HA nanoparticles made by the original desolvation method showed less 
hemagglutination than coated 3HA nanoparticles, and this difference in hemagglutination 
was reflected in correspondingly lower TNF-α production by dendritic cells. These 
preliminary results highlighted the importance of the outer nanoparticle coat layer in 
making protein nanoparticles with conformational antigens.   
Immunizing mice with 3HA-coated 3HA nanoparticles provided protection against 
a 10xLD50 influenza challenge. Although a challenge was not performed on mice 
immunized with soluble 3HA protein, we performed an immunization experiment with 
soluble 3HA protein in our evaluation of nanoparticle stability in Chapter 4. The ability of 
a non-conserved HA antigen, H7, to induce protection in nanoparticulate form 
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complements earlier M2e data demonstrating that conserved antigens in nanoparticles 
provide protective immune responses. Taken together, these data suggest that protein 
nanoparticles are a promising technology for developing both universal influenza vaccines 
and strain-specific influenza vaccines. 
An alternative approach to universal influenza vaccine development was explored by 
augmenting M2e with flagellin in an M2e-FliC fusion protein construct. To preserve this 
protein’s adjuvant activity and obtain substantial yields of nanoparticles, a desolvation-free 
method was used to create nanoparticles, and these desolvation-free nanoparticles were 
able to protect against a 4xLD50 influenza challenge. The strong efficacy of the fM2e fusion 
protein nanoparticles suggests that genetic fusion of FliC to M2e in a 1:1 ratio may add 
more adjuvant than necessary to the nanoparticles. Given that protein nanoparticles 
colocalize antigen and adjuvant proteins, incorporating full-length flagellin alongside 
antigen in protein nanoparticles could sidestep the issue of generating potentially unstable 
fusion proteins, and allow for independent control of antigen and adjuvant ratios. Along 
with incorporating less adjuvant, determining optimal adjuvant location, on or off the 
nanoparticle, is a critical question for nanoparticle vaccine design, and is addressed in the 
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CHAPTER 3. FUNDAMENTAL STUDIES OF PROTEIN 
NANOPARTICLE ADJUVANCY 
3.1 Introduction 
In prior work, protein nanoparticles made with the conserved influenza peptide 
M2e were found to induce protective immune responses in mice against two subtypes of 
influenza[1]. Mice immunized with M2e protein nanoparticles showed anti-M2e IgG and 
IgA responses in lung and nasal washes as well as M2e-inducible splenic IL-4 and IFN-γ 
responses, indicating both strong humoral and T-cell mediated immune responses. In 
contrast, immunization with soluble M2e triggered no protective immunity or immune 
correlates. In Chapter 2, we also found nanoparticles made from trimerized, H7 
hemagglutinin confer protection against an H7 influenza challenge, and that coating the 
hemagglutinin nanoparticles with an additional layer of hemagglutinin protein increased 
the nanoparticles’ hemagglutinating capabilities [2]. To understand how protein 
nanoparticles confer protective immunity and how particle properties, such as size and 
coating, affect the resulting immune response, an in vitro examination of nanoparticulate 
antigen processing is needed. 
In this chapter, we examine protein nanoparticle and soluble ovalbumin (OVA) 
uptake and processing, and the resulting markers of inflammation and maturation in 
dendritic cells in vitro. Protein nanoparticle size and coating were varied due to the 
immunomodulatory importance of particle size [3] and properly-conformed surface 
antigen [4]. Protein nanoparticle size and coating are the two controllable parameters of 
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protein nanoparticles made entirely from antigen, while other nanoparticle properties such 
as charge and hydrophobicity are intrinsically linked to the antigen protein of choice. We 
found both protein nanoparticle size and coating to be important modifiers of DC 
inflammatory cytokine production. Other aspects of protein nanoparticle antigen 
processing, such as uptake and acidification, were found to be significantly different from 
soluble antigen processing, but particle size- and coating-independent.  
Although dendritic cells are one of the key regulators of the adaptive immune 
response, other aspects of the nanoparticle-mediated immune response arise only from 
multiple cell types or even whole organs interacting with nanoparticles and soluble protein 
differently. To explore these interactions, we also looked at different in vivo responses to 
our coated 3HA nanoparticles and soluble 3HA protein. By assessing biodistribution, as 
well as lymph node and spleen cell responses, we sought to answer if (1) antigen 
persistence at the site of injection or in draining lymphatic organs could explain protein 
nanoparticles’ enhanced adjuvancy, and (2) whether germinal center B cell responses were 
enhanced by nanoparticulate antigen.  
To initiate an adaptive immune response, antigen must be presented by antigen 
presenting cells in an immunostimulatory context to cognate B and T cells of the adaptive 
immune system. Activated B cells can undergo proliferation in the lymph nodes or spleen 
to form a germinal center, a region of high B cell proliferation and somatic hypermutation 
that generates high affinity antibodies to antigens presented. Germinal centers grow in size 
in the presence of antigen from a vaccine or infection, and can last up to 3 or 4 weeks after 
initial antigen exposure [5]. Germinal center formation is crucial for high-affinity antibody 
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responses, B cell class switching to generate diverse antibody effector functions, and 
memory B cell formation to ensure lasting protection.    
Before a vaccine nanoparticle can stimulate effective germinal center formation, it 
must be presented to the adaptive immune system. Small nanoparticles in the range of 20-
200 nm in size can drain directly to the lymph nodes, while larger particles (500-2000 nm) 
have been found to associate with injection-site dendritic cells [6, 7]. Better injection site 
retention of large vaccine particles has also been reported [6]. Our 3HA nanoparticles lie 
between these two ranges. Although they are closer in size to the small range of 
nanoparticles, the order-of-magnitude size difference between soluble protein and protein 
nanoparticles will allow us to probe the difference between direct LN drainage and APC-
mediated antigen presentation.  
3.2 Materials and Methods 
3.2.1 Protein Nanoparticle Synthesis 
Nanoparticles were made by a modified desolvation method [1], and size was 
adjusted through the exact conditions as listed in Table 2. To make the particles, 0.4 mL 
pure ethanol was added at a constant rate to 0.1 mL of 6.2 mg/mL OVA (Invivogen, San 
Diego, CA) in phosphate-buffered saline (PBS) under constant stirring at 600 rpm. The 
amine-reactive crosslinker 3,3’-dithiobis[sulfosuccinimidylpropionate] (DTSSP) 
(ThermoFisher Scientific, Waltham, MA) was used to stabilize the resulting nanoparticles. 
The nanoparticles were crosslinked while stirring at room temperature for one hour, 
followed by centrifugation to collect the particles. Nanoparticles were resuspended by 
sonication in either 1 mL of 6.2 mg/mL OVA in PBS or 1 mL of PBS for coating or non-
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coating, respectively. Coating was performed for 2 hours while stirring at 4°C. Following 
collection by centrifugation, particles were resuspended in 0.5 mL of PBS, and additional 
DTSSP was added to a concentration of 6.18 mM to stabilize the outer coating. Coat 
crosslinking was performed for 2 hours while stirring at 4°C. The coat crosslinking reaction 
was quenched with 50 mM Tris base, and particles were collected by centrifugation and 
resuspended in 0.5 mL PBS.  
3.2.2 Protein Nanoparticle Characterization 
Nanoparticle size distribution and zeta potential were assessed by dynamic light 
scattering (DLS) and electrophoretic light scattering (ELS) respectively with a Malvern 
Zetasizer Nano ZS (Malvern Instruments, Westborough, MA). Protein concentration in the 
nanoparticle solution was assessed with a BCA assay according to the manufacturer’s 
instructions (Thermo Scientific, Waltham, MA). Nanoparticles were resuspended in water, 
air-dried, and sputter-coated with carbon prior to visualization with a Zeiss Ultra60 FE 
(Carl Zeiss Microscopy, Cambridge, UK) scanning electron microscope at 5.0 kV. 
Fluorescent protein nanoparticle coating was confirmed by flow cytometry. Coat 
antigenicity was assessed with ELISA using a horseradish peroxidase (HRP)-conjugated 
polyclonal anti-ovalbumin antibody (Thermo Scientific, Rockford, IL). 5.4 µg/mL OVA 
protein nanoparticles in PBS were coated on a 96-well plate overnight at room temperature. 
Each reagent incubation step was followed by three washes with 0.05% Tween-20 in PBS. 
Non-specific binding was blocked by a 1 hour incubation of the plate at 4°C with 1% 
bovine serum albumin (BSA) in PBS. The HRP-conjugated anti-OVA antibody in PBS 
was incubated at 1 µg/mL on the plate for 2 hours at 4°C. Chromogenic quantification was 
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assessed by the oxidation of tetramethylbenzidine by hydrogen peroxide (R&D Systems, 
Minneapolis, MN) according to the manufacturer’s instructions.  
3.2.3 Cell Culture 
The JAWS II immature dendritic cell line was obtained from the American Type 
Culture Collection (Manassas, VA) and cultured in MEM-alpha (Corning, Manassas, VA) 
supplemented to 4 mM glutamine and 5 ng/mL GM-CSF (Peprotech, Rocky Hill, NJ), 20% 
fetal bovine serum (FBS), and 1% penicillin/streptomycin (Amresco, Solon, OH). Cells 
were grown in a humidified incubator at 37°C in 5% CO2. For all experiments, cells were 
plated at a density of 105 cells/mL and incubated for 24 hours prior to stimulation unless 
indicated otherwise. 
3.2.4 Nanoparticle Uptake  
Nanoparticle uptake was assessed by flow cytometry. Fluorescent nanoparticles 
were made as described but with OVA containing 5 wt% AlexaFluor 488-conjugated OVA 
(Life Technologies, Grand Island, NY). JAWS II dendritic cells were plated in 24-well 
plates, and stimulated with 20 µg/mL fluorescent OVA nanoparticles or fluorescent soluble 
OVA. Cells were washed once with PBS, briefly trypsinized, collected by centrifugation, 
and resuspended in chilled trypan blue (Corning, Manassas, VA) to quench external green 
fluorescence. Cell fluorescence was measured at 6, 15 and 24 hours post-stimulation with 
a BD Accuri C6 flow cytometer (BD Biosciences, San Jose, CA). Nanoparticle 
internalization was confirmed by confocal microscopy. 
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3.2.5 Endosomal pH 
Endosomal pH was assessed by ratiometric fluorescence. FITC-(pH-sensitive 
fluorophore) and AlexaFluor 647-(pH insensitive fluorophore) conjugated OVA (Life 
Technologies, Grand Island, NY) were added to a final concentration of 15 wt% and 1 
wt%, respectively, to non-fluorescent OVA to make green/red-fluorescent nanoparticles as 
described above. Standard curves were generated in pH-adjusted PBS to correlate 
fluorescent intensity ratios to pH (Figure 20). 100 μg/mL green/red protein nanoparticles 
were incubated with JAWS DCs in 96-well plates for 2 hours. The nanoparticle solution 
was removed, the cells were washed with PBS, and fresh media was added. Following an 
additional incubation for 0-6 hours, the media was replaced with PBS, and fluorescence 
measurements were taken on a plate reader (BioTek, Winooski, VT) or a flow cytometer 
(BD Biosciences, San Jose, CA). Fluorescent intensities were calculated as averages of 
either a 5x5 fluorescent area scan of each well or the median fluorescence intensity, 
respectively. 
3.2.6 Nanoparticle Uptake Inhibition 
Fluorescent nanoparticle uptake was assessed in the presence of 42 µM 
chlorpromazine or 49 µM cytochalasin D. Concentrations of inhibitors were chosen based 
on (1) maximizing positive control uptake inhibition of fluorescent transferrin or 3 µm 
polystyrene beads as assessed by flow cytometry or confocal microscopy, respectively, and 
(2) minimizing cytotoxicity as assessed by a  lactate dehydrogenase assay (LDH). Percent 
inhibition of positive control and nanoparticle uptake was calculated by normalizing 
inhibited uptake by uninhibited uptake. Uptake inhibition studies were performed in 48-
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well plates. Cells were first pre-treated with uptake inhibitors for one hour. Afterwards, 
complete media containing fluorescent protein nanoparticles or soluble OVA at a 
concentration of 20 µg/mL and each appropriate uptake inhibitor was added. After 3 hours 
of incubation, the cells were washed once with PBS, fixed with 3.7% paraformaldehyde, 
washed with PBS again, and resuspended in trypan blue to quench extracellular 
fluorescence. Cells were scraped from the plate and their fluorescence measured by flow 
cytometry. Degree of uptake inhibition was calculated by median fluorescence intensities 
of 10,000 cells (Equation 1). 
3.2.7 In Vitro Inflammatory and Maturation Markers 
JAWS DCs were plated in either 24- or 48-well plates for measuring in vitro 
maturation and inflammation markers, respectively. Cells were stimulated with 20 µg/mL 
of soluble OVA or OVA protein nanoparticles. CD86 was assessed by flow cytometry after 
24 hours of stimulation. Cells were fixed with 3.7% paraformaldehyde and blocked with 
1% BSA in PBS for 1 hour. Cells were then incubated with 2 µg/mL rat-anti-mouse CD86 
(clone GL-1) or isotype control (clone aRTK2758) primary antibodies for 30 minutes, 
washed twice with 1% BSA in PBS, then stained with 1 µg/106 cells polyclonal PE-
conjugated goat-anti-rat Fc secondary antibody for 30 minutes. All antibodies were 
purchased from Abcam (Cambridge, MA). Cells were washed twice with PBS, scraped 
from the plate, and analyzed by flow cytometry. TNF-α was assessed in supernatants after 




3.2.8 Bone Marrow Derived Dendritic Cell (BMDC) Generation and Cell Culture  
Bone marrow from euthanized, ten-week old Balb/c mouse femurs and tibias was 
collected and cultured as previously described [8]. All animal work was compliant with the 
NIH Guide for the Care and Use of Laboratory Animals. Bone marrow progenitor cells 
were cultured in RPMI 1640 (ATCC, Manassas, VA) supplemented with 10% heat-
inactivated FBS, 50 µM β-mercaptoethanol, 1% penicillin-streptomycin, 2mM sodium 
pyruvate, 1x non-essential amino acids (Thermo Scientific, Grand Island, NY), and 25 
ng/mL each of IL-4 and GM-CSF (Peprotech, Rocky Hill, NJ). Cells were matured for one 
week, and the media was changed on days 2, 4 and 6. On Day 7, cells were harvested by 
scraping and plated for experiments. 
3.2.9 IL-1β Measurement 
BMDCs were plated at a density of 5x105 cells/mL in 24-well plates. Cells were 
stimulated with 20 µg/mL of soluble OVA or protein nanoparticles. Supernatants were 
collected after 48 hours and stored at -80°C. IL-1β was assessed by ELISA (R&D Systems, 
Minneapolis, MN). 
3.2.10 BSA Coating of Nanoparticles 
100 μg of small coated and uncoated OVA protein nanoparticles were incubated 
stirring in 0.5 mL of 10 mg/mL bovine serum albumin (BSA) in PBS for 2 hours at 4°C, 
collected by centrifugation, resuspended in PBS and crosslinked as described in Table 2. 
Nanoparticles were then assessed for BSA presence with an HRP-conjugated anti-BSA 
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antibody (Life Technologies, Grand Island, NY) using a standard ELISA protocol (R&D 
Systems, Minneapolis, MN). 
3.2.11 Confocal Microscopy 
Jaws II Dendritic cells were incubated with 100 µg/mL small, uncoated, green-
fluorescent protein nanoparticles for 6 hours. Cells were then washed with PBS, 
permeablized with 1% Triton-X in PBS, and washed twice more. Rhodamine-phalloidin 
(1:40) was used to stain the actin cytoskeleton, and incubated with the cells for 15 minutes 
at room temperature.  After 3 more PBS washes, the cells were imaged using a Zeiss 
confocal laser-scanning microscope. 
3.2.12 MHC I/II Upregulation 
C57BL/6 bone marrow was cultured and matured into BMDCs as described in 
Section 3.2.8, and seeded at a density of 3*105 cells/mL in 96-well plates. After 24 hours 
of stimulation with OVA protein nanoparticles, soluble OVA, or soluble OVA + 1 μg/mL 
LPS, cells were blocked with anti-CD16/32 (TruStain FcX, Biolegend), and incubated with 
APC-conjugated anti-H-2Kb-SIINFEKL (MHC I) and FITC-conjugated anti-I-Ab (MHC 
II) according to the manufacturer’s instructions (Biolegend). Cells were analyzed by flow 
cytometry (BD Accuri). 
3.2.13 3HA Nanoparticle Synthesis 
Coated 3HA nanoparticles were made according to the protocol in Section 2.1.2.3. 
To make fluorescent 3HA, 10 μL of 10 mg/mL Alexa Fluor 700 succinimidyl ester dye 
(Life Technologies, Grand Island, NY) in dimethyl sulfoxide (DMSO) was added to 50 μL 
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of 5 mg/mL 3HA protein in sterile 0.1 M sodium bicarbonate buffer (pH 8.3). The reaction 
was stirred at 800 rpm for 1 hour at room temperature on a Thermoshaker (Grant 
Instruments, Cambridge, UK), and excess dye was removed by buffer exchanging with 
PBS in a 3 kDa diafiltration tube until the filtrate was colorless. Protein concentration was 
measured by the BCA assay, and conjugated dye concentration was measured by 
fluorescence against a standard curve of the free dye on a spectrophotometer (BioTek, 
Winooski, VT). To make fluorescent nanoparticles, 144 μg fluorescent 3HA protein was 
added to 336 μg non-fluorescent 3HA protein (30% fluorescent 3HA by mass) and used to 
create nanoparticles as described above.  
3.2.14 Immunization and Biodistribution 
All animal studies were approved by the Emory University IACUC under protocol 
number 2001659 and the Georgia State University IACUC under protocol number A16024. 
Mice to be given fluorescent proteins and nanoparticles were fed a low-fluorescence diet 
for 2 weeks prior to immunization to reduce background autofluorescence (LabDiet, St. 
Louis, MO) [9], and treated with a depilatory cream (Nair) around the injection site one 
day before immunization.  
Groups of five, 6-8 week-old female Balb/c mice were injected with 10 μg of 
fluorescent or non-fluorescent 3HA nanoparticles or soluble protein, or PBS as a control. 
Mice injected with non-fluorescent protein and protein nanoparticles were sacrificed after 
10 days for spleen and draining lymph node (dLN) germinal center B cell staining. Mice 
given fluorescent protein and protein nanoparticles were used for antigen biodistribution 
studies.  
 64 
For in vivo imaging, mice were lightly anesthetized with 2 L/min of 5% isoflurane 
in medical grade oxygen. Once mice were no longer ambulatory, they were transferred to 
a Perkin Elmer IVIS Spectrum imaging system (Caliper Life Sciences, Perkin Elmer, 
Waltham, MA) and kept under anesthesia at 1 L/min of 5% isoflurane in medical grade 
oxygen. Mice were imaged laterally on the side of injection and dorsally at 0 hours, 6 hours, 
24 hours, and days 2, 4, 6, 7 and 8. On day 4, two mice from each group were sacrificed 
for ex vivo draining lymph node and spleen imaging, and on day 8, ex vivo imaging was 
performed on the remaining 3 mice. Fluorescence was quantified with LivingImage 
software (Perkin Elmer), using the standard size circular quantification tool to capture the 
fluorescence present between the knee and the upper edge of the quadriceps. 
3.2.15 Ex vivo Cell Staining 
Cells were harvested from homogenized organs and washed with PBS. Fc receptors 
were blocked by TruStain fcX (Biolegend) for 10 minutes on ice. Cells were then incubated 
with PE-conjugated anti-mouse CD95 (clone SA367H8) or FITC-conjugated anti-mouse 
GL-7 (clone GL7) antibodies for 30 minutes on ice (Biolegend). After two washes, cells 
were fixed with 1% paraformaldehyde and analyzed with a BD FACSAria flow cytometer 
(BD Biosciences, San Jose, CA). Data were analyzed with FlowJo software (FlowJo LLC, 
Ashland, OR). 
3.2.16 Statistics 
Significance was assessed by a one-way ANOVA or Student’s unpaired t-test at a 
significance level of p<0.05. All data shown is representative of at least three independent 
measurements unless indicated otherwise. 
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3.3 Results 
3.3.1 OVA Protein Nanoparticle Synthesis and Characterization 
Ovalbumin protein nanoparticles were made by a modified desolvation procedure 
[10]. Small- (~270 nm diameter) and medium-sized (~350 nm) nanoparticles were made 
by desolvation of ovalbumin at 1 mL/min. Increasing the rate of ethanol addition created 
large (~560 nm diameter) protein nanoparticles. Synthesis parameters are summarized in 
Table 2. Crosslinking nanoparticles in the desolvation media led to medium and large 
protein nanoparticles, while crosslinking in PBS created small nanoparticles (Figure 14). 
Zeta potential was unaffected by nanoparticle size (Figure 15). A summary of size, zeta 
potential and process yield data can be found in Table 3. 
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Table 2. Protocol details for creating OVA protein nanoparticles of different sizes. 
Coat solution was 6.2 mg/mL OVA in PBS. 
Step Small Medium Large 
Ethanol addition 1 mL/min 1 mL/min 7 mL/min 
Centrifugation 
7000 g for 5 mins 
followed by 
resuspension in PBS 
none none 
Crosslinking 
Aqueous, 0.82 mM 
DTSSP, stirring for 1 
hour 
In 80% ethanol, 0.82 
mM DTSSP, stirring 




stirring for 1 
hour 
Centrifugation 18,000 g for 32 mins 7000 g for 5 minutes 
7000 g for 5 
minutes 
Resuspension 
Sonication in 1 mL 
PBS or coat solution 
Sonication in 1 mL 
PBS or coat solution 
Sonication in 1 
mL PBS or 
coat solution 
Coating Two hours at 4°C Two hours at 4°C 




18,000 g for 32 mins 18,000 g for 32 mins 
7,600 g for 5 
mins 
Second Crosslinking 
Aqueous 6.2 mM, 
stirring for 2 hours 
Aqueous 6.2 mM, 
stirring for 2 hours 
Aqueous 6.2 
mM, stirring 
for 2 hours 
Quenching 
50 mM Tris base, 
stirring 15 mins. 
50 mM Tris base, 
stirring 15 mins. 





coating and second 
crosslinking 
18,000 g for 32 mins 18,000 g for 32 mins 
7,600 g for 5 
mins 
Resuspension 
Sonication in 0.5 mL 
PBS 
Sonication in 0.5 mL 
PBS 
Sonication in 















Figure 14.  Representative size distributions of OVA protein nanoparticles of 
different sizes. 
Figure 15. Zeta potential of all protein nanoparticle types measured in 1x PBS, 
average of three independent replicates. 
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Table 3. Size, polydispersity (PdI), zeta potential, and yield of protein nanoparticles 
of different sizes and coatings. Yield was defined as final mass over initial desolvated 
mass. Since extra mass was adsorbed through the coating step, yield for those 











Small 277 nm 0.113 -21.7 ± 3.0  79.7 ± 6.0 
Small Coated 271 nm 0.094 -21.5 ± 3.5  93.5 ± 7.5 
Medium 365 nm 0.116 -21.8 ± 3.5 90.1 ± 3.7  
Medium 
Coated 
357 nm 0.135 -20.5 ± 3.0 99.4 ± 21 
Large 567 nm 0.055 -22.1 ± 2.7 81.5 ± 3.8 
Large Coated 559 nm 0.050 -21.4 ± 2.0 100.3 ± 11 
While addition of ethanol to soluble protein is necessary for the desolvation 
process, the resulting solvent environment can lead to denaturation of some proteins. Given 
the importance of antigen conformation on the particle surface to trigger pro-immunogenic 
surface receptor-mediated pathways [11], we added a coating step after particle synthesis. 
Nanoparticles were resuspended in a solution of soluble OVA in PBS to adsorb antigen to 
the nanoparticle surface in the absence of desolvent. Successful coating was confirmed by 
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flow cytometry (Figure 16, left). ELISA with an anti-OVA antibody demonstrated 
increased antibody binding on the nanoparticle surface after coating (Figure 16, right). 
Coating the nanoparticles had no effect on particle size or zeta potential (Figure 15, Table 
3). Scanning electron micrographs of dried protein nanoparticles demonstrate a roughly 
spherical morphology and appear to have size distributions smaller than those obtained by 
DLS in the hydrated state (Figure 17).  
 
 
Figure 16. (Left) Fluorescent OVA-coated protein nanoparticles (right trace) had 
greater fluorescence than uncoated protein nanoparticles (left) as measured by flow 
cytometry. (Right) Anti-ovalbumin antibody binding was significantly enhanced (*, p 






3.3.2 Protein Nanoparticle Uptake in Dendritic Cells 
Using fluorescent protein nanoparticles and soluble OVA, we tracked antigen 
uptake in the JAWS II dendritic cell line by flow cytometry. Given the same dose of 
antigen, cells took up approximately 5-8 times more antigen as protein nanoparticles than 
the soluble form (Figure 19). Internalization of nanoparticles was confirmed by confocal 
microscopy (Figure 18). Protein nanoparticle enhancement of antigen uptake relative to 
soluble protein was greater than any uptake differences among protein nanoparticles of 
different sizes and coatings (Figure 19).  




Figure 18. Confocal microscopy was used to image JAWS II dendritic cells with OVA 
nanoparticles. (First column) Green-fluorescent OVA protein nanoparticles (first 
row) or soluble OVA protein (second row) were incubated with JAWS II dendritic 
cells, and the actin cytoskeleton (red, second column) was stained by rhodamine-
phalloidin. The merged image (third column) shows antigen associating with 
dendritic cells, and the z-stack (fourth column), indicates position of antigen with 
respect to the cell membrane.  
 
Figure 19. Uptake of OVA protein nanoparticles by JAWS II DCs as measured by 
flow cytometry after 6 hours, 15 hours, and 24 hours. PBS = PBS-treated cells, SOL 
= Soluble OVA, S,M,L = Small, Medium, Large, respectively, + = Coated 
nanoparticles. Traces were consistent across two independent replicates. 
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3.3.3 OVA Nanoparticles Experience Attenuated Acidification 
Upon uptake, endosomal pH was assessed with ratiometric fluorescence[12]. 
AlexaFluor 647- (a pH-insensitive red fluorophore) and FITC- (a pH-sensitive green 
fluorophore) conjugated OVA were incorporated into nanoparticles. A standard curve 
correlating pH to fluorescence ratio was generated by exposing the nanoparticles to pH-
adjusted PBS in the presence and absence of cells (Figure 20). While soluble protein was 
exposed to acidic conditions, all protein nanoparticles experienced attenuated acidification 
in comparison (Figure 21). No significant differences in pH were observed among protein 
nanoparticles of different sizes or coatings. 
 Figure 20. Standard curves of ratiometric fluorescence vs. pH were made from DCs 
incubated with protein nanoparticles and buffered to various pHs (A). Green 
fluorescence decreases with pH (B) while red fluorescence does not (C). Standard 
curve for soluble OVA was measured in DCs by flow cytometry (D).  
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Figure 21. Log-mean pH of red/green protein nanoparticles upon incubation with 
DCs for various times following a two-hour pulse of nanoparticles. Differences in log-
mean pH were significant (p < 0.05) between soluble OVA and all nanoparticles 
except small coated (red circles). Each point is shows an average and standard 
deviation of three independent replicates (n = 3). 
3.3.4 Differences in Uptake Pathways  
Uptake inhibitors were used to assess protein nanoparticle uptake routes in JAWS 
II DCs. Soluble ovalbumin is internalized via clathrin-mediated endocytosis [13], and 
nanoparticles on the order of 500 nm and larger are internalized primarily through 
phagocytosis [14], so inhibitors of these two pathways were used to examine uptake route. 
Chlorpromazine [15] and cytochalasin D [16] were used to inhibit clathrin-mediated uptake 
and phagocytosis, respectively. Concentration optimization was based on maximizing 
positive control uptake inhibition and minimizing cytotoxicity. Positive controls were 
chosen based on evidence for exclusive or predominant uptake by a particular pathway – 
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transferrin for clathrin-mediated uptake, and 3 µm polystyrene beads for phagocytosis [17, 
18]. Uptake inhibition fraction was calculated by the following formula: 
 




Equation 1. Formula used for calculating uptake inhibition of fluorescent OVA or 
OVA nanoparticles. 
Where Finhib and Funinhib are the median fluorescence intensities (MFI) of 10,000 
cells in the presence or absence of an uptake inhibitor, respectively, and Fauto is the median 
autofluorescence intensity of 10,000 cells. An uptake inhibition of 1 denotes complete 
inhibition, while an uptake inhibition of 0 denotes no inhibition. Figure 22 shows uptake 
inhibition for soluble OVA and OVA nanoparticles. Both soluble OVA and OVA protein 
nanoparticle uptake were strongly inhibited by chlorpromazine, and differences in 
inhibition were not significant (p > 0.05). Cytochalasin D strongly inhibited soluble OVA 
uptake, but inhibited OVA nanoparticle uptake to a significantly lesser degree (p < 0.05). 




Figure 22. Uptake inhibition of fluorescent protein nanoparticles was determined by 
flow cytometry and normalized by Equation 2. Cytochalasin D = CYD, 
Chlorpromazine = CPZ. Soluble OVA uptake was inhibited by CYD to a significantly 
greater degree than any protein nanoparticles were (*, p < 0.05). CPZ inhibited 
uptake of nanoparticulate and soluble OVA to a similar degree. Bars show average 
and standard deviation of three independent replicates (n = 3). 
3.3.5 OVA Nanoparticles Trigger DC Maturation and Fc Receptor Upregulation 
DC upregulation of the maturation marker CD86 was assessed by flow cytometry 
after stimulation with protein nanoparticles (Figure 23). Isotype controls were used to 
differentiate between upregulation of CD86 and Fc receptors upon stimulation. Protein 
nanoparticles trigger upregulation of CD86, with small, uncoated protein nanoparticles 
causing the greatest upregulation (Figure 23). However, OVA protein nanoparticles also 
induce upregulation of Fc receptors, which is not observed in response to soluble OVA or 







Figure 23. DC CD86 upregulation 24 hours post-protein nanoparticle treatment was 
assessed by flow cytometry. Black = unstained control, Red = isotype control, Blue = 









3.3.6 Inflammatory Cytokine Production is Nanoparticle Size- and Coating-Dependent 
Production of the pro-inflammatory cytokines TNF-α in JAWS dendritic cells and 
IL-1β in BMDCs was examined after protein nanoparticle and soluble OVA stimulation. 
IL-1β production was observed in response to soluble OVA and protein nanoparticles, but 
only small and medium coated protein nanoparticles induced greater upregulation than 
soluble OVA (Figure 26). Large nanoparticles did not trigger an enhanced IL-1β response 
regardless of coating. Conversely, TNF-α production in response to protein nanoparticles 
was lower than that of soluble OVA (Figure 25). Coating protein nanoparticles with 
additional OVA led to increases in the DC TNF-α responses to medium and large, but not 
small, protein nanoparticles. Although medium coated nanoparticles triggered the highest 
levels of TNF-α, they did not reach the levels of TNF-α induced by soluble OVA.  
Figure 24. DC CD86 upregulation 24 hours post-nanoparticle treatment, quantified 
as a fold-increase in (CD86 - Isotype) expression normalized to the PBS control group 
(CD86 - Isotype) expression. Error bars represent standard deviations of 3 




Figure 26. IL-1β production in response to protein nanoparticles was assessed by 
ELISA. Sol = Soluble OVA treatment, PBS = Negative control. Standard deviations 
are of three independent replicates. 
Figure 25. TNF-α production in response to protein nanoparticles was assessed by 
ELISA. Sol = Soluble OVA treatment, PBS = Negative control. Averages and 
standard deviations are of three batches of protein nanoparticles, each replicated 
three times (n = 9). 
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Figure 27. MHC II (left) and MHCI (right) upregulation by BMDCs in response to 
OVA protein nanoparticles, soluble OVA (sol), soluble OVA + 1 μg/mL LPS (LPS), 
or PBS control. Data is represented as % of cells that are MHC “positive”, or having 
a fluorescence intensity above a cutoff threshold. Each data point was derived from 
10,000 cells analyzed. 
3.3.7 Protein Nanoparticles do not Enhance MHC I and MHC II Presentation 
Upregulation of MHC II or MHC I-SIINFEKL was assessed by flow cytometry, and the 
percentages of cells expressing high levels of MHC II or MHC I-SIINFEKL are reported 
in Figure 27. No significant differences in MHC I-SIINFEKL expression were observed 
across any groups (right). LPS-treated BMDCs expressed significantly higher levels of 
MHC II than OVA protein nanoparticle types and PBS (left). No significant differences 
between protein nanoparticles, soluble OVA, and PBS were observed. Our observations of 
humoral responses generated to protein nanoparticles in previous in vivo studies appears 
contradictory to the lack of MHC II presentation observed here, although the display of 
MHC II on LPS-stimulated BMDCs could suggest that different timescales of MHC II 




3.3.8 3HA Nanoparticles Enhance Germinal Center B Cell Populations 
Ten days after immunization, mice given 3HA nanoparticles, 3HA soluble protein, 
or PBS were sacrificed. Their draining lymph nodes and spleens were homogenized and 
stained for CD95 and GL7, markers of active germinal center B cells [19, 20]. Mice given 
nanoparticles showed elevated numbers of germinal center B cells as compared to mice 
immunized with soluble protein or PBS (Figure 28). Germinal center B cell responses in 
the spleen showed significantly higher numbers in mice treated with nanoparticles in 
comparison to PBS-immunized mice (Figure 28). 
 
  
Figure 28. Cells from draining lymph nodes (IngLN) and spleens were stained for 
CD95+/GL7+ B cells (GC-B cells). Bars represent percentages of positive cells, error 
bars represent standard deviation of 5 mouse organs. (Courtesy of Dr. Jong Rok 
Kim) 
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3.3.9 Nanoparticles and Soluble Protein Drain the Injection Site at Similar Rates 
Fluorescent 3HA nanoparticles or soluble protein were injected intra-muscularly 
into mice and fluorescence distribution monitored over 8 days. Figure 29 shows 
representative fluorescent images of mice taken at Day 0 and Day 4, with the green circle 
showing representative areas used to quantify injection site (muscle) fluorescence across 
images. Over the first 24 hours, soluble protein showed a stronger loss in fluorescence than 
nanoparticles did (Figure 30, Figure 32). Soluble and nanoparticle injection site 
fluorescence decay between days 1 and 8 followed roughly the same rate (Figure 30). 
3.3.10 Nanoparticles are Retained in the Spleen Better than Soluble Protein  
Two mice were sacrificed on day 4 and three mice on day 8 for ex vivo lymphatic 
organ imaging. No fluorescence was detected in the spleen or lymph nodes on either day 
(Figure 31). Nanoparticle fluorescence in the spleen was elevated on Day 8 in comparison 
to soluble protein, and was significantly more fluorescent the spleens of mice immunized 
with PBS (Figure 31, Figure 33). 
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Figure 29. 3HA nanoparticles and soluble fluorescent 3HA visualized immediately 
after injection and 4 days after injection. The green circle in the figures show 




























Figure 30. Quantification of fluorescence at injection site. Lateral images of mice 
injected with fluorescent soluble 3HA, 3HA nanoparticles, or PBS had their right leg 
fluorescent radiant efficiency quantified with the LivingImage software, and the 
fluorescence was tracked over the course of 6 days. Error bars represent the standard 




Figure 32. Quantification of fluorescence in Figure 30, normalized to the highest 
observed at 6 hours. Error bars represent the coefficient of variance (SD/σ) 
normalized by the average fluorescence at each point. 
 
 
Figure 31. Draining inguinal lymph nodes (top row) and spleens (bottom row) were 
taken from sacrificed mice at days 4 and 8. 
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Figure 33. Spleens from Day 8 (bottom row of Figure 31) had their fluorescence 
quantified by the LivingImage software. One spleen from the NP group was excluded 
from quantification, as its bent shape obscured part of the fluorescence. Error bars 
represent standard deviation among the groups. * = p < 0.05 
3.4 Discussion  
Current nanoparticle vaccine research seeks to leverage the encapsulating 
biomaterial properties to enhance immunogenic responses to component antigens. Protein 
nanoparticles, made entirely from crosslinked antigen, demonstrate that altering the 
presentation of protein antigens from a soluble to a nanoparticulate form is sufficient for 
enhancing vaccine adjuvancy. Our prior work showed that protein nanoparticles made from 
influenza proteins enhanced antigen immunogenicity and immune protection [1]. Our 
hypothesis that differences in dendritic cell processing of nanoparticulate and soluble 
antigen led to the different in vivo immune responses motivated the present studies. We 
examined the differences between soluble OVA and OVA protein nanoparticles and the 
role of two fundamental protein nanoparticle properties, size and coating, in enhancing DC 
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responses, as well as the in vivo differences in biodistribution and GC-B cell proliferation 
in response to nanoparticulate and soluble 3HA. 
3.4.1 Initial Protein Nanoparticle Uptake and Processing is Size- and Coating-
Independent  
Initial DC uptake and processing was similar among OVA protein nanoparticles of 
different sizes and coatings. Protein nanoparticles greatly enhanced antigen uptake over 
soluble antigen (Figure 19), which has been seen for other types of nanoparticles with other 
cell types as well [10, 21]. However, protein nanoparticle size and coating did not 
significantly affect antigen internalization in the size range tested. While some studies 
found a negative correlation between particle size and uptake [12, 22], the size range over 
which uptake differences were observed spanned 50 nm to 3 µm. Still other work saw no 
influence of size on uptake within this wide size range [23], emphasizing the importance 
of nanoparticle material on uptake trends.  
Chlorpromazine inhibited uptake of soluble OVA and protein nanoparticles by 
approximately 90%, indicating clathrin-mediated uptake of both soluble and protein 
nanoparticle forms of OVA. Since soluble OVA is known to undergo clathrin-mediated 
uptake through the mannose receptor [13], the mannose receptor could be involved in OVA 
protein nanoparticle uptake as well. The comparable uptake of coated and uncoated protein 
nanoparticles is consistent with mannose receptor-mediated uptake, since glyco-antigens 
present in OVA would be accessible on either the coated or uncoated protein nanoparticles. 
Similar to our findings of coating-independent degree of uptake, a study by Thomann-
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Harwood et al. found coating alginate nanoparticles with mannan, a polysaccharide that 
shares a receptor with OVA, had no effect on particle uptake [4].  
 Treatment of DCs with cytochalasin D reduced protein nanoparticle uptake by 
roughly 50%, but reduced soluble OVA uptake by more than 80%. Given the strong 
inhibition of cytochalasin D on soluble OVA uptake, it was surprising to see protein 
nanoparticles still taken up despite cytochalasin D treatment. This phenomenon could be 
explained by the role of actin in clathrin-mediated endocytosis. Actin depolymerization 
with cytochalasin D treatment is a common strategy for inhibiting phagocytosis [16], but 
cytochalasin D cannot completely depolymerize F-actin associated with clathrin-coated 
structures[24]. Clathrin-coated vesicle formation from the plasma membrane requires actin 
polymerization proportional to the maximum circumference of the object being 
internalized [24]. By comparing antigen volume to circumference ratios for spherical 
soluble proteins and protein nanoparticles, we find that nanoparticle uptake requires much 
less actin polymerization than soluble antigen uptake for the same amount of antigen 












= 900 (2) 
Equation 2. Volume to circumference ratios of nanoparticles are much greater than 
those of soluble proteins, suggesting nanoparticles deliver more antigen to DCs than 
soluble protein does for a given amount of actin polymerization. 
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Given partial inhibition of clathrin-mediated uptake by cytochalasin D, the 
preceding observation could explain efficient inhibition of soluble OVA uptake but less 
efficient inhibition of OVA protein nanoparticle uptake. As with other experiments using 
endocytosis inhibitors, we cannot discount the impact of off-target effects, including 
potential compensatory upregulation of other endocytic mechanisms in response to 
cytochalasin D or chlorpromazine treatment.  
Upon antigen internalization, DCs acidified soluble OVA to a significantly greater 
extent than OVA protein nanoparticles. Although uptake inhibition data suggest a common 
uptake mechanism for soluble OVA and OVA protein nanoparticles, the attenuated 
acidification of protein nanoparticles as compared to soluble OVA suggests different 
internal routing for protein nanoparticles and soluble antigen. Our data is also consistent 
with lysosomal colocalization studies that show antigen in nanoparticle cores can achieve 
cytosolic delivery, while soluble or nanoparticle-adsorbed antigen cannot [25], although 
confocal microscopy studies assessing Lysotracker colocalization with fluorescent protein 
nanoparticles would be needed to confirm this hypothesis. The pH 4.7 experienced by 
soluble OVA is characteristic of endosomal fusion with lysosomes, a process promoting 
proteolytic antigen degradation [26]. Attenuated acidification is known to protect antigens 
from rapid degradation and lead to enhanced cross-presentation of MHC Class I-restricted 
antigen peptides [12, 27]. Cross presentation of exogenous antigen on MHC I by dendritic 
cells is necessary for CD8+ T cell responses, which are essential for providing immunity 
against intracellular bacterial and viral infections and cancerous host cells [28]. Our data 
showing attenuated protein nanoparticle acidification allows the possibility of endosomal 
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escape of some internalized protein nanoparticles, a phenomenon that would be consistent 
with the elevated IL-1β levels observed in response to protein nanoparticle treatment [29]. 
3.4.2 Inflammatory Cytokine Secretion is Size- and Coating-Dependent  
IL-1β is known to originate from activation of the inflammasome, a heterotrimeric 
enzyme complex assembled in response to internalization of certain types of particulate 
antigens [30]. IL-1β-production from inflammasome activation allows for the rapid 
cleavage of pro-inflammatory cytokines into their active form, triggering a local, innate 
immune response [5]. The NLRP3 inflammasome is the only one that does not have a 
specific ligand associated with it [31], and is implicated in nanoparticle-mediated 
inflammasome activation [30]. Not all nanoparticles can trigger inflammasome activation 
[30, 31]. Alum [32], silica [29], LPS-coated PLGA [33] and textured polymeric [34] 
particles have all been shown to trigger inflammasome activation, while uncoated PLGA 
particles [33] and lipid cubosomes [30] cannot. Recently, soluble ovalbumin was found to 
activate the inflammasome in a murine model [35], and our stimulation of BMDCs 
confirms this. Additionally, we see enhanced production of IL-1β in response to small and 
medium coated protein nanoparticles over large nanoparticles and soluble OVA. This 
suggests protein nanoparticle activation of the inflammasome is enhanced by small size 
and repeated surface antigen display, consistent with a viral-mimetic design strategy [36]. 
Our findings also demonstrate IL-1β production by BMDCs in the absence of pretreatment 
with LPS or other stimuli, a step commonly used for in vitro inflammasome activation, but 
known to bias the resulting inflammatory response [31]. 
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TNF-α enhances local inflammatory responses through activation of the NF-κB 
pathway in multiple cell types [37]. In addition, it directs DCs to begin maturation and 
migration to lymph nodes[5]. Given the strong IL-1β responses observed, it was surprising 
to see DC TNF-α responses to protein nanoparticles lower than soluble OVA. The patterns 
for TNF-α and IL-1β production are distinct from one another, suggesting different 
mechanisms of activation despite an overlap in signaling pathways and downstream targets 
[38, 39]. Studies suggest while both molecules are pro-inflammatory cytokines, only TNF-
α can act as a chemokine for recruiting innate immune cells to the site of inflammation, 
which could explain the lower baseline observed for TNF-α secretion than that of IL-1β 
[39].Given soluble OVA’s inherent inflammasome-stimulating capabilities, it is possible 
that epitopes responsible for inflammasome activation also trigger TNF-α production. This 
would be consistent with our results showing enhanced TNF-α production in response to 
protein nanoparticle coating for medium and large particles, but does not explain why 
coating small OVA protein nanoparticles does not enhance TNF-α production. 
Furthermore, our findings that small coated 3HA nanoparticles trigger more TNF-α than 
uncoated 3HA nanoparticles also suggest an antigen-dependence to protein nanoparticle-
induced TNF-α (Figure 3). Overall, the discrepancy in TNF-α responses between OVA and 
3HA nanoparticles and soluble protein also supports the claim that TNF-α signaling is not 
characteristic of all types of nanoparticle-mediated adjuvancy [40]. Although TNF-α is 
known to enhance monocyte and neutrophil extravasation at the site of inflammation [5], 
its role in promoting immunity following vaccination remains to be fully elucidated.  
DC responses to coated protein nanoparticles may be component-antigen 
dependent. Given the lack of pathogen-associated molecular patterns (PAMPs) or DC-
 90 
specific epitopes on ovalbumin, however, the enhanced inflammatory responses seen to 
coated OVA nanoparticles may be due to proteins other than OVA. Serum protein 
adsorption to nanoparticles in vitro and in vivo is ubiquitous and dependent on nanoparticle 
surface properties [41]. We found OVA-coated OVA protein nanoparticles bind less BSA, 
a representative serum protein, than uncoated OVA protein nanoparticles do (Figure 34). 
The protein corona on nanoparticles has been shown to remain attached during cellular 
uptake[42], and the uptake of non-immunogenic serum proteins on the protein 
nanoparticles may explain the attenuated DC inflammation observed. In vivo, the protein 
corona may have immunostimulatory effects if complement or immunoglobulin is 
adsorbed, and engineering vaccine nanomaterials to preferentially adsorb these proteins is 
an active area of research [43].  
 
Figure 34. Small coated and uncoated OVA nanoparticles were incubated in 10 
mg/mL BSA for 2 hours, collected by centrifugation, and crosslinked as described in 
Table S1. Nanoparticles were then assessed for BSA presence via ELISA. Uncoated 
OVA nanoparticles adsorbed significantly more BSA than OVA-coated OVA 

















While coating protein nanoparticles generally enhances DC inflammatory 
responses, we see deviations from this trend at small sizes for TNF-α. In general, cytokine 
responses are enhanced in response to coated and smaller-sized protein nanoparticles, 
although the enhancement in response to coating is greater than that of decreasing size. 
Therefore, we believe particle size plays a lesser role in inflammatory cytokine production 
than particle coating.   
3.4.3 DC Maturation 
All protein nanoparticle types led to slight CD86 upregulation, indicative of DC 
maturation, a process necessary for successful antigen presentation. DC maturation 
markers, including CD86 as well as CD80 and CD40, have been upregulated in response 
to other types of nanoparticles [23]; and while small and small coated protein nanoparticles 
qualitatively appeared to upregulate CD86 the most compared to soluble (Figure 23), large 
distributions of maturation marker expression make quantitative comparisons of 
upregulation difficult. Although protective humoral and cell-mediated immune responses 
have been observed in response to M2e and hemagglutinin protein nanoparticles (Figure 
7) [1, 2], we were unable to observe significant MHC II upregulation in BMDCs after 24 
hours of protein nanoparticle stimulation (Figure 27). This discrepancy, coupled with the 
observed upregulation of MHC II in response to soluble OVA + LPS, suggests that 
different adjuvants trigger different rates of MHC II upregulation and antigen presentation. 
Increases in isotype control fluorescence indicate Fc receptor upregulation in response to 
protein nanoparticle stimulation of DCs, but not in response to soluble OVA or to the 
positive control LPS. To our knowledge, this is the first time FcR upregulation has been 
observed in response to nanoparticle stimulation. While FcR-targeted nanoparticle 
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vaccines are being studied [44], further investigation into the upregulation phenomenon is 




3.4.4 Biodistribution and the Importance of Germinal Centers 
In vivo, the ability of hemagglutinin protein nanoparticles to induce germinal center 
formation is crucial for providing protective immunity, and corroborates the in vitro 
correlates of inflammation and maturation we observed with DCs. The ability of 
nanoparticle vaccines such as liposomes, polymeric particles, and micelles to induce 
germinal center formation has been previously documented [45-47]. Though some groups 
have found soluble antigen is unable to trigger germinal center formation [45], we cannot 
exclude that possibility with soluble 3HA, as elevated levels of LN GC-B cells were still 
detected in comparison to PBS. 
The elevated numbers of GC-B cells found in the spleens of mice immunized with 
nanoparticles correlates with the significant level of antigen retention found in the spleen 
as well (Figure 28, Figure 33). While literature suggests spleen-resident follicular dendritic 
cells are associated with this antigen and responsible for the germinal center response[5], 
flow cytometry or immunohistochemical staining would be needed to confirm this 
hypothesis. Overall, the higher retention of nanoparticulate over soluble antigen in the 
spleens of immunized mice, coupled with increased germinal center B cells in nanoparticle-
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immunized mice allude to splenic antigen retention as a key component of the mechanism 
linking nanoparticulate antigen to enhanced immune responses. 
Injection site drainage rates were similar between nanoparticle and soluble 3HA 
between 1 and 8 days. Although an initial loss of soluble 3HA was observed over the first 
24 hours, the amount of antigen persisting at the injection site was the same afterwards, 
suggesting uneven starting doses of antigen. Although antigen persistence at the injection 
site has traditionally been a goal of controlled-release vaccine therapeutics [48, 49], recent 
studies suggest that extended persistence of antigen at an injection site can lead to T cell 
dysfunction or deletion [50]. The clearance of our nanoparticles from the site of injection 
is a promising sign that our vaccine will not trigger adverse consequences associated with 
persistence, and precludes injection site retention from being a mechanism of protein 
nanoparticle adjuvancy. 
3.5 Conclusion 
In this chapter, we have examined differences in dendritic cell responses to OVA 
protein nanoparticles of different sizes and coatings, as well as in vivo biodistribution and 
germinal center formation in response to 3HA protein nanoparticles. Our in vitro data show 
that protein nanoparticles enhance antigen uptake in DCs, yet enhanced antigen delivery 
alone does not lead to an across-the-board increase in DC inflammation. The observation 
that protein nanoparticles experience attenuated endosomal acidification in comparison to 
soluble antigen supports the hypothesis of protein nanoparticles enhancing antigen cross-
presentation, which was also supported by the successful immunization of mice with M2e 
peptide protein nanoparticles [1]. Our incorporation of the full-length proteins OVA and 
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hemagglutinin [2] into protein nanoparticles suggests that multiple types of protein 
antigens can be incorporated into immunogenic protein nanoparticles. While readouts of 
protein nanoparticle uptake, uptake mechanism, and intracellular pH are independent of 
nanoparticle type, markers of inflammation are dependent on size and coating. Protein 
nanoparticles between 270-350 nm in diameter trigger greater inflammatory responses than 
560 nm particles, highlighting the importance of small sizes in protein nanoparticle design. 
Our data suggest a separation of initial antigen uptake and processing from downstream 
inflammatory outputs. On a fundamental level, this would imply that size- and coating-
mediated nanoparticle adjuvancy does not occur at the point of internalization. 
Consequently, nanoparticle size can play a complementary role to membrane receptor-
mediated adjuvants (i.e. TLR ligands) on the nanoparticle surface for optimal DC 
responses. In examining these responses, the observed decoupling of TNF-α and IL-1β 
production in response to soluble or nanoparticulate OVA underscores the importance of 
identifying in vitro inflammatory correlates to successful in vivo immunization. The 
observed IL-1β responses also implicate activation of the inflammasome in response to 
protein nanoparticles, supporting other work showing non-crystalline adjuvant 
nanoparticles can activate the inflammasome [33].  
Our in vivo data implicate splenic antigen retention and germinal center formation 
in the mechanism of protein nanoparticle adjuvancy. Taken together, these results suggest 
that coatings on vaccine nanoparticles should be directed toward activating specific 
responses rather than only enhancing cellular uptake, and that adjuvant receptor targets on 
spleen-resident immune cells are of particular importance. We explore this idea further 
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with immunoglobulin-mediated adjuvancy and Fc-receptor targeting of protein 
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CHAPTER 4. COLD-CHAIN-INDEPENDENT STORAGE 
OF PROTEIN NANOPARTICLE VACCINES 
4.1 Introduction 
While the other chapters of this thesis (and a significant fraction of vaccine research) 
are devoted to the development of new types of immunogenic vaccines, effective 
distribution of vaccines is a non-trivial problem, and a significant hurdle to eradicating 
diseases worldwide. The World Health Organization (WHO) estimates around 1.5 million 
people die each year from vaccine-preventable diseases [1]. Despite advances in vaccine 
development, vaccine distribution infrastructure remains inadequate in many parts of the 
world, and it is estimated that up to 40-50% of all vaccine doses are wasted in certain 
countries [2]. 
Crucial to current vaccine transport is the idea of the cold-chain – a series of 
refrigerated enclosures with tight temperature control that allows for stable transport of 
vaccine from manufacturer to patient. Tight controls on temperature are important for 
whole pathogen vaccines, as these are particularly prone to stability losses [3]. Membrane-
bound pathogens, such as bacteria and certain viruses including influenza, are especially 
prone to osmotic stress, and changing salt concentrations with evaporating solvent can lead 
to pathogen shrinkage and destruction [3, 4]. 
Although recombinant, subunit protein vaccines have been proposed as a means of 
working around stability issues with unstable whole pathogen vaccines, issues with low 
immunogenicity and appropriate adjuvant choice have slowed their development as a 
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viable alternative [3]. Our protein nanoparticles are a means of delivering antigen and an 
adjuvant in the same delivery vehicle, and are thus an excellent candidate for testing cold-
chain-independent vaccine stability. 
In the case that storage losses arise, lyophilization, or freeze-drying, has been shown 
to enhance vaccine stability [5, 6]. Protein nanoparticles in particular have been lyophilized 
previously, although increases in size due to aggregation and decreases due to particle 
collapse have been observed [7, 8]. Lyophilized and reconstituted protein nanoparticles 
made from β-galactosidase retained approximately 84% of enzyme activity, indicating the 
potential for antigen structure to be preserved in protein nanoparticle vaccines [8].  
Although Herrera-Estrada et al. showed enzyme activity in protein nanoparticles was 
preserved, the study did not examine whether surface protein was denatured, a key element 
of 3HA nanoparticles, and the most likely region of protein denaturation to occur. The 
hemagglutination assay measures properly conformed surface protein. In case 
hemagglutinating activity is lost, the use of stabilizing excipients may be needed. The 
addition of certain excipient sugars and salts as cryoprotectants during the freeze-drying 
process has also been shown to stabilize nanoparticles by forming an amorphous glass 
surrounding the particles, disrupting ice crystal formation [5]. A recent study of an 
excipient screen for influenza subunit vaccine formulation into a microneedle patch 
established an arginine/calcium heptagluconate buffer system to be optimal for preserving 
hemagglutinin structure and hemagglutinating activity for 6 months [9]. Although the 
microneedles tested were air-dried instead of lyophilized, lyophilization is hypothesized to 
be a gentler process on proteins, due to the instantaneous immobilization of proteins during 
 103 
flash freezing and the damaging effects of increasing ion concentration in an evaporating 
liquid [10]. 
We hypothesize that our crosslinked protein nanoparticles stored at room 
temperature and at 37°C will immunize mice equally well as nanoparticles made from fresh 
protein. We will use trimerized hemagglutinin (3HA) nanoparticles, described earlier in 
Chapter 2, for these stability experiments due to an easy in vitro readout of protein structure 
preservation. The hemagglutination assay is a simple in vitro test for the preservation of 
the biological activity of hemagglutinin, and will be used to test whether extended warm 
temperature storage results in activity loss. 
4.2 Materials and Methods 
4.2.1 Nanoparticle Synthesis and Characterization 
3HA nanoparticles were synthesized and characterized as described in Chapter 2 
[11]. Briefly, ethanol was added to a 1.6 mg/mL 3HA solution at a rate of 1 mL/min under 
constant stirring at 600 rpm in a 400 μL +100 μL volume ratio of ethanol to protein 
solution. The particles were collected by centrifugation, and resuspended in sterile PBS 
with sonication. 800 μg soluble 3HA protein was added at a final concentration of 1.6 
mg/mL to 480 µg desolvated 3HA nanoclusters and an amine crosslinking reaction was 
performed using 3 mM 3,3´-Dithiobis[sulfosuccinimidylpropionate (DTSSP, Thermo 
Scientific, Waltham, MA ) for 12 hours while stirring to coat the nanoparticles. Coated 
nanoclusters were collected by centrifugation, and protein concentration was measured by 
a BCA assay according to the manufacturer’s instructions (Thermo Scientific) to estimate 
the total protein content in nanoparticles. Dynamic light scattering (DLS) was performed 
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in PBS with a Malvern Zetasizer Nano ZS (Malvern Instruments, Westborough, MA) to 
assess nanoparticle size distributions. 
Hemagglutinating capability of 3HA nanoparticles was tested as previously 
described in Chapter 2 and elsewhere [11]. Briefly, 5 μg of 3HA protein or 3HA protein 
nanoparticles in 100 μL of phosphate-buffered saline was serially diluted by half across 11 
wells of a 96-well plate. 50 μL of 0.5% turkey RBCs were then added to each well, and 
incubated at room temperature for 1 hour. The hemagglutination titer was read as the last 
well in the serial dilution that did not form a red button of settled RBCs. 
4.2.2 Lyophilization and Extended Storage 
Extended wet storage of 3HA nanoparticles was performed in PBS at room 
temperature or 37°C. Nanoparticles and soluble protein were diluted to 200 μg/mL in six 
100 μL aliquots in 2 mL centrifuge tubes. The tubes were sealed with parafilm and 
incubated for up to 1 month at 37°C, and up to 3 months at room temperature. At each time 
point, one 100 μL aliquot was used to measure hemagglutination activity of the 
nanoparticles, while two 300 μL aliquots were stored at room temperature for in vivo 
immunizations. 
For lyophilization, solutions of 3HA nanoparticles were resuspended in either 
arginine/heptagluconate or ammonium acetate excipient buffer solutions. Nanoparticles 
were centrifuged and resuspended to a concentration of 50 μg/mL in 15% w/v 
arginine/heptagluconate buffer solution. The arginine/heptagluconate solution was made 
by adding 3.75 g of arginine and calcium heptagluconate (Sigma) each to 50 mL of 
deionized water, and adjusting the solution pH to 7.3. For ammonium acetate storage, 
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nanoparticles were resuspended to a concentration of 200 μg/mL in 150 mM ammonium 
acetate. Following buffer exchange, solutions of nanoparticles were flash frozen in liquid 
nitrogen. Frozen nanoparticle solutions were then exposed to 40 mTorr vacuum overnight 
in a freeze dryer (Millrock Technologies, Kingston, NY). Reconstitution of nanoparticles 
was performed by adding an identical volume of milliQ-purified water to lyophilized 
nanoparticles immediately after lyophilization.   
4.2.3 Immunization and Sample Collection 
All animal work was done in accordance with the IACUC guidelines of Georgia 
State University, under IACUC approval number A16024. Female, 6 week old Balb/c mice 
(Charles River, Wilmington, MA) were intra-muscularly immunized with 10 µg aged 3HA 
nanoparticles, 20 µg aged 3HA nanoparticles, 10 μg freshly prepared 3HA nanoparticles, 
10 μg soluble 3HA protein, or PBS as a control. Five mice per group were immunized 
twice i.m. at a 3-week interval. To compare antibody responses, sera were collected 2 
weeks after each immunization by submandibular venipuncture. 
4.2.4 Serum IgG Titer  
Serum IgG titer was assessed as previously described [11, 12]. Briefly, ELISA plates 
were coated with 1 μg/mL 3HA protein in PBS and incubated overnight. Plates were 
blocked with 1% bovine serum albumin (BSA) in PBS for 1 hour. Mouse serum samples 
were initially diluted 1:100 in 1% BSA, and serial half-dilutions were made in 1% BSA 
across the 96-well ELISA plate. Serum sample dilutions were incubated for 1 hour, and 1 
μg/mL HRP-conjugated goat-anti-mouse IgG (Life Technologies, Grand Island, NY) in 
1% BSA was used as a detection antibody. Chromogenic quantification was performed by 
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the oxidation of tetramethylbenzidine by hydrogen peroxide (R&D Systems, Minneapolis, 
MN) according to the manufacturer’s instructions. Two times the absorbance of naïve 
group’s serum samples was considered the cutoff for measuring the endpoint titer. 
4.2.5 Hemagglutination Inhibition Assessment 
Serum hemagglutination inhibition (HAI) activity was assessed according to a 
protocol adapted from the World Health Organization [13]. 10 μL mouse serum was 
incubated with 30 μL of receptor-destroying enzyme (RDE) (Denka Seiken Co, Tokyo, 
Japan) at 37°C overnight, followed by 56°C incubation for 30 minutes to inactivate non-
specific agglutinating proteins. Inactivated serum was diluted with 60 μL room temperature 
PBS, and centrifuged at 500xg for 8 minutes to collect treated serum samples. Eight, 25 μL 
serial half dilutions of 1:10 treated sera were mixed in a round-bottom 96-well plate with 
25 μL of 2 μg/mL 3HA protein and incubated at room temperature for 30 minutes. This 
concentration of 3HA was chosen based on the ability to agglutinate RBCs after 3 serial 
dilutions, as indicated in the WHO protocol. To this mixture, 50 μL of a 0.5% turkey RBC 
suspension (Lampire Biologicals, Pipersville, PA) was added, and the wells were incubated 
for 1 hour to develop. HAI titer was read as the inverse dilution of the last well able to 
prevent hemagglutination, or in which a red button was formed. 
4.2.6 Statistics 
IgG titers were assessed by the Kruskal-Wallis one-way analysis of variance for non-
parametric samples. Hemagglutination inhibition titers were analysed by comparing the 
number of wells neutralized to the standard HAI titer of 40 (2 wells) established by the 
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WHO as protective, using a one-sample t test. P values less than 0.05 were considered 
significant. 
4.3 Results 
4.3.1 Lyophilization Results in Hemagglutination Losses 
The agglutination activity of freeze-dried 3HA nanoparticles with arginine and 
calcium heptagluconate as excipients is summarized in Table 4. Nanoparticles in PBS lost 
significant hemagglutinating activity upon lyophilization and reconstitution. The 
arginine/heptagluconate buffer alone caused a diffuse red well color characteristic of 
hemagglutination. This was most likely due to the high salt concentration of the buffer 
leading to hemolysis, confounding the results of the lyophilization experiment. Since 
further buffer exchange or processing could lead to nanoparticle losses that would also 
decrease the hemagglutinating activity, a volatile excipient buffer that would sublimate 




Table 4. Hemagglutination activity of lyophilized and reconstituted 3HA 
nanoparticles. The number of wells agglutinated by lyophilized and reconstituted 
nanoparticles were identical across three independent replicates. 
Sample # of Wells Agglutinated 
Unlyophilized Nanoparticles 9 
Nanoparticles lyophilized in PBS 5 
Nanoparticles lyophilized in Arginine/Heptagluconate 9 
Arginine/Heptagluconate buffer control 9 
Table 5. Hemagglutination activity of lyophilized and reconstituted 3HA 
nanoparticles. The number of wells agglutinated by the nanoparticles were identical 
across three independent replicates. 
Sample # of Wells Agglutinated 
Unlyophilized Nanoparticles 10 
Nanoparticles lyophilized in PBS 7 
Nanoparticles lyophilized in Ammonium Acetate 3 
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Ammonium acetate was shown to be a good excipient buffer for retaining 
hemagglutinating activity in an influenza subunit vaccine microneedle patch [9], and was 
used for lyophilization of 3HA nanoparticles. However, nanoparticles lyophilized in the 
volatile excipient buffer ammonium acetate lost even more activity upon reconstitution 
than nanoparticles lyophilized in PBS (Table 5). Nanoparticle size also increased after 






Figure 35. Average 3HA nanoparticle size after lyophilization and 
reconstitution as determined by DLS. Error bars are representative of 
the standard deviation of nanoparticle size as determined by 
polydispersity. 
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4.3.2 Warm, Wet Storage of Nanoparticles Preserves Hemagglutinating Activity  
Liquid formulations of vaccines have several advantages over reconstituted, 
lyophilized vaccines, including avoiding dosing issues with incorrect reconstitution and 
potential sterility issues with reconstitution in the field [3]. Nanoparticles stored at 800 
μg/mL in PBS at 4°C, room temperature, or 37°C did not lose agglutinating activity after 
1 week, but did lose it after one month (Figure 36). 
 
Figure 36. Hemagglutinating activity of nanoparticles stored at 800 μg/mL in PBS at 
various temperatures for 1 month. Each data point represents the hemagglutinating 
activity of 1 sample tested. 
  Nanoparticles diluted to 200 μg/mL in PBS in parafilm-sealed 2 mL centrifuge 
tubes were stored for approximately 3 months. Nanoparticles stored in PBS at room 
temperature did not lose agglutinating activity after 112 days, while nanoparticles stored 
at 37°C retained full hemagglutinating activity for 2 weeks, and lost activity at 1 month 
(Figure 37). Soluble 3HA in PBS stored at room temperature lost no hemagglutinating 

































4.3.3 Stored and Fresh Nanoparticles Induce Similar Serum IgG Titers 
To compensate for any potential loss in hemagglutinating activity, we immunized 
mice with a single dose (10 μg) or double dose (20 μg) of nanoparticles stored for 112 days 
in PBS at room temperature. As controls, mice were immunized with 10 μg freshly-
prepared nanoparticles or 10 μg soluble 3HA protein. Serum samples were collected 2 
weeks after priming and boosting immunizations and were assessed for anti-3HA IgG 
titers. No significant differences in IgG titer were observed between the nanoparticles 
stored at room temperature and freshly made nanoparticles. The double dose of aged 
nanoparticles induced significantly higher titers compared to soluble protein after the 
priming immunization, but that significance disappeared after the boost immunization 
(Figure 38).   
Figure 37. Hemagglutinating activity of 3HA nanoparticles or soluble 
3HA protein over the course of approximately 3 months. Each data 






4.3.4 Aged Nanoparticles Induce Neutralizing Antibody Responses 
Hemagglutination inhibition (HAI) titer is a measurement of the ability of serum 
antibodies to block hemagglutinin binding to sialic acid residues. This measurement is 
directly correlated to the ability of an animal’s antibodies to block influenza viruses from 
infecting host cells, and is a means of measuring neutralizing antibody production. The 
World Health Organization has defined a serum HAI titer of 40 or above to provide good 
protection against influenza infection [14]. Groups immunized with 10 μg stored and fresh 
nanoparticles had significantly higher HAI titers than 40, while groups immunized with 
soluble protein or PBS did not have significantly higher titers than 40 (Figure 39). While 
the average titer of the 20 μg nanoparticle immunized group did not reach statistical 
significance (p = 0.057), this could be attributed to the low serum sample number in that 
group. 
Figure 38. Serum IgG titers from mice 2 weeks after a priming immunization  (left) 
or a boost immunization (right) of 10 μg room temperature-stored 3HA nanoparticles 
(Aged 1x), 20 μg room temperature-stored 3HA nanoparticles, 10 μg freshly prepared 
3HA nanoparticles (fresh) or 10 μg soluble 3HA (soluble). Each point is the IgG titer 











While 3HA nanoparticles were not stable to lyophilization with or without an 
ammonium acetate excipient, they could be stored in PBS at room temperature for an 
extended period of time, making lyophilization and excipients unnecessary. Structural 
losses upon lyophilization and subsequent reconstitution could have been due to 
nanoparticle-nanoparticle interactions with each other, as the volatile excipient performed 
even worse than PBS at preserving hemagglutination and nanoparticle size. Future studies 
of lyoprotective excipients for protein nanoparticles should examine sugars and polymers 
that form stabilizing interactions with proteins, and the use of ELISA instead of 
hemagglutination could provide a more quantitative and solute-independent readout of 
protein structure preservation.  
Figure 39. Log of hemagglutination inhibition titer from mice post-boost 
immunization. Dotted line represents an HAI titer of 40, defined by the WHO to 
provide protective antibody responses. * represents significantly different average 
titers from a titer of 40. Each data point represents a serum titer from one mouse. 
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Nanoparticles were stored at room temperature for 112 days in PBS with no loss in 
hemagglutinating activity. According to a report by UNICEF and the WHO, approximately 
1 month of cold chain is needed for transport of vaccines from a manufacturer in the 
developed world to a developing region [15]. Storage of protein nanoparticles for almost 3 
times this length without additional excipients is especially promising, given that viral and 
subunit vaccine storage typically requires the addition of polyethylene glycol or sucrose to 
achieve weeks-long cold chain-independent storage [16, 17].   
Nanoparticles stored at 37°C in PBS were able to retain hemagglutinating activity 
for 2 weeks, but started to lose activity at 1 month. Although we did not immunize mice 
with nanoparticles stored at 37°C, we hypothesize that a similarly high antibody titer would 
be achieved based on the correlation between in vitro vaccine hemagglutinating activity 
and in vivo immunization efficacy [18]. Two weeks of elevated temperature storage is more 
than enough time to reach rural health clinics from a distribution center [15], but may not 
be enough time to store the vaccine there for a prolonged period of time. Surprisingly, 
soluble 3HA was also able to retain hemagglutinating activity for 56 days. This could be 
due to the inherent stability of this particular protein, and of recombinant subunit antigens 
generally [3].  
The concentration dependence of hemagglutination loss observed suggests that a 
major factor in 3HA protein structural loss is nanoparticle-nanoparticle collisions. The 
observation that nanoparticle size increases after lyophilization and reconstitution would 
also correlate nanoparticle size increases with a loss in hemagglutination. Excipients to 
increase stability, wet or lyophilized, should therefore focus on compounds that can bind 
the 3HA proteins, and shield the nanoparticles from harmful interactions with one another. 
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Tanaka et al. found that saccharides in sufficient concentration to form a monolayer over 
proteins stabilized them to lyophilization, and that direct interaction of the protein and the 
sugar was responsible for the stabilizing effect [19]. Disaccharides such as trehalose (and 
less commonly sucrose) have been found to be the most effective lyoprotectants [19, 20]. 
Though these compounds are generally used to protect soluble proteins against 
denaturation during lyophilization, their mechanism of action suggests that they could 
protect protein nanoparticles in wet storage as well. 
Hemagglutination inhibition data showed that our room temperature-stored 
nanoparticles were just as effective at inducing neutralizing antibodies as freshly made 
nanoparticles. The WHO benchmark HAI titer of 40 allows us to compare our vaccine to 
an accepted standard of immunity, and our data suggests that our nanoparticles stored at 
room temperature can confer protective immunity. Given the ability of freshly-made 3HA 
nanoparticles to protect mice against a 10xLD50 challenge of H7N9 influenza [11], 
challenge studies should examine whether nanoparticles stored at warm temperatures can 
also confer protective immunity. 
The ability of 3HA nanoparticles to induce better HAI titers than soluble 3HA 
concurs with current nanoparticle vaccine literature theorizing that multivalent epitope 
presentation is a mechanism of recombinant antigen nanovaccine adjuvancy [3, 21, 22]. 
Our previous results in Chapter 3 demonstrating enhanced dendritic cell TNF-α and IL-1β 
responses to OVA-coated OVA protein nanoparticles also support this hypothesis. Though 
the hemagglutination assay only works for hemagglutinin and a few other pathogen 
antigens, the growing consensus on the importance of surface protein conformation 
suggests that it should be used as a preliminary measure of nanovaccine stability for all 
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types of antigen-displaying nanoparticle vaccines. Other in vitro readouts of protein 
conformation, such as some ELISAs, should be used as a preliminary assessment of the 
stability of non-hemagglutinating types of vaccine nanoparticles. Analogous to the HAI 
assay, competitive inhibition of ELISA coating antigen by anti-sera can also be used as a 
quantitative measure of neutralizing antibody formation.  
4.5 Conclusion 
In this chapter, we have shown that 3HA nanoparticles can be stored for up to 112 
days at room temperature with no loss in in vitro hemagglutinating activity or in vivo 
antibody and neutralizing antibody responses. This exceeds the estimate by the WHO and 
the United Nations Children’s Fund (UNICEF) of the time needed for cold chain-
dependent transport of a vaccine from a vaccine manufacturer in the developed world to a 
developing region off of the grid [15]. The fact that 3HA nanoparticles can remain 
immunogenic outside of cold-chain storage for more than three times that duration of time 
is a promising sign that nanoparticle vaccines made from recombinant protein antigens can 
survive both transport to and storage in the developing world. The 37°C storage time of 2 
weeks is sufficient to reach a rural health center in the developing world, but not necessarily 
enough time to store the vaccine there. Although this timeframe is useful for short-term 
vaccination drives, achieving extended storage at 37°C beyond 2 weeks will be useful for 
reaching more people and distributing vaccines that require a prime and boost 
administration. 
The current model of inactivated pathogen vaccine distribution is ready for 
disruption. Cold-chain-dependent vaccine transport to the developing world relies on large 
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volumes to bring down costs, a tradeoff that can result in up to 50% of vaccine doses being 
wasted [23]. As logistics of vaccine transport and storage improve and better healthcare 
infrastructure improves access to vaccines, recombinant subunit antigen nanoparticle 
vaccines that can be stored independent of the cold chain can cut down on the amount of 
vaccines wasted, and play a substantial role in improving global health. 
REFERENCES 
 
[1] Immunization Coverage, World Health Organization, 2016, p. 
http://www.who.int/mediacentre/factsheets/fs378/en/. 
[2] M. Zaffran, J. Vandelaer, D. Kristensen, B. Melgaard, P. Yadav, K.O. Antwi-Agyei, H. 
Lasher, The imperative for stronger vaccine supply and logistics systems, Vaccine 31 
(2013) B73-B80. 
[3] O.S. Kumru, S.B. Joshi, D.E. Smith, C.R. Middaugh, T. Prusik, D.B. Volkin, Vaccine 
instability in the cold chain: Mechanisms, analysis and formulation strategies, Biologicals 
42(5) (2014) 237-259. 
[4] H.J. Choi, J.M. Song, B.J. Bondy, R.W. Compans, S.M. Kang, M.R. Prausnitz, Effect 
of Osmotic Pressure on the Stability of Whole Inactivated Influenza Vaccine for Coating 
on Microneedles, Plos One 10(7) (2015). 
[5] W. Abdelwahed, G. Degobert, S. Stainmesse, H. Fessi, Freeze-drying of nanoparticles: 
Formulation, process and storage considerations, Adv Drug Deliver Rev 58(15) (2006) 
1688-1713. 
[6] J. Rexroad, C.M. Wiethoff, L.S. Jones, C.R. Middaugh, Lyophilization and the 
Thermostability of Vaccines, Cell Preservation Technology 1(2) (2002) 91-104. 
[7] M.G. Anhorn, H.C. Mahler, K. Langer, Freeze drying of human serum albumin (HSA) 
nanoparticles with different excipients, Int J Pharmaceut 363(1-2) (2008) 162-169. 
[8] L.H. Estrada, S. Chu, J.A. Champion, Protein nanoparticles for intracellular delivery of 
therapeutic enzymes, J Pharm Sci-Us 103(6) (2014) 1863-71. 
[9] M.J. Mistilis, M.R. Bommarius As Fau - Prausnitz, M.R. Prausnitz, Development of a 
Thermostable Microneedle Patch for Influenza Vaccination. LID - 10.1002/jps.24283 
[doi], (1520-6017 (Electronic)). 
 118 
[10] M.J. Pikal, Mechanisms of Protein Stabilization During Freeze-Drying annd Storage: 
The relative Importance of thermodynamic stabilization and glassy state relaxation 
dynamics, Freeze-Drying/Lyophilization of Pharmaceutical and Biological Products, 
Marcel Dekker, New York, 1999, pp. 161-198. 
[11] L. Wang, T.Z. Chang, Y. He, J.R. Kim, S. Wang, T. Mohan, Z. Berman, S.M. 
Tompkins, R.A. Tripp, R.W. Compans, J.A. Champion, B.-Z. Wang, Coated protein 
nanoclusters from influenza H7N9 HA are highly immunogenic and induce robust 
protective immunity, Nanomedicine: Nanotechnology, Biology and Medicine 13(1) (2016) 
253-262. 
[12] L. Wang, A. Hess, T.Z. Chang, Y.C. Wang, J.A. Champion, R.W. Compans, B.Z. 
Wang, Nanoclusters self-assembled from conformation-stabilized influenza M2e as 
broadly cross-protective influenza vaccines, Nanomed-Nanotechnol 10(2) (2014) 473-482. 
[13] Serological detection of avian influenza A(H7N9) virus infections by modified horse 
red blood cells: Haemagglutination-Inhibition Assay. 2013 (accessed September 12, 
2016.2017). 
[14] L.B. Brydak, M. Machala, Humoral immune response to influenza vaccination in 
patients from high risk groups, Drugs 60(1) (2000) 35-53. 
[15] Vaccines: Handled with Care, United Nations Children's Fund (UNICEF) and the 
World Health Organization (WHO)  (2004). 
[16] M. Pelliccia, P. Andreozzi, J. Paulose, M. D'Alicarnasso, V. Cagno, M. Donalisio, A. 
Civra, R.M. Broeckel, N. Haese, P.J. Silva, R.P. Carney, V. Marjomaki, D.N. Streblow, D. 
Lembo, F. Stellacci, V. Vitelli, S. Krol, Additives for vaccine storage to improve thermal 
stability of adenoviruses from hours to months, Nat Commun 7 (2016) 7. 
[17] A. Flood, M. Estrada, D. McAdams, Y.H. Ji, D.X. Chen, Development of a Freeze-
Dried, Heat-Stable Influenza Subunit Vaccine Formulation, Plos One 11(11) (2016) 18. 
[18] P. Pushko, T.M. Tumpey, F. Bu, J. Knell, R. Robinson, G. Smith, Influenza virus-like 
particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce 
protective immune responses in BALB/c mice, Vaccine 23(50) (2005) 5751-5759. 
[19] K. Tanaka, T. Takeda, K. Miyajima, Cryoprotective Effect of Saccharides on 
Denaturation of Catalase by Freeze-Drying, Chem Pharm Bull 39(5) (1991) 1091-1094. 
[20] W. Wang, Lyophilization and development of solid protein pharmaceuticals, Int J 
Pharmaceut 203(1-2) (2000) 1-60. 
[21] M. Kanekiyo, C.J. Wei, H.M. Yassine, P.M. McTamney, J.C. Boyington, J.R.R. 
Whittle, S.S. Rao, W.P. Kong, L.S. Wang, G.J. Nabel, Self-assembling influenza 
nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies, Nature 499(7456) 
(2013) 102-+. 
 119 
[22] M.F. Bachmann, G.T. Jennings, Vaccine delivery: a matter of size, geometry, kinetics 
and molecular patterns, Nat Rev Immunol 10(11) (2010) 787-796. 
[23] U. WHO, World Bank, State of the World's Vaccines and Immunization, 3rd ed., 
World Health Organization, Geneva, 2009. 
 
 120 
CHAPTER 5. MOLECULAR ADJUVANTS FOR 
ENHANCING NANOPARTICLE-MEDIATED ADJUVANCY 
5.1 Introduction 
Particulate vaccine carriers can control release of soluble antigens to the immune 
system and protect them from degradation [1]. However, nanoparticles have been found to 
be more than just passive antigen depots, and certain types of particles exhibit their own 
immunostimulatory effects on antigen presenting cells. The exact nature of this 
nanoparticulate-mediated adjuvancy is unknown, and many fundamental studies have 
examined the immunological effects of nanoparticle properties such as size [2], surface 
charge [3], shape [4], and material [5]. Generalized vaccine particle design principles are 
difficult to elucidate from these studies, however, due to our incomplete understanding of 
immunology of vaccination, and specifically the type of immune response needed to 
successfully vaccinate against a particular pathogen [6].  
The molecular adjuvants are another class of immunostimulants. Pathogen-
associated molecular patterns (PAMPs) are macromolecules that interact with specific 
pattern recognition receptors (PRRs) on or inside antigen presenting cells [1, 7]. Receptors 
that bind bacterially-derived or virally-derived macromolecules are hypothesized to initiate 
adaptive immune responses geared toward those particular classes of pathogens [7, 8]. 
Toll-like receptors (TLRs) are a class of membrane-bound PRRs that have been extensively 
studied for vaccine adjuvant use [9-11]. However, safety concerns over administration of 
pathogen-derived compounds require thorough investigation [12]. Currently, several 
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pathogen-derived vaccine adjuvants are undergoing clinical trials, but only two have been 
approved for use in humans [13].  
Flagellin (FliC) is a TLR-5 ligand shown to greatly enhance responses to influenza 
vaccination [14, 15]. Given the strength of FliC as an adjuvant, vaccines have been 
proposed with genetic fusion of antigenic peptides with the FliC protein [11, 16], including 
in our work described in Chapter 2. Nanoparticle vaccines have also been decorated with 
FliC [17, 18]. At least 6 clinical trials have been completed with FliC-fusion proteins [19]. 
The propensity of certain FliC-fusion proteins to aggregate, even at 4°C, may decrease 
their efficacy [11], and the sequence-dependent nature of FliC-fusion protein stability 
reduces its attractiveness as a platform technology. Nanoparticles with a stable, native FliC 
coat, or with native FliC admixed can combine the immunostimulatory properties of FliC 
with those of antigen-containing nanoparticles. The optimal location of antigen and 
adjuvant in nanoparticle vaccine formulations is still under active research [9, 20], and 
recent findings suggest that flagellated bacteria in the gut assist in TLR-5-mediated 
adjuvancy to subcutaneously-administered influenza vaccines [14]. Using TLR ligands as 
adjuvants, however, poses the risk of safety issues [11] and immune responses against the 
adjuvant itself [21]. 
The use of host-derived proteins as vaccine adjuvants may be able to address some 
of the issues associated with pathogen-derived adjuvants. Antibodies, or immunoglobulins 
(Ig), coat pathogens during the immune response to an infection, and these proteins may 
be able to act as in situ adjuvants rendering nanoparticles more immunogenic in vivo. While 
antibodies immobilized by affinity interactions on the nanoparticles’ surface should remain 
bound, any soluble Ig in the formulation should be recognized as host protein and 
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consequently non-immunogenic, and would simply enter the host’s circulating repertoire 
of antibodies. Additionally, the current, widespread good manufacturing practice (GMP) 
production of humanized antibodies offers a pathway for large-scale production of 
immunoglobulin-based adjuvants.  
The idea of immunoglobulin-mediated adjuvancy has been explored through the 
use of antibody-bound antigen, or immune complexes, as vaccines [22-25]. IgG2a 
complexed with soluble OVA was able to enhance specific anti-OVA antibody 
concentrations and CD4+ T cell responses by over an order of magnitude in comparison to 
soluble OVA[26]. Although several sources state that immunoglobulins enhance responses 
against soluble antigen and suppress them when bound to particulates [27], this assertion 
was based on evidence of anti-Rh factor IgG suppressing immune responses against fetal 
erythrocytes in pregnant women[28]. Immunosuppressive responses against IgG-
opsonized nanoparticulates have not been definitively reported. Moreover, a study 
comparing the inflammatory properties of soluble and insoluble immune complexes from 
rheumatoid synovial fluid found that the larger, insoluble immune complexes were more 
immunostimulatory than the soluble ones [24], supporting the hypothesis that particle size 
and immunoglobulin opsonization may synergistically enhance immune responses. 
The protein corona that forms on nanoparticles in serum in vivo consists of many 
protein types, and biomaterial-serum protein interactions is an active area of research[29]. 
Engineering biomaterial surfaces to bind antibodies can enhance immunogenicity by 
targeting the antigen particles to macrophages and dendritic cells via Fc receptors on these 
antigen-presenting cell types[30]. Follicular dendritic cells in particular can bind to IgG 
and IgM immune complexes to present to B cells undergoing germinal center reactions, a 
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process that generates antibodies of higher affinity and of diverse effector functions [7, 31, 
32]. Furthermore, antibody-opsonized nano- and microparticles provide a unique platform 
for activating the complement system, an inflammatory extracellular signaling cascade 
designed to neutralize infection, trigger local inflammation, and assist in the adaptive 
immune response [7, 33-35].    
In Chapter 2, we found that flagellin need not be associated in a 1:1 ratio with 
antigen for triggering an effective immune response. In Chapters 2 and 3, we saw the 
importance of nanoparticle coating in enhancing in vitro and in vivo responses for 3HA 
and OVA nanoparticles, respectively. The work in this chapter combines the ideas of these 
previous chapters – using molecular adjuvant coatings on the surface of nanoparticle 
vaccines to further enhance their adjuvancy.  
Our studies here examine adjuvant nanoparticle coatings of pathogen-derived 
flagellin (FliC) and host-derived antibodies IgM, IgG1 and IgG2a. Immunoglobulin M is 
the first antibody isotype made by antibody-producing B cells, and is a stronger activator 
of the complement system than the more prevalent IgG [36]. It is possible that IgM 
enhances the adaptive immune response to the antigen to which it is bound. Given its lower 
affinity and different Fc structure than the more prevalent IgG, IgM likely serves an 
immunoregulatory function in addition to any neutralizing capabilities it may have. This 
idea is supported by findings that knockout mice unable to produce secreted IgM have 
delayed production of affinity-matured antibodies to an antigen challenge, and that delay 
can be eliminated by the co-immunization of antigen and non-specific IgM [37]. Though 
IgM has been proposed as a potential vaccine adjuvant due to its interactions with 
complement, B cells and T cells [38], and IgM has been shown to enhance responses to 
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soluble protein [39], to the best of our knowledge, IgM has not been tested as part of any 
subunit vaccine formulation yet [40]. 
IgG1 and IgG2a are the most and second-most common antibodies found in serum 
[41]. Many effector functions have been associated with IgG immune complexes, including 
enhanced T cells responses [26], both up- and down-regulated antibody responses [27] and 
enhanced dendritic cell cross-presentation of antigen [42]. This may be due in part to the 
various Fcγ receptors that can bind IgG; at least 6 have been found in mice, and 8 in humans 
[43]. Since all subtypes of IgG bind to the various Fcγ receptors with varying affinities, it 
is difficult to draw a correlation between stimulatory and inhibitory receptors and IgG 
isotype. IgG1 and IgG2a have been correlated, however, as characteristic outputs of TH2 
and TH1 immune responses, respectively [44]. In testing the IgG1 and IgG2a responses to 
IgG1- and IgG2a-coated nanoparticles, we assessed whether opsonized protein 
nanoparticles could participate in immunofeedback cycles to modulate the resulting 
antibody response. 
For these studies, the vaccine nanoparticle core consists of model ovalbumin OVA 
protein nanoparticles [10, 45]. The FliC/IgM studies comparing OVA, FliC- and IgM-
coated OVA nanoparticles examines (1) whether IgM could be used as a host-derived 
vaccine adjuvant, and (2) whether pathogen-derived adjuvants were more effective bound 
or unbound from antigen nanoparticles. The studies with IgG1 and IgG2a coated OVA 
nanoparticles (1) compare the adjuvant capabilities of IgG1 and IgG2a-coated 
nanoparticles, and (2) whether IgG1 and IgG2a on nanoparticles can influence the IgG1 
and IgG2a antibody responses. Overall, this immunization study profiled differences in 
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host- and pathogen-derived adjuvant responses, and examined the adjuvant capabilities of 
immunoglobulin-coated nanoparticles. 
 
5.2 Materials and Methods 
5.2.1 Materials 
Endotoxin-free EndoFitTM ovalbumin was dissolved in sterile phosphate-buffered 
saline (PBS) for all nanoparticle formulations administered in vivo. Ovalbumin and 
endotoxin-free ovalbumin were purchased from Invivogen (San Diego, CA). Antibodies 
were purchased from Thermo Fisher Scientific (Rockford, IL) unless stated otherwise. 
5.2.2 FliC Expression and Purification 
The plasmid pET22b-flic was used to express recombinant FliC from Salmonella 
typhimurium[46]. The plasmid was transformed into E. coli BL21 for expression. 
Transformed E. coli were grown in 1 L Luria Bertani (LB) broth with 100 μg/mL ampicillin 
from 10 mL overnight cultures. Expression was induced after approximately 2 hours 
(OD600 ≈ 0.6) with 0.25 mM isopropyl β-D-1-thiogalactopyranoside (IPTG). Recombinant 
FliC was expressed over 24 h and purified using native Ni-affinity purification according 
to the manufacturer’s instructions (Ni-NTA agarose, Qiagen, Valencia, CA). Protein 
concentration was assessed with a BCA assay according to the manufacturer’s instructions 
(Thermo Fisher Scientific), and purity was assessed by SDS-PAGE and Western Blot, 
stained using a 488-Conjugated Penta-His antibody (Qiagen, Valencia, CA), (Figure 40). 
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5.2.3 Nanoparticle Synthesis and Characterization 
270 nm OVA protein nanoparticle cores and OVA-coated OVA (OVA-OVA) cores 
were made as previously described[45]. Briefly, 0.4 mL pure ethanol was added at a 
constant rate to 0.1 mL of 6.2 mg/mL OVA in phosphate-buffered saline (PBS) under 
constant stirring at 600 rpm. The amine-reactive crosslinker 3,3’-
dithiobis[sulfosuccinimidylpropionate] (DTSSP) (ThermoFisher Scientific) was used to 
stabilize the resulting nanoparticles. The nanoparticles were crosslinked in 0.82 mM 
DTSSP while stirring at room temperature for one hour, followed by centrifugation to 
collect the particles and resuspension in PBS by sonication. 
OVA nanoparticle cores were coated with FliC by resuspension in 0.9 mg/mL FliC 
in PBS, and stirred at 600 rpm overnight at 4°C. Coated particles were collected by 
centrifugation, and resuspended in 5.26 μM DTSSP to stabilize the adsorbed coat. After 
stirring at 600 rpm for 1 hour at 4°C, the crosslinking reaction was quenched with 50 mM 
Tris base, and the particles were resuspended by sonication in PBS. A similar method was 
used to coat OVA cores in 6.2 mg/mL soluble OVA solution to make OVA-OVA 
nanoparticles. 
OVA nanoparticle cores were coated with IgM or IgG by affinity immobilization. 
100 μg of OVA nanoparticle cores were mixed with 17.5 μg of anti-OVA mouse IgM 
(Chondrex, Redmond, WA) in 0.1 mL PBS, and stirred at 4°C for 30 minutes. Binding was 
quenched by the addition of 24 μg soluble OVA, and the particles were collected by 
centrifugation and resuspended by sonication in PBS. Mouse anti-OVA IgG1 (Chondrex) 
or IgG2a (Chondrex and Biolegend) was used to coat OVA nanoparticle cores, OVA 
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nanoparticle cores made with 10% Alexa Fluor 488-conjugated OVA (Life Technologies, 
Grand Island, NY), or OVA-OVA cores in a similar manner with 19 μg antibody per 100 
μg nanoparticles. For OVA-OVA nanoparticles, antibody density was varied by coating 
with 19 μg, 5 μg, or 2 μg of IgG antibodies. 
To compare affinity- and non-specifically -bound IgG on the nanoparticles, IgG 
quenched with soluble OVA was used to make quenched IgG-OVA nanoparticles. Briefly, 
10 μL of 1μg/mL IgG in PBS was incubated with an equal volume of either 10 mg/mL 
OVA or BSA in PBS for 2 hours at 4°C. The antibodies were then used to coat OVA cores 
or OVA-OVA cores by the procedure described above. 
Nanoparticle size distribution and zeta potential were assessed by dynamic light 
scattering (DLS) and electrophoretic light scattering (ELS) respectively with a Malvern 
Zetasizer Nano ZS (Malvern Instruments, Westborough, MA). Nanoparticle concentration 
was assessed with a BCA assay according to the manufacturer’s instructions (Thermo 
Scientific). Nanoparticles were resuspended in water, air-dried, and sputter-coated with 
palladium prior to visualization with a Zeiss Ultra60 FE (Carl Zeiss Microscopy, 
Cambridge, UK) scanning electron microscope at 5.0 kV. 
5.2.4 Antibody Coating Characterization 
Antibody coating was confirmed by a modified ELISA procedure. Briefly, 0.2 
μg/mL nanoparticles in PBS were incubated on ELISA plates overnight at room 
temperature. Ig concentration was evaluated using a standard curve of serially-diluted 
soluble anti-OVA IgM, IgG1, or IgG2a antibodies. Samples were blocked with 1% bovine 
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serum albumin (BSA) in PBS, and probed with 1 μg/mL of an HRP-conjugated anti-mouse 
IgM, IgG1 or IgG2a antibody. 
Complement activation was assessed by the MicroVue CH50 enzyme 
immunoassay kit (Quidel, San Diego, CA). Human serum was obtained from two, healthy, 
consenting donors with the approval of Georgia Institute of Technology IRB #H16083. 
Approximately 20 mL of blood was collected from each donor, and allowed to clot for 30 
minutes at 4°C. Blood was then centrifuged at 2000xG for 10 minutes, and the serum 
decanted off into sterile centrifuge tubes. Serum was stored at 4°C for up to 2 weeks and 
at -80°C for extended storage. To activate complement, 15 μg of nanoparticles were added 
to 14 μL serum, and incubated for 1 hour at 37°C. Terminal complement complex (TCC) 
formation was assessed according to the kit manufacturer’s instructions. 
5.2.5 FliC Coating Characterization 
FliC activity was characterized by a TLR-5-dependent luciferase activation assay 
in vitro. Hela cells (ATCC, Manassas, VA) were grown in DMEM supplemented with 10% 
fetal bovine serum (FBS), and cultured in humidified 5% CO2 at 37°C. Cells were 
incubated overnight at a density of 2*106 cells/well in a 6-well plate, and transfected the 
following day with 10 μg pUNO1-hTLR5, 2 μg pGL4.32-[Luc2/Nf-κB/Hygro] (Invivogen, 
San Diego, CA) and 15 μL Lipofectamine 2000 (Invitrogen, Grand Island, NY) in DMEM 
with 1% FBS. Transfected cells were plated the following day at a density of 5*104 
cells/well in a 96-well plate in DMEM with 1% FBS. 1 μg/mL nanoparticles were 
suspended in fresh DMEM + 1% FBS and used to stimulate transfected cells for 8 hours. 
Bright-Glo Luciferase Assay reagent (Promega, Madison, WI) was diluted 1:1 with serum-
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free DMEM and used to assess luciferase activity according to the manufacturer’s 
instructions. 
5.2.6 Immunization 
All animal work was compliant with the NIH Guide for the Care and Use of 
Laboratory Animals and all protocols and procedures employed were reviewed and 
approved by the Emory University and Georgia State Institutional Animal Care and Use 
Committees. Seven-week old female Balb/c mice (Jackson Laboratory, Bar Harbor, ME) 
were given 50 μL intra-muscular (i.m.) injections into the right hind-leg of 0.2 mg/mL 
nanoparticle formulations as described in Tables 7 and 8. Injections were repeated 21 days 
after priming for a boost administration. 
5.2.7 Sample Collection 
Blood was collected from immunized mice by submandibular venipuncture two 
weeks after prime and boost immunizations. Blood was allowed to clot at 4°C for at least 
30 minutes, and was centrifuged at 2700xG for 5 minutes to collect serum. Serum samples 
were stored at -20°C for further analysis. 
Following euthanasia on day 39, splenocytes were prepared from mouse spleens. 
Briefly, spleens extracted from mice were homogenized manually with the plunger of a 1 
mL syringe and cells collected by centrifugation at 300xG for 5 minutes. Cells collected 
were resuspended in red blood cell lysis buffer (150 mM NH4Cl, 10 mM NH4HCO3, 1 mM 
Na2EDTA, pH 7.4) for 5 minutes at room temperature, quenched with RPMI 1640 media 
(ATCC, Manassas, VA) and centrifuged for 5 minutes at 2300xG. Splenocytes collected 
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were resuspended in RPMI 1640 at 4°C and counted by flow cytometry (BD Accuri c6, 
BD Biosciences, San Jose, CA). 
5.2.8 Serum Antibody Assessment 
OVA-specific IgG antibody titers were assessed by ELISA, as previously 
described[10]. Briefly, serial two-fold dilutions of serum were analyzed using a standard 
ELISA procedure, with 1 μg/mL OVA in PBS as the capture antigen, 1% bovine serum 
albumin (BSA) in PBS as the blocking solution, and 1 μg/mL HRP-anti-mouse IgG in 1% 
BSA solution as the detection antibody. Chromogenic quantification was assessed by the 
oxidation of tetramethylbenzidine by hydrogen peroxide (R&D Systems, Minneapolis, 
MN) according to the manufacturer’s instructions. Two times the absorbance of naïve 
group’s serum samples was the cutoff for measuring the endpoint titer. OVA-specific IgG1 
and IgG2a concentrations were also assessed by ELISA, using HRP-conjugated anti-mouse 
IgG1 and IgG2a, and monoclonal mouse IgG1- or IgG2a-anti-OVA to create a standard 
curve (Chondrex, Redmond, WA). 
5.2.9 Cytokine ELISpot 
Splenocytes were seeded at a density of 2.5*106 cells/mL on interferon γ (IFN-γ) 
and interleukin 4 (IL-4) 96-well ELISpot membranes (R&D Systems, Minneapolis, MN). 
Splenocytes were stimulated with or without 50 μg/mL endotoxin-free OVA, and 
incubated at 37°C in humidified air with 5% CO2 for 36 hours. ELISpot membranes were 
developed according to the manufacturer’s instructions. Wells were imaged using a 
dissection microscope (Olympus SZX16, Olympus Corporation, Tokyo, Japan), and spots 
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were counted using ImageQuant TL’s colony counting software (GE Healthcare, 
Pittsburgh, PA). 
5.2.10 Splenocyte Flow Cytometry 
Splenocytes were seeded at a density of 2.5*106 cells/mL on 96-well plates, and 
stimulated with or without 50 μg/mL endotoxin-free OVA, and incubated at 37°C in 
humidified air with 5% CO2 for 60 hours. Cells were incubated with 1% bovine serum 
albumin (BSA) in PBS overnight at 4°C, and blocked with TruStain FcX anti-CD16/CD32 
(Biolegend, San Diego, CA) at a concentration of 1 μg/106 cells for 1 hour on ice. Alexa-
Fluor 488-conjugated anti-CD44 and Alexa-Fluor 647-conjugated anti-CD62L (Biolegend, 
San Diego, CA) were added to each well at a final concentration of 1 μg/106 cells and 0.25 
μg/106 cells, respectively, and incubated on ice for 1 hour. Cells were collected by 
centrifugation, resuspended in PBS, and analyzed by flow cytometry.  
5.2.11 Affinity Maturation 
Affinity maturation of anti-OVA serum antibodies was measured using bio-layer 
interferometry with the ForteBio Octet RED96 system (Pall Corporation, Port Washington, 
NY). Streptavidin Dip-and-Read Biosensors were used to immobilize 50 μg/mL 
biotinylated-OVA (Axxora Life Sciences, San Diego, CA). OVA-loaded biosensors were 
incubated with serum samples diluted 1:50, 1:100, and 1:200 in PBS for 5 minutes, 
followed by a 5-minute incubation in PBS to measure kon and koff respectively. The 
resulting binding curves were analyzed using the Octet Data Analysis software package 
Version 9.0.0.4 to determine KD values.   
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5.2.12 BMDC Cell Culture 
Bone marrow-derived dendritic cells (BMDCs) were cultured from the femurs and 
tibias of 12-week old Balb/c mice [47]. Bone marrow progenitor cells were cultured in 
RPMI 1640 (ATCC, Manassas, VA) supplemented with 10% heat-inactivated FBS, 50 µM 
β-mercaptoethanol, 1% penicillin-streptomycin, 2mM sodium pyruvate, 1x non-essential 
amino acids (Thermo Scientific, Grand Island, NY), and 25 ng/mL each of IL-4 and GM-
CSF (Peprotech, Rocky Hill, NJ). Cells were matured for one week, and the media was 
changed on days 2, 4 and 6. On Day 7, cells were harvested by scraping and plated at a 
density of 2*104 cells/well in 96-well plates for experiments. 
5.2.13 BMDC Uptake of Nanoparticles 
BMDCs were incubated with IgG1- and IgG2a-coated OVA nanoparticles to 
examine nanoparticle uptake [47]. For uptake studies, BMDCs were pre-incubated with or 
without 2 μg/mL anti-CD16/32 TruStain FcX Fc blocker (Biolegend) for 15 minutes at 
room temperature, and were then incubated with 20 μg/mL fluorescent IgG1- and IgG2a-
coated OVA nanoparticles for 3 hours at 37°C. Cells were scraped from the wells, collected 
by centrifugation, and resuspended in chilled trypan blue to quench external fluorescence. 
Cells counts and fluorescence was recorded by flow cytometry (BD Accuri). 
5.2.14 TNF-α Secretion and CD86 Upregulation 
BMDCs were incubated with 20 μg/mL of high, medium, and low density IgG-
coated OVA-OVA nanoparticles for 24 hours at 37°C. Supernatants were collected and 
assayed for TNF-α by ELISA according to the manufacturer’s instructions (R&D Systems). 
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Cells were collected by scraping, and resuspended in 1% BSA in PBS at 4°C overnight to 
block non-specific blocking. Cells were incubated with 1 μg/mL anti-CD16/32 TruStain 
FcX (Biolegend) for 1 hour on ice, and stained with 1 μg/mL Alexa Fluor 647-conjugated 
anti-CD86 (clone GL-1, Biolegend) for 1 hour. Cells were collected by centrifugation, 
resuspended in PBS, and analyzed by flow cytometry (BD Accuri). 
5.2.15 Statistical Analysis 
Serum antibody titers were analyzed using the Mann-Whitney U test. Antibody 
concentrations and T cell counts were analyzed using one-way ANOVA followed by 
Sidak’s multiple comparisons test. Comparisons between two groups were performed 
using Student’s t test, while comparisons between multiple groups was performed by one-
way ANOVA followed by Sidak’s multiple comparisons test. All statistical analyses were 
conducted using GraphPad Prism 6 (GraphPad, La Jolla, CA). P values of p < 0.05 were 
considered statistically significant (* = p < 0.05, ** = p < 0.01). To test our hypotheses for 
the IgM and FliC studies, statistical comparisons were assessed between G1 and G3, 
between G2 and G4, and for T cell counts, between G6 and all other groups. Comparisons 
between these groups that were significant are noted in the figures, while comparisons that 




5.3.1 Flagellin Expression and Purification 
Recombinant flagellin was expressed in E. coli BL21 and purified by Ni-NTA affinity 
chromatography. An SDS-PAGE gel shows a single band in the elution indicating purity, 
and a western blot indicates the 55 kDa band is the flagellin. 
 
Figure 40. SDS-PAGE (left) and Western blot (right) run after Ni-affinity purification 
of recombinant FliC. CL = Cleared lysate, FT = Flow-through post-Ni-NTA loading, 
W = Wash, E = Elution. 
5.3.2 Coated Nanoparticle Synthesis and Characterization  
Monodisperse, 270 nm OVA nanoparticle cores and OVA-coated OVA 
nanoparticles (OVA-OVA nanoparticles) were made as previously described in Chapter 3 
[45]. Coating the nanoparticles did not significantly alter nanoparticle size (Table 6). IgM-
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coating of the nanoparticles without a soluble OVA quenching step resulted in large, 1000 
nm particles, suggesting IgM crosslinking of multiple nanoparticles (Figure 41). Coating 
of FliC and Ig on OVA nanoparticles was assessed by FliC supernatant depletion and by 
anti-Ig ELISA, respectively. Coverage was reported as an approximate mass adjuvant per 
mass OVA. SEM images of nanoparticles were consistent with post-processing shrinkage 
of nanoparticles in comparison to DLS sizes (Figure 42) [47]. 
 
Table 6. Physical characterization data of the different nanoparticles synthesized.  
1A Size (nm) Zeta Potential 
(mV) 
Other Info 
OVA-OVA NPs 270 ± 88 nm -14.4 ± 1.5 Core Yield: 92% 
OVA-FliC NPs 255 ± 92 nm -10.7 ± 0.8  Coating Coverage: 15% mass 
FliC/mass OVA 
OVA-IgM NPs 265 ± 119 nm -12.0 ± 0.7 Coating Coverage: 0.5% mass 
IgM/mass OVA 
OVA-IgG1 NPs 232 ± 95 nm -11.0 ±0.95 Coverage: 55% mass 
IgG1/mass OVA 











Figure 41. Preliminary coating of OVA nanoparticles (green) with anti-OVA IgM 
resulted in the formation of microparticles (red), suggesting crosslinking of OVA 
nanoparticles by the pentameric IgM. Quenching the coating process by addition of 
soluble OVA following IgM resulted in no change in nanoparticle size (blue). 
Figure 42. Representative scanning electron micrograph of OVA-coated-OVA 
nanoparticles. Outer scale bar, 200 nm. Inset scale bar, 30 nm. 
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5.3.3 Coat Activity 
Coat activity was confirmed by testing FliC and Ig functionality. Since FliC is a 
TLR-5 agonist, FliC-coated nanoparticles were used to activate a TLR-5-dependent 
luciferase assay. FliC-coated OVA nanoparticles activated TLR-5 signaling, and did not 
significantly differ in activity compared to soluble FliC admixed with OVA nanoparticles 
(Figure 43). IgM’s ability to activate complement was assessed by incubating IgM-coated 
nanoparticles with human serum and using ELISA to detect activated complement [34]. 
Uncoated OVA nanoparticles were found to activate complement, and the IgM coating on 
these particles did not significantly enhance complement activation (Figure 44A). IgG1 




































Figure 43. OVA-FliC nanoparticles and OVA-OVA nanoparticles with soluble FliC 
(sFliC) admixed demonstrated similar levels of TLR-5-dependent NFκB activation in 
Hela cells as compared to OVA-OVA nanoparticles. Each bar is an average of two 
technical replicates (n = 2). 
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Figure 44. Complement activation as determined by anti-TCC ELISA after mixing 
nanoparticles with human serum. IgM-coated OVA nanoparticles, IgG1 coated, and 
uncoated OVA nanoparticles demonstrated similar levels of complement activation. 





















































Figure 45. Fluorescent uptake of IgG-coated nanoparticles. (A) Uncoated OVA 
nanoparticles compared to IgG-coated OVA nanoparticles, (B) IgG1-coated OVA 
nanoparticles in the presence/absence of Fc blockers,(C) IgG2a-coated OVA 






























5.3.4 IgG-coated OVA Nanoparticle Uptake 
IgG-coated nanoparticles were taken up by BMDCs to a lesser extent than uncoated 
OVA nanoparticles (Figure 45A). Furthermore, uptake of these nanoparticles was reduced 
in the presence of an FcγR-blocking antibody, indicating an FcγR-mediated uptake 
pathway was being utilized by the IgG-coated OVA nanoparticles (Figure 45B, C). 
5.3.5 TNF-α Secretion to IgG-Coated OVA Nanoparticles 
TNF-α secretion by BMDCs after 24 hours of IgG-coated OVA nanoparticle 
stimulation was assessed. IgG1-coated nanoparticles induced significantly higher TNF-α 
responses than uncoated OVA nanoparticles, while IgG2a-coated nanoparticles did not 
(Figure 46). IgG1 immune complexes (IgG1-IC) induced significantly less TNF-α than 
IgG1-coated nanoparticles did. IgG2a ICs and IgG2a-coated nanoparticles were not 
statistically different. 
5.3.6 CD86 Upregulation in Response to IgG-Coated OVA Nanoparticles 
BMDC upregulation of CD86 after 24 hours of stimulation was also measured. All 
types of nanoparticles, uncoated and IgG coated, triggered an approximately 5-fold 
increase in the population of CD86+ cells (Figure 47). 
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Figure 46. TNF-α secretion by BMDCs after 24 hours of stimulation by IgG1- or 
IgG2a-coated OVA nanoparticles. IgG1 and IgG2a complexed with soluble antigen 




5.3.7 Antibody Production 
Anti-OVA serum IgG titers were assessed two weeks after priming and boosting 
(Table 7, Table 8). Following the priming immunization, OVA-IgM nanoparticles (Figure 
48, G3) induced non-zero responses in all mice, and induced significantly greater responses 
than OVA-coated OVA nanoparticles (Figure 48, G1, left). Following a boost 
immunization of the same formulations, the IgG titers were not significantly different 
among the groups (Figure 48, right). No significant differences in titer were observed 
Figure 47. CD86 upregulation in response to BMDC stimulation with OVA core 
nanoparticles or IgG-coated OVA nanoparticles. Color-coded numbers in the top 
right of each graph indicate the percentage of the population above the red threshold. 
Each trace consists of 10,000 cells measured. 
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between OVA-FliC nanoparticles (G2) and OVA nanoparticles admixed with soluble FliC 
(G4). All groups in the IgG study triggered non-zero antibody responses after the first 
immunization. No groups had significantly different titers from each other after the prime 




Table 7. Immunization groups and sample collection schedule for the FliC and 
IgM study. Each group had 5 mice. 
Table 8. Immunization groups and sample collection schedule for the IgG study. 
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Figure 48. Anti-OVA IgG titers were assessed two weeks after priming (left) and 
boosting (right) immunizations. Group numbers on the x-axis correspond to the 
groups in Table 7. Each data point is the average titer of two technical replicates, and 
titers were assessed for each of the 5 mice per group. (* = p < 0.05) 
FliC/IgM Study Serum Antibody Titers 
Figure 49. Anti-OVA IgG titers were assessed two weeks after priming (left) and 
boosting (right) immunizations. Group numbers on the x-axis correspond to the 
groups in Table 8. Each data point is the average titer of two technical replicates, and 
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5.3.8 Serum IgG Subtype Responses 
Anti-OVA IgG subtype concentrations were also assessed after priming and 
boosting. OVA-IgM nanoparticles induced significantly higher levels of IgG1 than OVA-
OVA nanoparticles did after both priming and boosting (Figure 50A, B, G3). Appreciable 
IgG2a responses only appeared after the boost immunization in all adjuvanted nanoparticle 
groups (Figure 50C, D). No significant differences were observed between OVA-FliC 










Figure 50. Anti-OVA serum antibody concentrations of IgG1 and IgG2a, as assessed 
by ELISA from the FliC/IgM study. Each point represents the average concentration 
as determined by two technical replicates. (* = p < 0.05) 
FliC/IgM Study Serum Antibody Subtypes 
Post-Prime Post-Boost 
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IgG subtype differences were also characterized in response to IgG nanoparticles. 
No significant differences were observed in IgG1 production after a prime or boost 
administration of IgG-coated nanoparticles (Figure 51A, B). While IgG2a responses post-
prime were minimal (Figure 51C), IgG2a responses post-boost were significantly reduced 
in response to co-administered Ig1-coated and IgG2a-coated nanoparticles, as compared to 
uncoated and IgG2a-coated nanoparticles (Figure 51D). Uncoated OVA nanoparticles also 
induced significantly greater IgG2a responses post-boost than IgG1 nanoparticles did.  
 
  
IgG1/IgG2a Study Serum Antibody Subtypes 
Figure 51. Anti-OVA serum antibody concentrations of IgG1 and IgG2a, as assessed 
by ELISA from the IgG study. Each point represents the average OD450 as 
determined by two technical replicates. 
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5.3.9 T Cell Cytokines 
ELISpot was used to examine the ability of OVA-stimulated splenocytes from 
immunized mice in the FliC/IgM study to produce IFN-γ and IL-4. Both OVA-IgM (Figure 
52, G3) and OVA-FliC + OVA-IgM (G5) immunized mice produced significant amounts 
of IFN-γ-secreting splenocytes. OVA+sFliC (G4) and OVA-FliC + OVA-IgM (G5) 
immunized mice produced significant amounts of IL-4 (Figure 52, right). 
 
 
5.3.10 Memory T Cell Expansion 
OVA-stimulated and unstimulated splenocytes were stained for CD44 and CD62L 
and assessed by flow cytometry to profile memory T cell activation. CD44+/CD62L+ 
double-positive T cells are indicative of central memory T cells, while CD44+/CD62L- 
single-positive cells are indicative of effector memory phenotypes[48]. Normalizing the 
number of stimulated, positive cells by the number of unstimulated, positive cells allowed 





























































































































































Figure 52. IFN-γ (left) and IL-4 (right) -secreting T-cell counts in 2.5*105 splenocytes 
post-stimulation with 50 μg/mL OVA. Each data point is an average of two technical 
replicate counts. (* = p < 0.05) 
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nanoparticles (Figure 54, left, G3) induced a significant upregulation of central memory T 
cells, and no particle types induced appreciable upregulation of effector memory T cells 
(Figure 54, right). None of the nanoparticle types induced significant upregulation of either 





Figure 54. Memory T cell expansion from the FliC/IgM study. Fold change of 
CD44+/CD62L+ (left) and CD44+/CD62L- (right) splenocytes after stimulation with 50 
μg/mL OVA. Each data point is the ratio of the average number of positive cells in a 
stimulated vs an unstimulated sample of splenocytes. Each average was derived from 
two technical replicate samples of 10,000 cells each. Example gating is shown in 
(Figure 55). (* = p < 0.05 in comparison to G6)   
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Figure 53. Memory T cell expansion from the IgG study. Fold change of 
CD44+/CD62L+ (left) and CD44+/CD62L- (right) splenocytes after stimulation with 50 
μg/mL OVA. Each data point is the ratio of the average number of positive cells in a 
stimulated vs an unstimulated sample of splenocytes. Each average was derived from 
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Splenocytes from PBS control mice(G6) Splenocytes from IgM-NP-immunized 
mice 
Figure 55. Example gating used on splenocytes from immunized mice. Numbers of 
cells considered double-positive in calculations for Figure 54 and Figure 53 were 
counted from the upper right quadrant of all samples. 
5.3.11 Affinity Maturation 
Anti-OVA antibody affinity in sera from the FliC/IgM study was measured with 
the Octet RED system. Average log(KD) values for post-prime and post-boost sera were 
compared to test for affinity maturation. Significant affinity maturation was found in mice 
immunized with OVA-OVA nanoparticles (Figure 56, G1) and OVA-FliC (G2) 
nanoparticles (p < 0.01) but not in mice immunized with OVA-IgM nanoparticles (G3), 



















Figure 56. Affinity maturation as assessed by bio-layer interferometry. Each point 
consists of a KD value derived from a single association-dissociation run on the Octet 
RED96. Each column contains KD values obtained from sera from a particular group 
post-prime (G#P) or post-boost (G#B). Replication was assessed over 3 dilutions of 4 
different serum samples (n = 12). Group 5 was assessed at only two dilutions of two 
serum samples (n = 4). 
5.3.12  Varying IgG Density on OVA-OVA Nanoparticles 
The low density of IgG2a coated on OVA nanoparticles in comparison to IgG1 
(Table 6) motivated us to examine coating OVA-OVA nanoparticles as a way of increasing 
antibody density, instead of “bare” desolvated OVA nanoparticles. An additional layer of 
OVA on the nanoparticles’ surface increases epitope availability as determined by 
polyclonal antibody binding (Figure 16, right), and should therefore enhance monoclonal 
antibody binding as well. We also looked at coating different amounts of IgG on OVA-
OVA nanoparticles to test whether IgG density had an effect on BMDC activation. Coating 
with 19 μg and 5 μg of antibody revealed no significant difference in surface IgG, but 















































All OVA-OVA nanoparticles had less IgG on the surface than uncoated OVA cores 
did (Figure 57). Despite this, all forms of IgG-coated OVA-OVA nanoparticles were able 
to induce strong TNF-α responses in BMDCs (Figure 58). In particular, IgG2a-coated 
OVA-OVA particles of all coating densities triggered significantly stronger IgG responses 


















































































Figure 57. IgG density on OVA-OVA nanoparticles was measured by ELISA. Error 
bars represent the standard deviation of three technical replicates (* = p < 0.05). IgG 








5.3.13 IgG Adsorption versus Binding 
To test whether OVA nanoparticles were non-specifically adsorbing IgG, antibodies 
were pre-incubated with soluble OVA first, then used to coat nanoparticles. With the Fab 
region of the antibodies blocked by soluble OVA, no antibodies should bind specifically, 
and any antibodies on the nanoparticle surface must be non-specifically adsorbed. At the 
same time, unquenched IgG is able to bind nanoparticles with its Fab region, and any 
difference in binding between unquenched and quenched IgG must be due to affinity-
bound antibody. On both uncoated and coated OVA nanoparticles, non-specific IgG 
binding constituted a large portion of the antibodies on our nanoparticles (Figure 59). 
However, on OVA-OVA nanoparticles, we saw significant differences in antibody binding 
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Figure 58. IgG1 and IgG2a coated at high, medium and low densities on OVA-OVA 
nanoparticles were used to stimulate BMDCs, and TNF-α was assessed by ELISA. 
Error bars represent the standard deviataion of 4 technical replicates. (* = p < 0.05)  
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bound antibody were obtained on the surface of coated OVA nanoparticles (Figure 59, 
right). 
5.4 Discussion 
In Chapter 3, we found protein nanoparticle coating can alter dendritic cell 
inflammatory responses[45]. In addition to coating our nanoparticles with antigen, the 
studies in this chapter explore the in vivo immune responses to FliC, IgM, and IgG adjuvant 
coatings on nanoparticles. 
5.4.1 Flagellin-Mediated Adjuvancy 
When OVA-FliC nanoparticles and OVA nanoparticles admixed with soluble 
flagellin were used to immunize mice, both groups developed similar levels of anti-OVA 
IgG titers (Figure 48) and serum anti-OVA IgG1/IgG2a concentrations (Figure 50). Our 





























































Figure 59. Uncoated OVA nanoparticles and OVA-OVA nanoparticles were coated 
with anti-OVA IgG or IgG-OVA immune complexes (IgG Q). Error bars represent 
the standard deviation of 3 technical replicates (* = p < 0.05) 
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nanovaccines [17, 49]. The production of high IgG2a levels after the boost immunization 
is consistent with other literature showing FliC on nanoparticles generates a TH1-biased 
response[17]. However, the most drastic difference between the two forms of FliC adjuvant 
presentation was that affinity maturation of anti-OVA serum antibodies was triggered by 
OVA-FliC nanoparticles, but not by OVA nanoparticles with soluble FliC. 
The phenomena of affinity maturation and class switching have classically been 
reported in the literature to occur in parallel upon immunization or infection[7]. To the best 
of our knowledge, only recently have the two phenomena been studied independently of 
one another[50]. Our observation that different modes of FliC presentation lead to 
differences in affinity maturation while not affecting class switching to IgG2a supports 
growing evidence that adjuvant presentation method can influence the resulting immune 
response[51]. Further work should examine whether affinity maturation is mediated by 
surface presentation of other TLR-based adjuvants on nanoparticles as well, since 
nanoparticles can facilitate ligand access to certain intracellular TLRs. A broader study of 
soluble vs nanoparticle-bound TLR ligands can also address whether stimulation of 
antigen-internalizing APCs or downstream immune effector cells is more immunogenic on 
an adjuvant-by-adjuvant basis. 
5.4.2 IgM as a Host-Derived Adjuvant 
Potential safety issues have been raised for TLR ligand-based adjuvants that may 
dissociate or diffuse away from the antigen[6]. Unlike FliC, host-derived IgM that may 
dissociate from the nanoparticles is probably not going to be seen as immunogenic as 
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soluble FliC, and thus an OVA nanoparticle + soluble IgM group was not included in the 
study design.  
Antibodies have been proposed as host-derived adjuvants before[38, 52]. Most of 
these studies have been with soluble immune complexes consisting of soluble antigen 
bound to a cognate antibody[53, 54]. This strategy targets the antigen to Fc receptor-
bearing antigen presenting cells, yet does not exploit a second feature of antibody-mediated 
adjuvancy – the activation of complement.  
Complement activation can be triggered by the proximity of two IgG Fc domains, 
or one IgM Fc domain exposed upon antigen binding[36]. Activation of complement is 
necessary for vaccination not only as an innate host defense mechanism[7], but also for 
bridging innate and adaptive immune responses[55]. Triggering complement activation 
may further enhance the potency of immunoglobulin-adjuvanted vaccines, and the 
nanoparticle antigen delivery platform is well-suited to mediate this effect. 
The IgM-coated OVA particles did not trigger significant complement activation 
as compared to uncoated OVA nanoparticles (Figure 44). While strategies for enhancing 
IgM density on the particle surface may increase the likelihood of stronger complement 
activation, OVA-IgM nanoparticles still significantly enhanced antibody and T cell 
responses even in the absence of significant complement activation. 
Anti-OVA IgG endpoint titers significantly increased after one immunization with 
OVA-IgM nanoparticles, as compared to unadjuvanted OVA-OVA nanoparticles. 
Following the boost immunization, OVA-IgM nanoparticles induced elevated levels of 
IgG2a, whereas unadjuvanted OVA nanoparticles did not. Unexpectedly, unadjuvanted 
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OVA-OVA nanoparticles induced affinity maturation of antibodies, whereas OVA-IgM 
nanoparticles only triggered IgG2a antibody class switching and not affinity maturation. 
The inverse relationship between these phenomena has, to the best of our knowledge, never 
been reported before. If IgM could trigger a diversification of antibody effector functions, 
while at the same time preserving a pool of B cells that have not over-matured in their 
response to a particular antigen, IgM could be used to combat original antigenic sin. This 
phenomenon occurs when antibodies raised against an initial exposure of antigen are 
poorly protective against a slightly mutated version, and is a challenge in developing 
vaccines against highly mutable pathogens, such as influenza. 
The strong IgG2a responses elicited by IgM were supported by the high levels of 
IFN-γ-producing T cells, both indicators of a strong TH1 response. The TH1 and TH2 
responses are mutually inhibitory[56], and during many infections, one response can be 
protective while the other can be fatal. The TH1 response is induced in response to viral 
and bacterial infections[7], and therefore priming a TH1-biased T cell response with anti-
viral and anti-bacterial vaccines is critical for successful immunization. 
Since successful vaccination requires immunological memory, the generation of 
memory T cell responses is crucial. CD44 and CD62L can be used to identify central 
memory T cells (TCM, CD44
+/CD62L+) and effector memory T cells (TEM, CD44
+/CD62L-
)[20]. OVA-IgM nanoparticles stimulated strong TCM differentiation (Figure 54) whereas 
the other nanoparticle formulations, including those with FliC, could not. This supports the 
case for IgM as an adjuvant for promoting cell-mediated immunity. However, none of the 
nanoparticle formulations induced strong TEM responses (Figure 54), indicating that the 
nanoparticles and adjuvants used were unable to completely polarize the T cell response to 
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a TH1 or TH2 response[57]. These results are in contrast with those by Zhang et al., who 
found that immunizing mice with antigen encapsulated and admixed with PLGA 
nanoparticles triggered strong TEM but not TCM responses [20]. 
In the group combining both OVA-FliC and OVA-IgM particles (G5), we saw high 
IFN-γ production characteristic of OVA-IgM nanoparticles, low central memory T cell 
production characteristic of OVA-FliC nanoparticles, and high IL-4 production, which was 
uncharacteristic of either component nanoparticle alone. Although the benefits of 
combining these two types of adjuvanted nanoparticles are not immediately obvious, there 
is a synergistic effect as evidenced by the IL-4 response. Other work has shown that 
delivery of two types of adjuvants in separate particles elicits greater effects compared to 
adjuvant co-delivery in the same particle[9]. 
5.4.3 Challenges with IgG as an Adjuvant 
IgG2a-coated nanoparticles triggered significantly greater complement activation 
than uncoated OVA particles, which is consistent with literature describing IgG2a but not 
IgG1 as a complement-activating antibody subtype [52]. Although IgG1-coated 
nanoparticles significantly enhanced BMDC TNF-α production in comparison to uncoated 
nanoparticles, neither in vitro metric translated into enhanced immunogenicity in vivo. 
The fact that the combination group of IgG1- and IgG2a-coated nanoparticles 
showed significantly inferior IgG2a responses to mice immunized with IgG2a-coated 
nanoparticles alone or uncoated nanoparticles is surprising. Since uncoated OVA 
nanoparticles induce IgG1 and IgG2a antibodies, the immune system may perceive the 
presence of uncoated nanoparticles as an “unresolved insult” that requires an increased 
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antibody response. The introduction of IgG1- and IgG2a-coated nanoparticles may be 
perceived, therefore, as a pathogen that the body has already developed a response against, 
and consequently signals that an additional adaptive immune response is not required. The 
hypothesis that a combination of IgG1- and IgG2a-coated particulates promotes negative 
immunofeedback regulation would imply that this combination of antibodies is not suitable 
for enhancing nanovaccine adjuvancy. Experiments to test the negative immunofeedback 
hypothesis should examine the effects of IgG- and IgM-opsonized nanoparticle vaccines 
on IgG antibody responses. Opsonized nanoparticles could be given as a priming 
immunization or a boost immunization following an unopsonized nanoparticle prime 
immunization, in order to elucidate the potency of immunofeedback mechanisms in naïve 
and exposed populations.   
The fact that IgG1 and IgG2a coating density was not consistent between the two 
types of coated nanoparticles confounds the effects of antibody isotype and density. 
Antibody density on OVA-OVA nanoparticles did not affect the TNF-α response, although 
the difference in density between the highest and lowest types of nanoparticles was only 
about a factor of 2. The greater than 30-fold discrepancy between IgG1 and IgG2a binding 
to uncoated nanoparticles means the TNF-α data cannot justify discounting density as a 
factor in explaining our in vivo results. High antibody densities on antigen, such as those 
of IgG1 on our nanoparticles, could occlude important epitopes needed by germinal center 
B cells to develop high affinity antibodies to conformational epitopes [58]. At the same 
time, too low of an antibody density on the nanoparticles could decrease complement 
activation, another important process in initiating adaptive immunity [34, 55]. Further 
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studies should investigate the role of antibody density on vaccine nanoparticles in 
triggering immune responses, as an optimal coating density probably exists. 
The TNF-α responses observed in response to coated and uncoated OVA 
nanoparticles are very different than those observed in Chapter 3. In addition to using 
primary BMDCs instead of JAWS cells, the cells here were stimulated for 24 hours instead 
of 6. The discrepancy between the two data sets could represent, therefore, different 
timescales of DC inflammation associated with different types of nanoparticles, although 
future comparisons would have to be made using the same types of cells at each timepoint 
for conclusions about inflammation patterns to be drawn. 
In our quenched antibody coating studies, we found that a large portion of bound 
IgG1 and IgG2a was non-specifically bound, even on coated OVA nanoparticles. We chose 
mouse anti-OVA antibodies for coating our nanoparticles to allow the Fc region of the 
antibody to interface with the host’s immune system, and non-specifically bound IgG may 
not be able to interact with the cells and proteins of the immune system as efficiently. 
Supporting evidence for this was recently published by Holt et al., examining complement 
activation by IgG specifically or non-specifically adsorbed to microparticles [35]. IgG with 
Fc domains oriented outwards was able to sequester complement on the surface of the 
nanoparticle, while randomly adsorbed IgG generated soluble TCC away from the 
nanoparticles’ surface, which could decrease the adjuvancy of the nanoparticle. 
Additionally, given that Fc sequestration is a strategy employed by pathogens to evade the 
host’s immune response [59], it is important that antibody-coated nanoparticle vaccines 
retain the Fc-out conformation. Future studies should look into minimizing improper 
binding of antibodies during the coating process. 
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When equal coating concentrations of IgG1 and IgG2a were mixed with coated and 
uncoated nanoparticles, IgG1 bound to the nanoparticles much more efficiently than IgG2a 
did. This may suggest that the large discrepancy in coating density may be a fundamental 
property of the immunoglobulin subclasses themselves, potentially due to IgG2a being 
hypothesized to have more effector functions than IgG1 [60], and thus requiring tighter 
regulation of its binding. Future studies should design nanoparticles with comparable 
coating densities of IgG on nanoparticles’ surfaces to not only deconvolve the effects of Fc 
density on immunostimulation, but to also reduce the possibility of antigen occlusion by 
antibodies reducing the immunogenicity of the nanoparticles. 
Our finding that all uncoated, IgG1- and IgG2a-coated nanoparticles all triggered 
BMDC maturation is consistent with our results in Chapters 2 and 3 showing upregulation 
of CD86 in JAWS dendritic cells in response to OVA and 3HA nanoparticles. CD86 
upregulation in primary BMDCs was much more dramatic than upregulation by the JAWS 
cell line, suggesting that BMDCs should be used in future studies. Taken together, the 
upregulation findings suggest that a fundamental component of protein nanoparticle 
adjuvancy is triggering dendritic cell maturation. Molecular adjuvants that are used to coat 
protein nanoparticle vaccines should therefore primarily be triggers of inflammation, rather 
than maturation, to maximize synergistic effects between the two. 
To the best of our knowledge, the exact function of each of the IgG subtypes remains 
unclear and a subject of active investigation. Though the pentameric IgM molecule is 
conserved between humans and mice, the diversity of IgG subtype numbers, ranging from 
one in rabbits to 4 in humans and mice to 8 in elephants may suggest that the existence of 
IgG subtypes is a coincidence rather than a conserved evolutionary trait [60]. Though our 
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data suggest that IgM could act as a host-derived adjuvant, more information on the 
immunological processes associated with each IgG subtype will be needed to determine 
whether IgG-mediated immunofeedback is subtype dependent. Additionally, controlling 
for the effects of antigen occlusion and antibody density through particle design will be 
necessary to provide conclusive insight into IgG-mediated immunofeedback. 
5.4.4 A Note on Controls Across Studies 
Comparing the FliC/IgM and IgG studies, it is important to highlight the differences 
between the G1 control groups. In the FliC/IgM study, OVA-OVA nanoparticles were used 
as the unadjuvanted control, whereas in the IgG study, uncoated OVA cores were the 
unadjuvanted control. The motivation for the FliC/IgM study came from the observation 
in Chapter 2 that coated 3HA nanoparticles triggered protective immunity, and we sought 
to replace the antigen coating on the nanoparticles with an adjuvant coating instead. The 
IgG study was designed to answer a more fundamental question; if IgG on nanoparticles 
would bias the resulting immune response. Though both coated and uncoated particles 
could be considered valid controls for either study, a crucial difference between the two 
was that uncoated OVA cores in the second study triggered strong IgG1 and IgG2a 
responses, while OVA-OVA nanoparticles only triggered IgG1 production. An explanation 
for this may lie in our observation in Chapter 3 that uncoated OVA nanoparticles bind 
serum proteins better than coated OVA nanoparticles do, which could lead to a more 
immunogenic nanoparticle. Nevertheless, the IgG2a response to uncoated OVA cores calls 
into question whether IgM-coated OVA nanoparticles triggered class switching, or whether 
this was an artefact of an incomplete coating of IgM on the surface of an uncoated 
nanoparticle. While direct comparisons across the two studies are difficult to draw because 
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of the different conditions under which they were conducted, the higher levels of 
CD44+/CD62L+ TCM proliferation in response to IgM-OVA nanoparticles than uncoated 
OVA nanoparticles would seem to suggest that IgM at the very least is responsible for 
enhancing central memory T cell responses.  
The uncoated OVA control also calls into question whether the OVA cores + soluble 
FliC experienced enhanced adjuvancy due to the FliC adjuvant or to the uncoated 
nanoparticles. Without ELISPOT or biolayer interferometry data for the uncoated OVA 
particle group, it is hard to answer that question. However, because administering a soluble 
adjuvant inherently meant administering an uncoated nanoparticle, our comparison 
between adsorbed and detached flagellin still remains valid. Follow-up experiments to 
compare flagellin adsorbed to or detached from other types of nanoparticles to could further 
support or refute our conclusions drawn here. 
Finally, it is important to note the diversity of immunological metrics measured 
inherently translates into a wide range of effect sizes and, consequently, many 
measurements with overlapping error bars and differences of low significance.  Since 
serum antibody levels are one of the terminal outputs that many immunological pathways 
converge upon, these should be regarded as the primary results from which to draw 
statistical conclusions. Other mechanistic measurements, such as those of helper T cells, 
can further describe the immune responses observed, but their effect sizes will be 
inherently lower as a result of their upstream position in the immunological pathway, and 
are harder to draw statistical conclusions from. 
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5.5 Conclusions  
In this work, we tested the efficacy of host-derived adjuvants, IgM and IgG, as well 
as the use of a pathogen-derived adjuvant both on nanoparticles and admixed with them.  
Given the enhanced adjuvancy we observed with IgM, our finding that IgG did not enhance 
the immune response in comparison to uncoated OVA nanoparticles was surprising. The 
large amount of non-specifically adsorbed IgG may have played a role, and future studies 
should investigate methods to minimize non-specific IgG binding by altering reaction time, 
IgG concentration, rate of IgG addition, and other parameters. Additionally, studies to 
ensure proper IgM orientation should also be performed in conjunction with IgM density 
optimization. The finding that the combination of IgG1- and IgG2a-coated nanoparticles 
reduced IgG2a responses may suggest a negative feedback mechanism involving both 
subtypes regulates antibody class switching. From a therapeutic development perspective, 
our results suggest combinations of antibody coatings should be avoided until individual 
antibody subtypes have their adjuvant effects established.   
Perhaps our most surprising finding was that antibody affinity maturation and 
IgG2a class switching did not correlate with one another. The two processes are normally 
associated with each other in the development of an antibody response [7]. We found all 
nanoparticle types except OVA-OVA nanoparticles and IgG1-OVA/IgG2a-OVA 
nanoparticles triggered class switching. Unadjuvanted OVA-OVA nanoparticles and FliC-
coated OVA nanoparticles triggered affinity maturation, while IgM- and soluble FliC-
adjuvanted nanoparticles did not. Our results stand in contrast to those by Corley, et al., 
who showed that IgM-bound soluble antigen (IgM-ICs) accelerates affinity maturation 
responses to T-dependent antigens[39]. Future work should examine the differences in 
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immune responses to soluble and nanoparticulate immune complexes, and whether such a 
difference can be exploited to tune the affinity of the humoral immune response. Affinity 
maturation is necessary for generating high affinity, neutralizing antibodies, which can be 
protective against highly conserved pathogens[61]. For pathogens that mutate or change 
yearly, such as influenza, however, the generation of high-affinity neutralizing antibodies 
results in a loss of antibody diversity, and can contribute to the phenomenon known as 
original antigenic sin, in which antibodies are only made to epitopes found on the first 
strain of virus the immune system encountered[7]. If vaccine adjuvants can delay the 
affinity maturation process while promoting diversification of antibody effector functions 
via class switching, it is possible that the memory B cell repertoire generated from the 
immunization will be more effective at combatting rapidly mutating pathogens.  
The work of this chapter confirms the hypothesis set forth in Chapters 2 and 3 – 
that molecular adjuvants can be used as coatings on protein nanoparticle vaccines to bias 
the resulting immune response. In particular, host-derived immunoglobulins are a 
promising new class of adjuvants that can interact with multiple parts of the immune 
system. Given the role that Fc receptors play in proper presentation of antigen by follicular 
dendritic cells to germinal center B cells [62], it is possible that immunoglobulin-opsonized 
nanoparticles enhance the germinal center response. Flow cytometry or 
immunohistochemical studies could elucidate the exact role of opsonizing immunoglobulin 
in the germinal center response. Immunoglobulin coatings on nanoparticle vaccines is 
consistent with the pathogen-mimetic paradigm of nanovaccine development, and is a 
relatively unexplored field. If the challenge of optimizing specific antibody binding can be 
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met, these host-derived proteins could provide the next generation of safe and effective 
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CHAPTER 6. CONCLUSIONS AND FUTURE 
DIRECTIONS 
The studies performed in this work establish protein nanoparticles as a promising 
platform technology for enhancing recombinant antigen adjuvancy. The simple method of 
desolvation employs a non-toxic solvent, ethanol, to generate a high yield of nanoparticles 
that consist primarily of antigen. As we demonstrated in Chapters 2, 3 and 5, desolvated 
nanoparticles can be further modified by coating with antigen or adjuvant to enhance or 
alter the immune response. As immunologists learn more about the protective 
immunological correlates associated with different pathogens, the immunomodulatory 
capacity of coated protein nanoparticles, and coated nanoparticle vaccines in general, will 
become increasingly relevant. Outlined below are the key insights this thesis contributes to 
the growing literature on nanoparticle vaccines. 
6.1 Mechanistic Insights into Protein Nanoparticle Adjuvancy 
In Chapter 3, the in vitro studies of OVA nanoparticle-dendritic cell interactions 
established that protein nanoparticles enhance antigen uptake and reduce antigen 
acidification by dendritic cells, but these markers alone did not lead to increased 
inflammatory responses. Inflammation was instead found to depend on size and coating, 
with nanoparticles between 270-350 nm in size more inflammatory than 500 nm 
nanoparticles. This inflammatory size range, which overlaps with that of some viruses, is 
consistent with the pathogen-mimetic paradigm of nanoparticle vaccine design. 
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The in vivo studies with 3HA nanoparticles show that components of the immune 
system that are downstream of dendritic cells also play a role in interacting with protein 
nanoparticle vaccines. While antigen retention at the site of injection did not play a role in 
enhancing adjuvancy, nanoparticles were retained better than soluble protein in the spleen 
after 8 days. In the spleen and draining lymph nodes, nanoparticles also enhanced germinal 
center B cell responses better than soluble protein did. Further evidence for B cell 
involvement was found in Chapter 4, as fresh and aged 3HA nanoparticles induced higher 
levels of neutralizing antibodies than soluble 3HA did. The enhanced ability of 
nanoparticles to induce neutralizing antibodies is additional supporting evidence for the 
pathogen-mimetic design strategy of multimeric antigen display on the nanoparticle 
surface. Taken together, our results implicate dendritic cells, B cells, and splenic antigen 
retention in mediating protein nanoparticle adjuvancy. 
6.2 Flagellin Adjuvancy   
The findings in Chapter 2 that FliC-M2e fusion protein nanoparticles are capable of 
inducing protective immune responses suggested that flagellin may not need to be 
incorporated in a 1:1 ratio with antigen protein. We explored this idea further in Chapter 
5, using full-length flagellin to coat desolvated protein nanoparticles. Our results showed 
that FliC-coated nanoparticles retained their TLR-5-stimulating activity, and enhanced the 
immune response to the underlying antigen core. Corroboration of these findings by using 
FliC-coated antigen nanoparticles in an influenza challenge study would establish adjuvant 
coatings as an adjuvant dose-sparing alternative to FliC-fusion proteins. 
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6.3 Nanoparticle Stability 
Our successful extended cold chain-independent storage of 3HA nanoparticles in 
Chapter 4 suggests the viability of protein nanoparticles as an appropriate vaccine 
technology for the developing world. To further validate its potential, future studies should 
examine how to extend viable storage at 37°C beyond 2 weeks, as storage at elevated 
temperatures is especially important for transport to tropical and sub-tropical regions of the 
world. Given the importance of adjuvant coatings on protein nanoparticles that we 
observed in Chapter 5, storage of different types of adjuvant-coated protein nanoparticles 
should also be tested to ensure that the molecular adjuvants used can retain their 
stimulatory abilities outside of the cold-chain. 
Wherever stability cannot be maintained, a screen of stabilizing excipient 
compounds could be used to find sugars and buffer salts that assist in preservation of 
protein structure. Alternatively, protein nanoparticles with components prone to hydrolysis 
could be entrapped in a non-aqueous vaccine delivery vehicle, such as in microneedle 
patches [1]. In addition to enhancing protein stability, microneedles can provide an easier 
means of vaccine administration than hypodermic needles, and provide access to the 
antigen presenting cell-rich layers of the dermis [2]. 
6.4 Immunoglobulins as Nanoparticle-Bound Adjuvants 
Although FliC showed promising results as an adjuvant coating, we tested the 
adjuvant efficacy of the host-derived proteins IgG and IgM because of potential issues with 
pathogen-derived adjuvant toxicity. IgM-coated OVA nanoparticles significantly enhanced 
memory T cell responses in vivo, and triggered IgG class switching but not affinity 
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maturation. Future studies should examine the hypothesis that delayed affinity maturation 
responses translate into more cross-protective immune responses in in vivo challenge 
models of highly mutable pathogens. 
     Contrary to observations in the literature, the IgM coating on our nanoparticles did not 
significantly induce complement activation. Future studies should vary IgM density on the 
nanoparticle surface to look for complement activation in vitro and other 
immunomodulatory effects in vivo. 
Though IgG2a-coated nanoparticles were able to activate complement, we did not 
observe any enhancement of antibody or memory T cell responses in vivo in response to 
IgG-coated nanoparticles. Upon further study, OVA nanoparticles were found to have a 
significant amount of non-specifically adsorbed antibodies, which may have led to non-
immunogenic clearance instead of immunostimulatory antigen presentation. By adding 
antibodies to OVA-coated-OVA particles, we were able to both increase the amount of 
properly-oriented antibodies and enhance TNF-α secretion in response to nanoparticles by 
BMDCs. This leads us to believe IgG may still prove useful as an adjuvant, though care 
needs to be taken in future work to minimize non-specifically adsorbed antibodies.  
6.5 Perspectives and Future Work 
Vaccine design is moving away from the isolate-inactive-inject paradigm and toward 
more engineered vaccine formulations for directing the immune response. Protein 
nanoparticles made from crosslinked antigen could be a safe, effective, and cold-chain-
independent platform technology for enhancing recombinant antigen immunogenicity. The 
combination of particulate and molecular adjuvants holds great potential for engineering 
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specific immune responses to antigens from different pathogens, and the findings of this 
thesis can help guide molecular adjuvant choice for other types of vaccine nanoparticles. 
Specifically, molecular adjuvants should focus on generating APC inflammation and 
biasing APC inflammatory responses toward generating the desired adaptive immune 
responses. While multimeric epitope and TLR-ligand display can be used to generate 
immunogenic nanoparticles in line with the pathogen-mimetic design strategy, 
immunoglobulin-coated nanoparticles are also consistent with the pathogen-mimetic 
design strategy. Host-derived immunoglobulins could be a safer alternative to pathogen-
derived adjuvants, and the synergistic effects between nanoparticulate and 
immunoglobulin-mediated adjuvancy is a promising area of investigation.  
Future work to build on our FliC-coated nanoparticles should look at other TLR 
ligand-coated nanoparticles versus admixed TLR ligands. Additionally, dose-sparing 
studies should be performed comparing FliC-coated nanoparticles to FliC-fusion proteins 
to confirm whether nanoparticle colocalization can reduce the amount of adjuvant needed 
for an immunization.  
Building on our stability studies, strategies to extend the 37°C wet storage of protein 
nanoparticles should be investigated. Methods for prolonging storage can include the 
addition of excipient salts, disaccharides, or biodegradable polymers that can bind to the 
protein nanoparticles and shield them from nanoparticle collision-induced denaturation. 
The wet storage of immunoglobulin-coated nanoparticles or other adjuvant-coated 
nanoparticles should also be tested. If wet storage is not possible for certain types of 
adjuvanted nanoparticles, excipients should also be tested for enhancing extended wet 
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storage. At the same time, the stable incorporation of nanoparticles into microneedle 
patches should also be pursued for enhancing delivery of vaccine to the APCs of the dermis. 
Of particular interest is the future development of immunoglobulin coatings of 
nanoparticulate vaccines. The following sections outline three studies that could be 
undertaken to further develop immunoglobulins as adjuvants. 
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6.6 Hapten-Mediated Immunoglobulin Coupling 
To avoid the necessity of 
developing new types of 
antibodies for each new antigen 
nanoparticle, a chemically 
conjugated hapten coating on the 
surface of the vaccine 
nanoparticles can serve as an 
adapter between the antibody 
coating and the antigen core. 
Figure 60 illustrates how the 
small molecule 
trinitrobenzenesulfonic acid 
(TNBS) can be used to 
chemically add trinitrophenol 
(TNP) groups to the surface of a 
nanoparticle, which can then be 
bound by anti-hapten antibodies. 
Instead of relying on affinity 
interactions between antibodies 
with different target epitopes, a standard anti-hapten affinity interaction can be optimized 
and used across many different vaccine nanoparticle types. 
 
Figure 60. Proposed coating scheme involving 
conjugating protein nanoparticles with a small 
molecule hapten (TNP) first, then binding anti-
TNP immunoglobulin to the surface. This plan 
should allow for better antibody density control, 
greater fraction of properly-oriented antibodies, 
and increased versatility of the immunoglobulin 
adjuvant as a platform technology. 
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6.7 Examining Density Effects  
Once the hapten coating protocol is established, different densities of hapten and 
antibody can be used to coat the nanoparticles. By controlling hapten conjugation density, 
we can theoretically achieve a much higher antibody coating density than would be 
possible through only binding native antigen epitopes. Varying antibody density on the 
particle surface should reveal an optimal coating density – too many antibodies can mask 
epitopes needed for B cell antigen presentation, too few antibodies could be insufficient 
for complement activation or other Fc-mediated adjuvant effects. In addition to exploring 
antibody density effects, controlling antibody density across different subtypes will allow 
for conclusions on subtype-mediated immunofeedback to be drawn. As monoclonal 
antibodies are still relatively expensive compared to influenza vaccines [3], cost 
considerations should also be taken into account for minimizing immunoglobulin use. 
6.8 Additional Antibody Isotype Testing 
Other antibody isotypes may also be immunogenic on protein nanoparticles, and 
should be investigated for their adjuvant potential as well. In particular, IgE and IgA are 
especially important in providing mucosal protection. Recently, IgE has been identified as 
a potent weapon in cancer immunotherapy [4, 5], although IgE-adjuvanted vaccines have 
so far been limited to intravenous administration of IgE-opsonized cancer cells [6], and 
recombinant, Fcε-expressing cancer cells [7]. Immunoglobulin E is most commonly 
associated with anti- parasite and allergic responses. It is the last antibody isotype in the 
class-switching series, and can trigger powerful immune responses that can range from 
parasite neutralization to systemic anaphylaxis [8]. Of all the antibody classes, IgE has the 
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greatest potential for generating strong immune responses, and the administration route 
needs to be carefully examined to avoid the risk of anaphylaxis.  
Immunoglobulin A is predominantly found in mucosal secretions [8], IgA-NPs 
administered through mucosal routes (i.e. intra-nasal) may be more immunogenic than 
IgA-NPs administered through the traditional intra-muscular route. Given the importance 
of mucosal immunity in influenza and other respiratory diseases, and the fact that our 
protein nanoparticles have generated immune responses through both of these routes 
previously [9, 10], IgA would seem to be a reasonable choice of adjuvant for an influenza 
vaccine.  
Although our studies are primarily motivated by vaccine development, testing 
various antibody isotypes and densities as nanoparticle coatings can yield fundamental 
insight into the feedback-based regulation of the immune system. Using antibodies on 
nanoparticles to downregulate the antibody response could eventually have implications in 
treating autoimmune diseases and organ transplant recipients, while therapeutics that 
upregulate anti-cancer antibodies could become a cornerstone of the next generation of 
ADCC-dependent cancer therapies.    
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APPENDIX A. SEQUENCES OF RECOMBINANT 
INFLUENZA PROTEINS USED 
6.9 M2e Peptides  





6.10 H7 Hemagglutinin Sequences 
Red = H7 Hemagglutinin Sequence, Green = GCN4 Trimerization Motif, Blue = His Tag 
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